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Neuromuscular diseases (NMDs) include many diseases which impair muscle function, either 
directly through pathologies of the muscles, or indirectly through pathologies of the nerves or 
neuromuscular junctions. NMDs are progressive diseases which can cause muscle weakness or 
spasticity and an increasing demand for supportive devices and medical and non-medical support. 
The aim of this thesis is to provide insight into the impact of having an NMD on functioning 
and quality of life. Therefore, the main focus of this thesis was to identify the most relevant disease-
specific and health-related disabilities, to develop a psychometrically sound measurement 
instrument based on these disabilities, and to evaluate the impact of these disabilities on perceived 
quality of life. A second objective was to develop an easy to apply instrument to measure disease 
severity in NMDs. The third objective was to examine the prevalence and severity of stigmatization 
in persons diagnosed with an NMD and its impact on quality of life.  
This chapter introduces the central concepts of this thesis and specifies its aims and outline. 
 
Neuromuscular diseases 
Neuromuscular diseases (NMD) can be acquired or hereditary. Their causes are dysfunction of the 
anterior horn cell or sensory ganglion cell (neuronopathy), peripheral nerve (neuropathy), 
neuromuscular junction (myasthenia) or muscle (myopathy).1 These diseases vary according to their 
characteristics, such as pattern of inheritance, origin of genetic mutation, incidence, symptoms, age 
at onset, rate of progression and prognosis. Today, the manifestations of neuromuscular diseases 
span several medical specialities including neurology, rehabilitation, rheumatology, immunology, 
cardiology, pulmonology and gastroenterology. An integrated and multidisciplinary approach to the 
management of these patients has become a standard of care.2 
NMDs is a very broad term which encompasses many diseases which vary greatly in their 
onset and diagnosis, such as a common neuropathy (due to diabetes) or rare diseases such as 
Amyotrophic Lateral Sclerosis and congenital Arthrogryposis multiplex. Therefore, epidemiology 
in NMDs is an active field of inquiry. Epidemiologic interest is growing in NMDs in the world’s 
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more advanced healthcare regions.3 NMDs occur worldwide and the determination of prevalence 
and incidence depends on a consensus of diagnostic criteria.4 In the Netherlands the ISNO 
foundation CRAMP database provides a good indication of Dutch adult individuals with NMDs 
diagnosed in university hospitals.5 Its estimated prevalence rate is as least similar to that of 
Parkinson’s disease, from around 100 to 300 incidents per 100.000 based on the published peer 
reviewed literature for the available incidence and prevalence rates within a group of about 30 
neuromuscular disorders. If we assume this group is the tip of the iceberg, the true incidence rates 
are likely to be much higher.4 
The large number of NMDs can be classified6 into four major subgroups based on their most 
common characteristics: motor-neuron disorders, muscle disorders, junction disorders and 
peripheral nerve disorders. For the characteristics and some examples of these NMD subgroups, see 
Box 1. 
 
Consequences of neuromuscular diseases 
Most NMDs involve loss of sensation and the progressive loss of physical functioning from 
progressive muscle weakness in the upper and lower extremities. These are the most common 
symptoms alongside weakness in the muscles responsible for breathing or swallowing and speech 
functions.17, 18 Around 59% of patients perceive difficulties in physically demanding mobility 
activities in the common muscle diseases,19, 20 for example difficulty in walking long distances, up 
to a total inability to perform essential activities of daily living such as walking, going to the toilet 
and preparing meals. This declining physical functioning impacts on mental and social 
functioning.17, 21  
 It is known that the balance of emotional and psychological functioning is usually impaired 
in people with a neuromuscular disease.17, 22 The impact of NMDs on mental functioning, however, 




Box 1 NMD subgroups  
NMDs can be classified into four major subgroups based on their most common characteristics: 
 Motor-neuron disorders are disorders where the motor-neurons in brain and or spinal cord 
deteriorate or die. They can be inherited as well as acquired. A well-known disease is Amyotrophic 
Lateral Sclerosis (ALS),7 and less well-known are Progressive Spinal Muscular Atrophy8 and Primary 
Lateral Sclerosis.9  
 Muscle disorders are disorders which affect the muscles based on abnormalities in the genes 
and/or enzymes. The most common inherited muscle disorder in childhood is Duchenne muscular 
dystrophy, in which the cytoskeletal protein dystrophin enzyme is lacking due to a gene mutation.10 
Another inherited muscle disorder with an onset at different life stages is Myotonic Dystrophy,11, 12 a 
progressive systemic condition due to abnormally high trinucleotide expansion.  
 Junction disorders are disorders with impaired neuromuscular transmission leading to 
fluctuating muscle weakness. Most junction disorders are acquired and caused by autoimmune 
dysregulation. Myasthenia Gravis13 is the most common junction disorder.  
 Peripheral nerve disorders are diseases which concern peripheral neuropathies. They can be 
inherited and acquired and present variously.14 A common peripheral nerve disorder is 
Polyneuropathy.15 Hereditary Motor and Sensor Neuropathy is a neuromuscular disease which also 
includes motor and sensor abnormalities.16  
 
is negatively associated with pain23, fatigue24, 25 and depression.26 The impact of an NMD on 
social functioning depends on the severity of the disease.27 For example, severely fatigued patients 
have poorer ‘social functioning’ than those without fatigue,24 and decline in physical functioning 
due to NMDs impacts negatively on occupational functioning.28 Some NMDs include cognitive 
impairments which can deteriorate interpersonal and social relationships and contribute to a reduced 
HRQoL.29-31  
 
International Classification of Functioning, Disability and Health 
The International Classification of Functioning, Disability and Health32 (ICF) describes all aspects 
of human functioning and can therefore help describe the consequences of NMDs. The ICF is a 
framework for organizing and documenting information on functioning and disability32. The ICF is 
based on the biopsychosocial model, which integrates a person’s features (medical model) and the 
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overall context in which the person lives (social model). The functioning of an individual in a 
specific domain reflects an interaction between the health condition and the contextual: 




Figure 1 ICF framework representing the interactions between the components.32 
 
In other words a person’s functioning in a specific domain is a dynamic interaction or complex 
relationship between the health condition and contextual factors. NMDs (health conditions) are the 
reason for a variety of NMD-related disabilities affecting functioning. The ICF is a framework for 
describing and organizing information on functioning and disability and describes four components 
into which human functioning is classified: body functions, activities, participation and 
environment, functioning and disability, and the ICF components are defined in Box 2.  
The ICF provides a standard language and a conceptual basis for the definition and 
measurement of disability, and it also provides classifications and codes, hence providing a 
common framework for the development of health outcome measures.32-34 It recognises the role of 
environmental factors in the development of disability, as well as the role of health conditions.35 
 
 
Box 2 ICF-definitions of functioning and disability and specifications for the ICF- components.32 
  
Definitions:  
Functioning: functioning is an umbrella term for body functions, body structures, activities and 
participation. It denotes the positive aspects of the interaction between an individual (with a 
health condition) and that individual’s contextual factors (environmental and personal factors). 
Disability: disability is an umbrella term for impairments, activity limitations and participation 
restrictions. It denotes the negative aspects of the interaction between an individual (with a 
health condition) and that individual’s contextual factors (environmental and personal factors). 
 
Functioning and disability in each ICF component  
Body functions: body functions are the physiological functions of body systems (including 
psychological functions). 
Body structures: body structures are the anatomical parts of the body such as organs, limbs and 
their components. 
Impairments: Impairments are problems in body function and structure such as significant 
deviation or loss. 
Activity: activity is the execution of a task or action by an individual. 
Activity limitations: activity limitations are difficulties an individual may have in executing 
activities. 
Participation: Participation is the involvement in a life situation. 
Participation restrictions: participation restrictions are the problems an individual may 
experience in life situations. 
Environmental factors: environmental factors are the physical, social and attitudinal 
environment in which people live and conduct their lives. These are either barriers to or 




Health-related stigmatization is typically characterized by the social disqualification of individuals 
and populations with particular health problems.36 To understand stigma or disgrace in chronic and 
acute diseases better, Scambler and Hopkins introduced a recognisable and generally accepted 
distinction between ‘enacted’ and ‘felt’ stigma.37, 38 Enacted stigma refers to actual discrimination 
and is often associated with conditions which have particular moral attributes attached to them 





overall context in which the person lives (social model). The functioning of an individual in a 
specific domain reflects an interaction between the health condition and the contextual: 




Figure 1 ICF framework representing the interactions between the components.32 
 
In other words a person’s functioning in a specific domain is a dynamic interaction or complex 
relationship between the health condition and contextual factors. NMDs (health conditions) are the 
reason for a variety of NMD-related disabilities affecting functioning. The ICF is a framework for 
describing and organizing information on functioning and disability and describes four components 
into which human functioning is classified: body functions, activities, participation and 
environment, functioning and disability, and the ICF components are defined in Box 2.  
The ICF provides a standard language and a conceptual basis for the definition and 
measurement of disability, and it also provides classifications and codes, hence providing a 
common framework for the development of health outcome measures.32-34 It recognises the role of 
environmental factors in the development of disability, as well as the role of health conditions.35 
 
 
Box 2 ICF-definitions of functioning and disability and specifications for the ICF- components.32 
  
Definitions:  
Functioning: functioning is an umbrella term for body functions, body structures, activities and 
participation. It denotes the positive aspects of the interaction between an individual (with a 
health condition) and that individual’s contextual factors (environmental and personal factors). 
Disability: disability is an umbrella term for impairments, activity limitations and participation 
restrictions. It denotes the negative aspects of the interaction between an individual (with a 
health condition) and that individual’s contextual factors (environmental and personal factors). 
 
Functioning and disability in each ICF component  
Body functions: body functions are the physiological functions of body systems (including 
psychological functions). 
Body structures: body structures are the anatomical parts of the body such as organs, limbs and 
their components. 
Impairments: Impairments are problems in body function and structure such as significant 
deviation or loss. 
Activity: activity is the execution of a task or action by an individual. 
Activity limitations: activity limitations are difficulties an individual may have in executing 
activities. 
Participation: Participation is the involvement in a life situation. 
Participation restrictions: participation restrictions are the problems an individual may 
experience in life situations. 
Environmental factors: environmental factors are the physical, social and attitudinal 
environment in which people live and conduct their lives. These are either barriers to or 




Health-related stigmatization is typically characterized by the social disqualification of individuals 
and populations with particular health problems.36 To understand stigma or disgrace in chronic and 
acute diseases better, Scambler and Hopkins introduced a recognisable and generally accepted 
distinction between ‘enacted’ and ‘felt’ stigma.37, 38 Enacted stigma refers to actual discrimination 
and is often associated with conditions which have particular moral attributes attached to them 




(such as HIV/AIDS). Felt stigma refers to feelings of shame rather than an experience of actual 
discrimination.  
Although it seems reasonable to assume that NMD patients are at risk of stigmatization, 
little is known about the prevalence and severity of health-related stigma in NMDs. Stigmatization 
of NMDs could be caused by the enduring disabilities they entail, which can impair almost any 
aspect of our physical, emotional, social or cognitive functioning.39, 40 For instance, differences in 
illness manifestation appear to contribute to differences in quality of life across populations: greater 
anxiety and lower perceptions of control have been documented for epileptic populations relative to 
healthy populations and other groups living with chronic illnesses.41 Certain characteristics of 
neurological disorders (e.g. seizures and tremors) could also be visible to others, resulting in 
stigmatizing social experiences.42 Finally, stigma associated with neurological conditions and 
illness manifestation can contribute to poorer quality of life outcomes.  
 
Quality of Life  
Healthcare developments in the 1980s resulted in an emerging consensus on the importance of the 
patient’s perspective in monitoring medical care outcomes.43, 44 The main concerns at that time were 
the rising costs of healthcare and improvement in the quality of care by managing medical care 
outcomes.45 As a result, the development of measurement instruments for the evaluation of health-
related quality of life (HRQoL) has become increasingly important in evaluating healthcare 
outcomes. In the mid-1980s, the World Health Organization (WHO) initiated the conceptualization 
and development of measurement instruments to evaluate people’s subjective QoL. The WHO 
defines QoL as individuals’ perception of their position in life in the context of the culture and 
value systems in which they live and in relation to their goals, expectations, standards and 
concerns.46, 47 This focus resulted in projects assessing QoL around the world. QoL is a broad-
ranging, complex concept affected by a person’s physical health, psychological state, level of 
independence, social relationships, personal beliefs and relationship to salient features in the 
 
 
environment.48 Unfortunately, there is no absolute consensus in the scientiﬁc literature on the 
essential domains of QoL.49-52 
 The consequences of NMDs have an enormous impact on QoL.17, 53, 54 Generic QoL 
measures for QoL in NMDs are available,44, 55 as well as some NMD-specific QoL measures.20, 56-58 
 
Patient-reported outcome measurements 
Patient-reported outcome measurements (PROMs) are measurement instruments based on a report 
that comes directly from the patient (i.e., a study subject) about the status of a patient’s health 
condition without amendment or interpretation of the patient’s response by a clinician or anyone 
else.59 A PROM can be recorded by the patient directly, or by an interviewer, provided the 
interviewer records the patient’s response exactly.59  
PROMs can be divided into generic and disease-specific measures. Generic measurement 
instruments consist of generic questions and permit the comparison of results between different 
populations and different programmes, a very important objective for policy analysis and decision 
making.60 Disease-specific measurement instruments consist of disease-specific questions and can 
be more responsive to the attributes of patients with the disease of interest.61 
 
Psychometric properties  
The psychometric properties of measurement instruments reflect their strength in outcome 
measurement, and need to be sound for obtaining evidence. These properties include reliability, 
validity and sensitivity to change.62, 63  
Reliability concerns the overall consistency of a measure. A measure is said to have a high 
reliability if it produces similar results under consistent conditions. Reliability can be evaluated by 
examining the internal reliability consistency, which refers to high correlations among test items, 
and by examining repeatability: test-retest reliability is established by administrating the test to two 
groups of subjects at different time points and correlating the scores obtained.64  
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measurement instrument.69, 70 
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Chapter 2 reports on the results of the study on the content validity of the initial ICF Core Set for 
NMD. Chapter 3 reports on the development of the Neuromuscular Diseases Impact Profile 
designed for the evaluation of NMD-related disabilities and the examination of their psychometric 
properties. In Chapter 4 the psychometric evaluation of the NMDIP is continued by examining the 
test-retest reliability and the Relative Validity of the NMDIP. Chapter 5 describes the impact of 
NMD-related disabilities on QoL using the NMDIP. Chapter 6 describes the translation and 
adaptation of two valid extremity function scales, and reports on the examination of the 
psychometric properties of this easy to apply self-report measurement instrument, the Extremity 
Function Index, designed for the evaluation of disability severity. Chapter 7 reports the translation 
of a well-known measurement instrument for the assessment of stigma and describes the impact of 
stigma on QoL. The main results of this thesis are summarized and discussed in Chapter 8, 
followed by a consideration of some methodological issues, their implications for practice and 
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Background: Understanding of the consequences of a neuromuscular disease (NMD) can improve 
when a valid sample of disease-specific categories based on the International Classification of 
Functioning, Disabilities, and Health (ICF) is available. 
Objective: To examine the content validity of the initial ICF Core Set for neuromuscular diseases 
(NMDs). The initial ICF Core Set was developed for three chronic neurological diseases.  
Design: A qualitative method. 
Methods: To examine the content validity of the initial ICF Core Set for NMD, concepts in 
established disease-specific health-related Quality of Life Questionnaires (HRQOL) were compared 
with ICF categories. Next, the selected ICF categories were linked to the ICF categories in the 
initial ICF Core Set.  
Results: All concepts in the HRQOL questionnaires, except one body function concept, were 
covered by the initial ICF Core Set. However, the NMD Core Set reflects a broader scope 
concerning health problems than the concepts in the HRQOL questionnaires do, especially 
concerning the “Participation” and “Environmental Factors” components. 
Conclusion: The NMD Core Set, as well as a measurement based on this Core Set, can contribute 
to a better understanding of the consequences of NMDs and can also serve as a basis for clinical 
practice, research, social security systems, and educational programs. 
Clinical rehabilitation impact: The newly developed NMD Core Set can be a basis for enhancing 
the development of rehabilitation interventions and improving overall health care for patients with a 
NMD. 
 
Keywords: Neuromuscular Diseases, International Classification of Functioning, Disabilities and 




A neuromuscular disease (NMD) is a chronic and progressive neurological disorder that affects the 
muscle and/or the peripheral nervous system. Neuromuscular diagnoses may be classified into four 
major NMD groups: (i) motor neuron disorders (MND), (ii) muscle disorders (MD), (iii) nerve-
muscle junction disorders (NMJD), and (iv) peripheral nerve disorders (PND).1 Patients with a 
MND suffer from progressive muscle weakness and muscle atrophy; eventually most patients will 
die as a result of problems with swallowing and breathing.2-4 Patients with a MD suffer from 
chronic and progressive muscle weakness leading to an insidious decline in mobility5; the clinical 
course in these diseases varies greatly in different patients and different diseases. Patients with a 
NMJD may suffer from droopy eyelids, double vision, swallowing and speech problems, and a 
limb-girdle weakness. Symptoms fluctuate and stabilize or even improve over the course of time.6 
Finally, patients with a PND may suffer from impaired sensory feeling, muscle twitching, 
cramping, numbness, tingling, and a host of other symptoms. Symptoms are, in most cases, slowly 
progressive.7  
Symptoms of NMDs can lead to vulnerability, with a considerable impact on general health 
status and everyday life, and with possible limitations in terms of tasks or participation in social life 
with regard to housing, work, and income. The impact of these symptoms may increase with the 
progressive course of most of the NMDs.8, 9  
Due to better diagnostics, a increasing number of NMD patients is identified and receiving 
medical treatment. Therefore, life expectancy for patients with a NMD has increased.10 
In order to reduce the patient’s vulnerability and to improve his or her independent daily 
functioning, it is important for healthcare professionals and researchers to deepen the knowledge of 
a patient’s actual functioning and disability. Health-status measuring instruments can be helpful 
tools.  
Over the last two decades many health-measuring instruments have been developed for the use 
in both, clinical practice as well as in research. There are generic HRQOL instruments, for example, 
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the 36-item Short Form Health Survey Questionnaire (SF-36).11 In addition, there are generic and 
domain specific measuring instruments to assess activities of daily living, for example, GARS 
(Groningen Activity Restriction Scale)12 or to assess participation in life situations, for example, the 
IPAQ (Impact on Participation and Autonomy Questionnaire).13 An example of a disease specific 
HRQOL instrument with a broad scope concerning the consequences of a NMD is the Individual 
Neuromuscular Quality of Life Questionnaire (INQOL).14  
Due to the prolific development and the increasing use of health-measuring instruments, there 
are now “competing” instruments in many areas, and there is no consensus about which 
components are important and how to measure these components.15 Furthermore, comparisons of 
health status across chronic diseases are problematic; the differences in aspects contributing to the 
content of physical, emotional, or social functioning constructs is a good example of this. 
Consequently, it is opportune to develop an internationally accepted frame of reference in order to 
measure functioning, disability and health in patients with a MND. 
Since HRQOL can be defined as an individual’s perceptions of health and health-related 
domains of well-being, the ICF categories can serve as the basis for the operationalization of 
HRQOL.16 These ICF categories systematically describe all aspects of functioning and health. 
Health domains are classified in the “Body Functions and Structures” component and in the 
“Activity and Participation” component. Since an individual’s functioning and disability occurs in a 
context, the ICF also includes a list of “Environmental Factors”.17  
However, the ICF in its original form with about 1500 categories is hardly practicable and lacks 
feasibility.18 Therefore, Stucki and colleagues19, 20 have suggested defining short lists – so-called 
Core Sets – of ICF categories which are relevant for specific conditions (e.g., stroke)21 or multiple 
sclerosis.22, 23 An example of a measuring instrument based on a selection of ICF categories, and 




For the development of an assessment tool reflecting the broad range of the most important 
consequences of NMDs, the initial ICF Core Set for patients with a chronic neurological disorder 23 
provides a good basis. Because this initial ICF Core Set was a consensus set for three neurological 
diseases and therefore not NMD-specific, we decided to further examine the content validity of the 
initial ICF Core Set with the goal to obtain an NMD Core Set.  





To examine the content validity of the initial ICF Core Set, we used a qualitative method. We 
systematically linked the concepts in the questions belonging to the domains and scales of three 
established disease-specific HRQOL measuring instruments with the categories appraised as 
relevant for neurological diseases in the initial ICF Core Set.23 
 
Procedure 
Linking the HRQOL concepts to the categories in the initial ICF Core Set was performed in three 
steps, namely: 1) meaningful concepts in the questions of the selected disease-specific 
questionnaires were identified by the two experts; 2) these concepts were linked to the categories of 
the full version of the ICF employing the ICF linking-rules25, 26; and 3) the matched ICF categories 
were compared with the categories in the initial ICF Core Set. Newly identified ICF categories were 
included in the final NMD Core Set when this category was found in at least two of the three 
measuring instruments.  
The linking procedure was performed by two healthcare professionals: one professional with 
expertise in ICF (HAS: member of the Dutch WHO-FIC collaborating center) and one professional 
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with expertise in NMDs (IB: Nurse Practitioner NMDs). These experts worked independently 
within the steps of the linking procedure. 
Categories were included in the sample when both investigators unequivocally considered the 
selected category to be appropriate for analysis. Differences were resolved through discussion with 
reference to a third and fourth reviewer (JBMK, KW) if necessary.26  
 
The initial ICF Core Set 
The initial ICF Core Set was developed to indicate relevant categories of functioning and health for 
patients with a chronic neurological disorder such as multiple sclerosis, Parkinson’s Disease, and 
neuromuscular disease. Therefore, a written Delphi study was performed using three disease-
specific panels composed of patients and proxies, and medical and non-medical healthcare 
professionals (n=98). The panels were asked to make a selection from among the 1500 categories 
found in the ICF reflecting relevant disease-specific health problems. As a result, sixty-eight ICF 
categories were considered to be the most relevant and they belonged to the ICF components: 
“Body Functions and Structures” (20 categories), “Activities” (21 categories), “Participation” (17 
categories), and “Environmental Factors” (10 categories). No significant differences were found 
between the appraisal of categories by patients/proxies and healthcare professionals. Agreement 
across the disease panels appeared to be very strong.23 
 
Disease-specific HRQOL measuring instruments 
We searched for HRQOL measuring instruments that at least covered the dimensions of “physical 
functioning,” “psychological functioning,” and “social functioning,” and represented at least one of 
the four groups in the classification of NMD according to Rowland and McLeod.1  
We searched the Medline, Embase, Psychinfo, and Pubmed databases from 2000 until 2010 
using the following keywords: (i) neuromuscular disease, (ii) quality of life, (iii) disability, and (iv) 
outcome assessment. No measurement was found for the peripheral nerve disorder group.  
 
 
We found the following instruments used for analysis: 
Individual Quality of Life Questionnaire (INQOL) 
The INQOL is a measurement developed to assess HRQOL among patients with muscle disorders14 
and consists of 42 questions within ten domains. Four of the domains focus on the impact of key 
muscle disease symptoms (weakness, locking, pain, and fatigue), five of the domains concern the 
impact on particular areas of life (e.g., independency, relationships, body image), and one domain 
concerns the effects of treatment. The test-retest reliability demonstrated good stability14 in eight 
subscales. In an Italian study, the Cronbach’s alpha was estimated twice in the test-retest sample. In 
both cases its values were high, varying from 0.88 to 0.95.27 
 
Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) 
The ALSAQ-40 is a measurement developed to assess HRQOL among patients with amyotrophic 
lateral sclerosis, a disease within the motor neuron disorder group.28 The ALSAQ-40 consists of 40 
questions within five domains, namely: (i) Eating and Drinking, (ii) Communication, (iii) 
ADL/Independence, (iv) Physical Mobility, and (v) Emotional Well-being. The internal reliability 
coefficients of the five ALSAQ-40 dimensions at both administrations were all above the 0.91.28 In 
an Italian study, the ALSAQ40 scales showed good internal consistency (Cronbach’s alpha 
>0.86).29 
 
Myasthenia Gravis Quality of Life 60 (MGQOL-60) 
The MGQOL-60 is a measurement developed to assess HRQOL among patients with a junction 
disorder. The MGQOL-60 consists of 60 questions derived from interviews with experts and patient 
focus groups. Items were grouped into seven domains: (i) Mobility, with nine items, Cronbach’s 
alpha = .89; (ii) Symptoms, with eight items, Cronbach’s alpha = .74; (iii) Emotional Well-being, 
with eleven items, Cronbach’s alpha = .88; (iv) General contentment, with seven items, Cronbach’s 
alpha = .74; (v) Thinking and Fatigue, with four items, Cronbach’s alpha = .91; (vi) Family/social 
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well-being, with nine items, Cronbach’s alpha = .72; and (vii) Additional concerns, with twelve 




We identified 142 concepts in the three HRQOL measurements: 42 concepts were derived from the 
INQOL, 40 concepts from the ALSAQ-40, and 60 concepts from the MGQOL-60.  
Results of the linking procedure are provided in Tables 1-4, showing the content of the ICF 
components of “Body Function and Structures”, “Activities”, “Participation”, and “Environmental 
Factors”, respectively.  
 
Newly identified ICF categories not covered by the initial ICF Core Set 
The initial ICF Core Set did not cover seven concepts. One newly identified ICF category was 
found in two measuring instruments (INQOL and MGQOL-60): Muscle endurance functions 
(b740).  
From the MGQOL-60, three other concepts could not be linked to categories in the initial ICF 
Core Set: Functions of structures adjoining the eye (b215), Driving (a475), and Friends (e320). 
From the ASLSAQ-40, three concepts could be linked to the ICF categories: Voice functions 
(b310), Fluency and rhythm of speech functions (b330), and Climbing (a4551).  
 
Measurement concepts not covered by the ICF 
Six concepts could not be linked to an ICF category. Three concepts from the INQOL: (i) 
“Independency” (in the question “Your independence”), (ii) “Appearance” (in the question “The 
way you look”), and (iii) “All kinds of activities” (in the question “Things you do”); and three 
concepts from the MGQOL-60: (i) “Bedridden” (in the question “I am forced to spend time in 
 
 
bed”), (ii) “I am satisfied with my sex life”, and (iii) “I am proud of how I am coping with my 
illness”.  
 
Table 1 The number of categories belonging to the component of “Body Function and Structures” 
associated with INQOL, MGQOL-60 and ALSAQ-40 items 
ICF category INQOL MGQOL-60 ALSAQ-40 
 Mental functions  
b1300 Energy level -# 4 - 
b134 Sleep functions - 1 - 
b140 Attention functions - - - 
b144 Memory functions - - - 
b152 Emotional functions 3## 19 12 
b160 Thought functions - 1 - 
 Sensory functions and pain  
b210 Seeing functions - - - 
b280 Sensation of pain 4 - 1 
 Voice and speech functions    
b320 Articulation functions - 1 2 
 Functions of cardiovascular and respiratory systems  
b455 Exercise tolerance functions 4 1 1 
 Ingestion functions  
b5105 Swallowing - - 1 
b525 Defecation functions - - - 
 Genitourinary and reproductive functions  
b620 Urination functions - - - 
b640 Sexual functions - - - 
 Muscle and movement functions  
b730 Muscle power functions 4 2 - 
b735 Muscle tone functions 4 - - 
b740 Muscle endurance functions* 3 3 - 
b760 Control of voluntary movement functions - - - 
b765 Involuntary movements functions - - - 
b770 Gait pattern functions - - - 






* Newly added ICF category; #a dash indicates the ICF category is not addressed by the  
 HRQOL measurement concept; ## a digit indicates the frequency at which an ICF category 
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Table 1 The number of categories belonging to the component of “Body Function and Structures” 
associated with INQOL, MGQOL-60 and ALSAQ-40 items 
ICF category INQOL MGQOL-60 ALSAQ-40 
 Mental functions  
b1300 Energy level -# 4 - 
b134 Sleep functions - 1 - 
b140 Attention functions - - - 
b144 Memory functions - - - 
b152 Emotional functions 3## 19 12 
b160 Thought functions - 1 - 
 Sensory functions and pain  
b210 Seeing functions - - - 
b280 Sensation of pain 4 - 1 
 Voice and speech functions    
b320 Articulation functions - 1 2 
 Functions of cardiovascular and respiratory systems  
b455 Exercise tolerance functions 4 1 1 
 Ingestion functions  
b5105 Swallowing - - 1 
b525 Defecation functions - - - 
 Genitourinary and reproductive functions  
b620 Urination functions - - - 
b640 Sexual functions - - - 
 Muscle and movement functions  
b730 Muscle power functions 4 2 - 
b735 Muscle tone functions 4 - - 
b740 Muscle endurance functions* 3 3 - 
b760 Control of voluntary movement functions - - - 
b765 Involuntary movements functions - - - 
b770 Gait pattern functions - - - 






* Newly added ICF category; #a dash indicates the ICF category is not addressed by the  
 HRQOL measurement concept; ## a digit indicates the frequency at which an ICF category 








Table 2 The number of categories belonging to the component of “Activities” associated with INQOL, 
MGQOL-60, and ALSAQ-40 items 
ICF category INQOL MGQOL-60 ALSAQ-40 
 Communication  
a330 Speaking -# - 1 
a350 Conversation - - - 
a360 Using communication devices and techniques - - - 
 Mobility  
a410 Changing basic body position - - 3 
a415 Maintaining a body position - - - 
a420 Transferring oneself - - - 
a440 Fine hand use - - 2 
a445 Hand and arm use - - 2 
a450 Walking and moving - 1 5 
a465 Moving around using equipment - - - 
a470 Using transportation - - - 
 Self-care  
a510 Washing oneself - - 1 
a520 Caring for body parts - 1 1 
a530 Toileting - - - 
a540 Dressing - - 1 
a550 Eating - 1 2 
a560 Drinking - - 1 
a570 Looking after one’s health - 1 - 
 Domestic life    
a630 Preparing meals - - - 
a640 Doing housework - - 1 
 Community, social and civic life    
a920 Recreation and leisure 1## - - 
#a dash indicates the ICF category is not addressed by the HRQOL measurement concept;  
## a digit indicates the frequency in which an ICF category was addressed by an HRQOL  
measurement concept  
 
 
 Table 3    The number of categories belonging to the component of “Participation” associated with  
      INQOL, MGQOL-60, and ALSAQ-40 items 
ICF category INQOL MGQOL-60 ALSAQ-40 
 Communication  
p350 Conversation -# - 1 






 Mobility  
p465 Moving around in different locations - - - 
p470 Using transportation - - - 
 Self-care  
p510 Washing oneself - - - 
p520 Caring for body parts - - - 
p530 Toileting - - - 
p540 Dressing - - - 
p570 Looking after one’s health - - - 
 Domestic life  
p610 Acquiring a place to live - - - 
p630 Preparing meals - - - 
 Interpersonal interactions and relationships  
p750 Informal social relationships 5## - - 
p760 Family relationships 3 1 - 
p770 Intimate relationships - - - 
 Major life areas    
p850 Remunerative employment 1 1 - 
 Community, social and civic life    
p910 Community life - 1 - 
p920 Recreation and leisure - 1 - 
#a dash indicates the ICF category is not addressed by the HRQOL measurement concept;  
## a digit indicates the frequency in which an ICF category was addressed by an HRQOL  
measurement concept 
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Table 4 The number of categories belonging to the component of “Environmental Factors” associated with 
INQOL, MGQOL-60, and ALSAQ-40 items 
ICF category INQOL MGQOL-60 ALSAQ-40 
 Products and technology  








e120 Products and technology for personal indoor and 







e125 Products and technology for communication - - - 
e155 Design, construction and building products and 







 Support and relationships  
e310 Immediate family - 6 - 
e340 Personal care providers and personal assistants - - - 
 Services, systems and policies  
e5400 Transportation services - - - 
e5700 Social security services - - - 
e5702 Social security policies - - - 
e580 Health services, systems and policies 7## 6 - 
#a dash indicates the ICF category is not addressed by the HRQOL measurement concept;  
## a digit indicates the frequency in which an ICF category was addressed by an HRQOL  
measurement concept  
 
 
Categories in the initial ICF Core Set not covered by the measurement concepts 
In total 58 categories of the initial ICF Core Set were not covered by the concepts in the INQOL: 
fifteen categories for the “Body Function and Structures” component, twenty categories for the 
“Activities” component, fourteen categories for the “Participation” component, and nine categories 
for the “Environmental Factors” component. 
In total 51 categories of the initial ICF Core Set were not covered by the concepts in the 
ASLSAQ-40: fifteen categories of the “Body Functions and Structures” component, ten categories 
of the “Activities” component, sixteen categories of the “Participation” component, and ten 
categories for the “Environmental Factors” component.  
In total 49 categories of the initial ICF Core Set were not covered by the concepts in the 
MGQOL-60: twelve categories of the “Body Functions and Structures” component, seventeen 
categories of the “Activities” component, thirteen categories of the “Participation” component, and 
seven categories of the “Environmental Factors” component. 
 
 
Final NMD Core Set 
As a result the ICF category, “Muscle endurance function” (b740) was added to the “Body 
Functions and Structures” component of the initial ICF Core Set. The final NMD Core Set now 
consists of 69 “very relevant” categories, belonging to the ICF components: “Body Functions and 
Structures” (21 categories), “Activities” (21 categories), “Participation” (17 categories), and 
“Environmental Factors” (10 categories).  
 
Discussion 
The objective of this study was to examine the content validity of the initial ICF Core Set for the 
NMDs.  
Based on our findings, we can conclude that the initial ICF Core Set covered all the relevant 
health problems of NMDs except for one “Body Function” category. The final NMD Core Set 
consists of 69 ICF categories that belonged to all ICF components.  
In comparison with concepts in the disease-specific HRQOL measurement instruments, the 
NMD Core Set has a broader scope, especially for the “Participation” and “Environmental Factors” 
components. The under representation of “Environmental Factors” in the three HRQOL 
measurements was also found in comparable studies using an HRQOL measurement for stroke31, 
and multiple sclerosis measurement.23  
As a result of this study, we were able to add an important category to complete the NMD Core 
Set: “Muscle endurance functions” (b740). Furthermore, in clinical practice this is an important and 
recognizable issue. Fatigue and muscle weakness have a major impact on the functioning of NMD 
patients.  
Some concepts belonging to “Personal Factors” – such as “Independency”, “Appearance”, 
“Coping”, and “Satisfaction” – could not be linked to ICF categories, because “Personal Factors” 
have not been classified in the ICF up until now.  
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 We decided to use HRQOL measuring instruments for the validation of the initial ICF Core Set 
because of the expected broad scope of these questionnaires. However, it turned out that these 
instruments were few in number. Furthermore, we found that each of these measuring instruments 
mainly focused on one specific ICF component. For example, the ASLSAQ-40 has a strong focus 
on the “Activity” component, while the INQOL gears its focus towards the “Body Functions” 
component, and the MGQOL-60 mainly focuses on the “Body Functions” component. These 
findings further justify our intention to develop a new ICF-based functional health-status 
measurement with a broad and balanced scope that includes all ICF components. 
We think the methods and procedures applied contributed in a positive way to the results of our 
study. There are reasons for assuming this. First, because we validated the initial ICF Core Set that 
was meticulously developed in a Delphi study, in which the ICF categories were selected by a 
varied and extensive Delphi panel. Second, we applied a proven method to evaluate the content 
validity of this initial ICF Core Set by linking concepts from established disease specific measuring 
instruments, representing three of the four NMD-classification groups, to the items in the initial ICF 
Core Set. Finally, a reliable linking procedure was carried out by experts in NMDs and ICF so that 
all relevant expertise was present.  
As a consequence of the meager number of disease-specific measuring instruments with a broad 
scope available, one potential limitation of this study is that we could not find an established 
measurement for the NMD peripheral nerve disorders group. Therefore, we were not able to 
validate the initial ICF Core Set for this group of NMDs. However, considering our findings for the 
other three groups, we think that no essential items are missing in our final NMD Core Set. 
In the ICF, the “Activity” and “Participation” components are listed together. In this context the 
NMD Core Set does not consist of 69 but of 59 ICF categories, because ten categories are listed in 
both components. For example, for the “Recreation and Leisure” category d920, we made a 
distinction between a920, “Can you participate in recreation and leisure”? (Capacity) and p920, “Do 
you take part in recreation and leisure”? (Performance).  
 
 
We decided to apply the distinction between both components (Table 2 and Table 3) with respect to 
the participants in the Delphi study and the initial ICF Core Set (23). Furthermore, Jette and 
colleagues32 identified distinct concepts within physical functioning that conformed to the 
components “Activity” and “Participation” as proposed in the ICF. Another important reason for 
our decision was that the distinction between these components is common in HRQOL measuring 
instruments and is reflected in the domains of physical and social functioning. This distinction is 
also relevant for the development of the next step, an ICF-based questionnaire.  
Our choice for the biomedical classification of Rowland (1) could provide a potential limitation 
because of its medical focus. Therefore, this classification may not accurately portray the 
consequences of the disease, namely, functioning and disabilities. However, based on our findings, 
we can now conclude that the NMD Core Set is a consensus set for functioning and disabilities for 
all NMDs.  
The ICF proved to be a useful classification for the linking of the concepts in the HRQOL 
questionnaires.26 The ICF categories concerning mobility and muscles are goals of nursing 
interventions both in specialized rehabilitation nursing as well as in general health care.17 The 
newly developed NMD Core Set can be a basis for enhancing the development of rehabilitation 
interventions and improving overall health care for patients with an NMD. 
Based on our findings, we can conclude that the NMD Core Set is a valid selection of categories 
reflecting a broad scope of functioning and disabilities related to NMD, one that is broader than the 
established disease-specific HRQOL measuring instruments, especially in terms of the components 
of “Participation” and “Environmental Factors”. Therefore, the NMD Core Set provides a solid 
basis for the development of a health-status measuring instrument reflecting the most relevant 
aspects of functioning and health for patients with NMDs.  
Conclusion, the NMD Core Set as well as a measurement based on this Core Set can contribute 
to a better understanding of the NMDs and can also serve as a basis for clinical practice, research, 
social security systems, and educational programs. 
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Objectives: To develop a measure that is based on the International Classification of Functioning, 
Disability and Health (ICF), and reflects the prevalence and severity of disabilities related to 
neuromuscular disorders, and to evaluate the psychometric properties of this measure. 
Methods: A preliminary questionnaire was developed, based on the categories of the ICF Core Set 
for Neuromuscular Diseases. Next a cross sectional postal survey was carried out among 702 
patients (70% response rate) diagnosed with a neuromuscular disease. Finally, psychometric 
properties were examined. 
Results: The preliminary Neuromuscular Disease Impact Profile (NMDIP) consisted of 45 items. 
Factor analysis showed that the NMDIP comprised domains representing 3 ICF-components: 5 
factors in the Body Functions component, and 2 factors in the Activities component, and 1 factor in 
the Participation component. Scales showed moderate to good internal consistency (α=0.63-0.92) 
and mean inter-item correlation coefficients (0.38-0.77). Convergent and discriminant validity 
analysis indicated that the NMDIP measures the impact of neuromuscular disease on physical, 
mental, and social functioning. The NMDIP discriminates between groups who differ in extent of 
limitations.  
Conclusion: The NMDIP is an ICF-based measure that reflects the neuromuscular disease-related 
disabilities. It consists of 36 items divided over 8 scales with satisfactory psychometric properties 
and 4 single items.  
 
Keywords 
Neuromuscular disease; Health measure; International Classification of Functioning Disability and 




Neuromuscular diseases (NMD) may be acquired or hereditary. Causes are dysfunction of the 
anterior horn cell or sensory ganglion cell (neuronopathy), peripheral nerve (neuropathy), 
neuromuscular junction (myasthenia), or muscle (myopathy).1 Common symptoms of 
neuromuscular diseases include muscle weakness, impairment in muscle endurance, involuntary 
muscle activity (stiffness, myotonia, cramp, and fasciculation), sensory loss, autonomic dysfunction 
and impairment in control of voluntary movements. Sensations of pain and fatigue are common 
consequences of these muscle and nerve disturbances.2, 3 These symptoms have a profound impact 
on daily activities and participation in life situations.4, 5  
In clinical practice and research there is a need for reliable and validated assessment tools as well 
as outcome measures that cover the broad range of health problems in neuromuscular patients.6  
Over the last two decades many health measurement instruments have been developed for use 
both in clinical practice and in research. As a result, there are generic health-related quality of life 
(HRQoL) instruments with a broad scope, for example, the Medical Outcome study Short Form 
Questionnaire (SF-36).7 An example of a disease-specific HRQoL instrument with a broad scope is 
the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40).8 In addition, there are 
generic and domain-specific measures to assess limitations in daily living, for example the 
Groningen Activity Restriction Scale (GARS)9, or to assess participation in life situations, for 
example, the Impact on Participation and Autonomy Questionnaire (IPAQ).10  
The International Classification of Functioning, Disability, and Health (ICF) is a classification 
developed by the World Health Organization (WHO) and aims at providing a unified and 
standardized language for describing and classifying health domains and health-related states, and 
hence providing a common framework for the development of health outcome measures.11, 12 
The ICF comprises 4 key components. The first component, Body Functions and Structures, 
refers to functions of body systems, and to anatomic parts. The second component, Activities, refers 
to “task or action execution by the individual”. The third component, Participation, refers to 
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“involvement in life situations”. The Environmental Factors that interact with these 3 components, 
are described in the fourth component of the ICF.11  
In the model of functioning that underlies the ICF classification system, the components body 
functions and structures, activities and participation are summarized under the concepts 
“functioning” and “disability”. These are associated both with health status and with personal and 
environmental factors. Functioning is an umbrella term encompassing all body functions, activities 
and participation. Similarly, disability is an umbrella term for impairments in body functions, 
limitations in activities and restrictions in participation.11 ICF Core Sets have been the first 
approach to providing ICF-based instruments for clinical practice and research.13 An example of 
such ICF-based measures is the Multiple Sclerosis Impact Profile (MSIP).14 This measurement 
instrument has shown to be a feasible assessment tool in practice and psychometrically sound 
measures in research. To the best of our knowledge there is no broad ICF-based health measure 
covering all 600 NMDs. Therefore the aim of this study was to develop an ICF-based measure, the 
Neuromuscular Disease Impact Profile (NMDIP), with the intention of reflecting the prevalence and 
severity of a broad range of disabilities related to neuromuscular diseases, using the ICF features 







Sample and procedures 
A cross-sectional postal survey was conducted among patients diagnosed with a neuromuscular 
disease and registered at the department of Neurology of the University Medical Center Groningen, 
the Netherlands. Criteria for inclusion were: diagnosed with a neuromuscular disease, aged 18 years 
or older, and able to read and write in Dutch.  
In total 1003 eligible patients were selected from the hospital patient record system with the aim 
of representing the four major NMD groups defined by Rowland: motor neuron disorders, muscle 
disorders, junction disorders and, peripheral nerve disorders.15 To prevent any inappropriate sending 
of the questionnaire, we crosschecked for deceased patients using the national population register.  
Patients received information about the study and were invited to participate. Respondents 
completed the preliminary NMDIP, generic and domain-specific questionnaires, along with some 
demographic and disease-specific questions. Reminders were sent out after two weeks.  
Ethical approval was obtained from the local ethics committee. Reference: METc 2009.310. 
 
Preliminary NMDIP 
The preliminary NMDIP was developed as a disease-specific and ICF-based measure to assess 
disability among patients with an NMD. We used the 69 ICF categories of the NMD-Core Set.3 
These categories are divided over the 4 ICF components. Selected categories were operationalized 
in order to estimate the patient’s objectified opinion (impairment in body functions, limitations in 
activities or restrictions in participation) of the incidence and severity of a disability, and to estimate 
the support from relevant environmental factors. Furthermore, ICF terminology for “disabilities” 
was applied, ICF item labels were used when formulating the subject of the question (e.g., 
“urination” functions instead of “bladder” functions), and ICF codes (e.g., b280 or p920) were 
documented for each question.(14) Illustrative examples were annexed (using fourth-level ICF-
items) to some questions to ensure an adequate response. To record the presence and severity of a 
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problem in functioning, we applied response scales with scoring options specified for each ICF 
component, based on “qualifiers” proposed by the ICF.14  
The preliminary questionnaire was reviewed by patients, clinicians, nurse specialists, experts on 
the ICF and methodologists (n=24) for clarity, comprehensiveness, redundancy and patient burden. 
A modified questionnaire was pre-tested in a random sample of 3 clinicians and 50 patients who 
were not involved in the first appraisal of the questionnaire. Unclear or ambiguous items and 
instructions were identified and some modifications of the questionnaire were made.  
Finally, the preliminary NMDIP reflects an objectified view of the prevalence and severity of 
NMD-related disabilities and consists of 45 items representing the 4 ICF components.  
 
Measurement instruments 
For evaluating the psychometric properties of the NMDIP, 2 generic and 2 domain-specific 
measures were used.  
The SF-36 is a broad and generic HRQOL measure that consists of 36 items divided over 8 
domains.7 For each domain, item scores were transformed to a scale that ranges from 0 (worst 
health) to 100 (best health). In a previous study among Dutch multiple sclerosis patients the SF-36 
domains showed satisfactory levels of internal consistency: Cronbach’s alpha ranged between 0.74 
and 0.96.14 
The World Health Organization Quality Of Life (abbreviation version) (WHOQOL-BREF) is a 
broad and generic measure of global QoL16, and consists of 26 items divided over 4 domains. For 
each domain, item scores were transformed to a scale that ranges from 0 (worst health) to 20 (best 
health). In a previous study among Dutch multiple sclerosis patients the WHOQOL-BREF showed 
good levels of internal consistency: Cronbach’s alpha ranged between 0.80 and 0.81.14 
The GARS is a domain-specific instrument to measure limitation, and consists of 18 items 
divided over 2 domains.9 A 4-category response format is used, ranging from 1 (no problem in 
performing without help) to 4 (impossible to perform). Scores are summed for each subscale. The 
 
 
GARS showed strong levels of internal consistency: Cronbach’s alpha ranged between 0.95 and 
0.97 in a study in a Dutch sample of multiple sclerosis patients.14 
The IPAQ is a domain-specific questionnaire focusing on person-perceived participation and 
autonomy.10, 17 The instrument assesses 2 aspects of participation: perceived participation and the 
perceived problem. In this study we applied the perceived participation part that consists of 24 items 
divided over 5 domains. Items are scored on a 5-point rating scale with discrete responses, ranging 
from 1 (very good) to 5 (very poor). Scores are summed for each domain. In a previous study 
among Dutch multiple sclerosis patients, the IPAQ showed good levels of internal consistency: 
Cronbach’s alpha ranged between 0.86 and 0.94.14 
 
Item reduction  
Exploratory factor analysis with oblique rotation (Geomin)18, 19 was used to examine whether the 
domains measured by the NMDIP represent the 4 ICF components. To improve the content validity 
the prevalence of each item was examined before entering items in the factor analysis. Items with a 
low prevalence (≤ 20%) were excluded from further analysis.20, 21 Factor analyses were performed 
using Mplus 6 software.18 Given the categorical nature of the variables, methods based on 
polychoric correlations and the robust-weighted least squares estimators22 were used. Goodness-of-
fit of the underlying factorial structure was measured by the root mean squared error of 
approximation (RMSEA, adequate if below 0.06) and the standardized root mean square residual 
(SRMR, adequate if below 0.08), the Comparative Fit Index and the Tucker-Lewis Index. For the 
latter 2 indices, it is recommended that values should be greater than 0.95.19, 23 Items with factor 
loadings ≥0.40 were selected for scale construction. 
Items that could not meet the criteria of scalability were taken into consideration for use as a 
single indicator.  
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The maximum number of missing items allowed to be replaced by the mean scale score was 
determined by a sufficient Cronbach’s alpha in relation to the number of scale items.21, 24  
 
Psychometric evaluation 
The distribution of scale scores was evaluated by calculating the median, mean and standard 
deviation and observed score range. Proportion of patients with worst and best possible scores (floor 
and ceiling effect) were calculated. Proportions ≤20% were considered acceptable.20 
Internal consistency was examined with Cronbach’s alpha25 and the mean inter-item correlation 
coefficient (MICC) for each scale.26, 27 Alpha was considered sufficient if ≥ 0.70.28, 29, and MICC if  
≥ 0.30.26  
To test whether NMDIP scales measure physical, psychological, social, and environmental 
domains of functioning, as they purport to measure, convergent and discriminant validity were 
assessed by examining the extent to which correlation values between NMDIP scales and 
concurrent measures were consistent with hypotheses.30, 31 Regarding convergent validity, we 
hypothesized that the NMDIP scales would have a strong correlation (≥0.70)32 with scales that 
cover the same domain in concurrent measures. For example, NMDIP scales for physical functions 
should correlate highly with the SF-36 “Physical Functioning scale”. To support discriminant 
validity, we hypothesized that the NMDIP scales would correlate weakly (<0.40) with scales 
measuring different domains in NMDIP or concurrent measures. For example, NMDIP scales for 
physical function would correlate weakly with mental or emotional scales of the SF-36. 
Regarding known-groups validity30, 31, we hypothesized that the NMDIP scales should be able to 
discriminate between subgroups of respondents known to differ on relevant clinical characteristics. 
The level of limitations due to a neuromuscular disease was used to create such relevant subgroups 
of respondents. Therefore, the generic question “Extent of limitations” was used. Respondents were 
asked to answer the question “To what extent are you limited due to a neuromuscular disease?” on 
 
 
an 11-point scale with a score range from 0 (not limited at all) to 10 (severely limited). Next, 
respondents were divided into 2 groups: those with a “lower extent of limitations” (score 1-4), and 
those with a “higher extent of limitations” (score 5-10).  
 
Statistics 
Patient characteristics were analysed using descriptive statistics. Spearman’s correlation coefficient 
(rho) was used to examine convergent and discriminant validity. Known-groups validity was 
assessed using the independent Mann-Whitney U test.  
To estimate the magnitude of the difference in scores between subgroups of respondents, the 
nonparametric effect size (coefficient r) for unrelated samples was calculated for statistically 
significant group differences (alpha=0.05).33 Coefficient r is calculated by dividing the z statistic 
(obtained from the Mann-Whitney U test) by the root of the sample size (n). To interpret the 
nonparametric effect sizes using coefficient r. Cohen suggested the following thresholds for 
interpretation: an r of < 0.10 indicates a trivial effect, an r of ≥ 0.10 to < 0.24 a small effect, an r of 
≥ 0.24 to < 0.37 a moderate effect, and an r ≥ 0.37 a large effect. An r ≥ 0.10 reflects a clinically 




In total 702 participants (70% response rate) completed the questionnaires. Demographics and 
disease-specific characteristics are described in Table 1. Average age was 59 years (SD 16, range 
19-92 years), while slightly more than half of the patients were younger than 65 years. Mean 
number of “Years since diagnosis” was 12 years (SD 11, range 0-65 years).  
Approximately 30% of the patients were retired due to a neuromuscular disease. The motor 
neuron disorder subgroup was a relatively small sample compared with the other neuromuscular 
disease subgroups according to the classification of Rowland.15 
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nonparametric effect size (coefficient r) for unrelated samples was calculated for statistically 
significant group differences (alpha=0.05).33 Coefficient r is calculated by dividing the z statistic 
(obtained from the Mann-Whitney U test) by the root of the sample size (n). To interpret the 
nonparametric effect sizes using coefficient r. Cohen suggested the following thresholds for 
interpretation: an r of < 0.10 indicates a trivial effect, an r of ≥ 0.10 to < 0.24 a small effect, an r of 
≥ 0.24 to < 0.37 a moderate effect, and an r ≥ 0.37 a large effect. An r ≥ 0.10 reflects a clinically 




In total 702 participants (70% response rate) completed the questionnaires. Demographics and 
disease-specific characteristics are described in Table 1. Average age was 59 years (SD 16, range 
19-92 years), while slightly more than half of the patients were younger than 65 years. Mean 
number of “Years since diagnosis” was 12 years (SD 11, range 0-65 years).  
Approximately 30% of the patients were retired due to a neuromuscular disease. The motor 
neuron disorder subgroup was a relatively small sample compared with the other neuromuscular 
disease subgroups according to the classification of Rowland.15 




Table 1 Sample characteristics (n = 702) 
Variable Total sample 
Gender (%)  
 Female 350 (50) 
 Male 352 (50) 
 Age, years mean (SD)[range] 59(16)[19-92] 
 Years since diagnosis MEAN (SD) [range]  12 (11) [0-65] 
Relationship status (%)  
 Relationship (married/partnership) 498 (71) 
 Single (unmarried/widowed/divorced) 186 (27) 
Educational level (%)  
 Primary school/vocational training  235 (33) 
 Secondary school/vocational training  270 (38) 
 Higher education/vocational training  161 (23) 
 University    28 (4) 
Employment status (more answers possible) (%)  
 Enrolled in a training or study course    36 (5) 
 Employment (part-time or full-time) 173 (25) 
 Voluntary work (part-time or full-time)   42 (6) 
 (Partially) retired due to NMD 213 (30) 
 Housewife/househusband 171 (24) 
 Retired due to age 244 (35) 
NMD category (%)  
  Motor neuron disorder    43 (6) 
  Muscle disorder  154 (22) 
  Junction disorder  234 (33) 
  Peripheral nerve disorder  271 (39) 
NMD: neuromuscular diseases; SD=standard deviation. 
 
Non-respondents did not differ from respondents in terms of gender, but were significantly 
younger (mean 53, SD 19 years) than respondents (mean 59, SD 16 years).  
 
Content validity 
Nine of the original 45 items showed a low prevalence (≤ 20%) and were not entered in the factor 
analysis. These items were from the component “Activities” (“a350 Conversation”, “a360 Using 
communication devices and techniques”, and “a465 Moving around using equipment”), the 
component “Participation” (p510-p540 items concerning “Personal care”, “p360 Communication 
devices and techniques, “p630 Eating and drinking”,  “p610 Acquiring a place to live”, and “p850 
Remunerative employment”), and from the component “Environmental Factors” (“e340 Personal 





The EFA models showed a (very) good fit for the 5-factor model for the Body Functions 
component, the 2-factor model for the Activities component, and the 1-factor model for the 
Participation component. Comparative Fit Index and Tucker-Lewis Index values were above 0.95, 
SRMR values were below 0.08 as recommended. The RMSEA values were below 0.06 for the 
Body Functions component and Participation component, while the value for the Activities  
component was slightly higher (0.069) but still acceptable. For the Environmental Factors 
component no satisfying fit was found. Factor analysis reduced the remaining 36 items of the initial 
NMDIP to 32 items: 
 Five factors within the Body Functions component included 15 items (Table 2). 
Interpretation of item content, using the ICF first- and second level category labels led to the 
following scale labels: “Muscle Functions” (MuF), “Movement Functions” (MoF), 
“Swallowing and Speech Functions” (SSF), “Excretion and Reproductive Functions” (ERF), 
and “Mental Functions and Pain” (MFP). 
  Two factors within the Activities component included 14 items (Table 3)These factors were 
given the labels, “Activities of Moving around”(AMA) and “Self-care and Domestic 
Activities” (SDA).  
 One factor within the Participation component included 3 items (Table 4). This factor was 
labelled “Participation in Life Situations” (PLS). 
 
Finally the Body Functions component items “Seeing functions” and the Environmental 
Factor component items “Immediate family”, “Social security services”, and “Health services” with 
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Table 2 Factor Analysis with Body Functions component categories (n=702) 
 Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 
Muscle Functions (MuF)       
Impairment in…      
 b730 Muscle power functions 0.612 0.473 0.032 0.015 -0.054 
 b740 Muscle endurance functions 0.677 0.329 -0.003 -0.020 0.195 
Movement Functions (MoF)      
Impairment in…      
 b760 Control of voluntary movements functions 0.009 0.777 -0.100 0.023 -0.038 
 b765 Involuntary movements functions -0.315 0.849 0.106 -0.022 0.044 
 b780 Sensation related to muscles and movement 0.045 0.590 -0.041 0.053 0.198 
Swallowing and speech functions(SSF)      
Impairment in…      
 b320 Speech functions 0.024 0.144 0.842 0.008 -0.013 
 b5105 Swallowing functions 0.246 -0.035 0.687 0.053 0.054 
Excretion and reproductive Functions(ERF)      
Impairment in…      
 b525 Defecation functions 0.022 -0.030 -0.002 0.656 0.168 
 b620 Urination functions -0.052 0.028 0.036 0.785 -0.032 
 b640 Sexual functions 0.046 0.281 0.026 0.426 0.043 
Mental Functions and Pain(MFP)      
Impairment in…      
 b134 Sleep functions -0.028 -0.008 -0.055 0.091 0.680 
 b1300 Fatigue 0.460 0.019 0.062 0.011 0.593 
 b152 Emotional functions -0.020 -0.014 0.100 -0.148 0.725 
 b160 Thought functions -0.230 0.040 0.259 0.023 0.539 
 b280 Sensation of pain  0.078 0.267 -0.238 0.040 0.527 
Bold figures are sufficient factor loadings selected for scale construction. 
 
Table 3 Factor Analysis with Activities component categories (n=702) 
 Factor 1 Factor 2 
Activities of Moving around (AMA)   
Limitations in…   
  a410  Changing body position 0.860 0.005 
 a415  Maintaining body position 0.639 0.270 
  a420  Transferring oneself 0.711 0.251 
 a450  Walking  0.952 -0.035 
 a470  Using transportation 0.589 0.330 
 a920  Recreation and leisure 0.411 0.354 
Self-care and Domestic Activities (SDA)   
Limitations in…   
 a440  Fine hand use -0.003 0.758 
 a445  Hand and arm use -0.102 0.894 
 a510  Washing oneself 0.272 0.709 
 a520  Caring for body parts -0.007 0.904 
 a530  Toileting 0.335 0.585 
 a540  Dressing 0.200 0.754 
 a630  Preparing meals 0.057 0.863 
 a640  Doing housework 0.398 0.458 




Table 4 Factor analysis with Participation components (n = 702) 
 Factor 1 
Participation in Life Situations(PLS) 
Restriction in… 
 
 p460/p470   Mobility  0.690 
 p740-p760  Relationships  0.719 
 p910/p920  Recreation and leisure 0.903 
Bold figures are sufficient factor loadings selected for scale construction. 
 
Scale features are shown in Table 5. Internal consistency for seven NMDIP scales for the total 
sample was good and moderate for one scale. Cronbach’s alpha ranged from 0.63 to 0.92 and mean 
inter-item correlation coefficient ranged from 0.38 to 0.77. Four scales showed a high floor effect. 
The NMDIP scales within the NMD groups showed acceptable to good internal consistency.  
(Table 6). For some scales the Cronbach’s alpha was weak but this was compensated by a sufficient 
mean inter-item correlation coefficient, except for the “Swallowing and Speech Functions” scale in 
the peripheral nerve disorder group and the “Excretion and Reproductive Functions” scale in the 
muscle disorder group.   
 The final version of the NMDIP consists of 36 items divided over 8 scales and 4 single 
items. (See Appendix I). 
 















Median  Mean SD Alpha MICC 
NMDIP scales            
  Muscle Functions 658 2 0-8 0-8 8 3 4 3.4 1.9 0.87 0.77 
  Movement Functions 594 3 0-12 0-12 18 0 2 2.4 2.1 0.72 0.47 
  Swallowing and Speech  Functions  669 2 0-8 0-6 59 1 0 0.7 1.1 0.69 0.53 
  Excretion and Reproductive  Functions 509 3 0-12 0-12 27 0 1 1.8 3.1 0.63 0.38 
  Mental Functions and Pain  597 5 0-20 0-16 7 0 4 1.8 1.8 0.80 0.59 
  Activities of Moving around  702 6 0-18 0-18 18 2 4 5.1 4.8 0.90 0.62 
  Self-care and Domestic Activities  701 8 0-24 0-24 28 1 2 4.7 6.0 0.92 0.59 
  Participation in Life   Situations  695 3 0-12 0-12 49 0 1 1.7 2.4 0.72 0.47 
NMDIP single item            
  Seeing functions 666 1 0-4 0-4   0 0.68 0.88   
  Immediate family 697 1 0-2 0-2   0 0.51 0.73   
  Social security services 268 1 0-2 0-2   1 0.74 0.77   
  Health services 693 1 0-2 0-2   0 0.66 0.75   
MICC=mean inter-item correlation coefficient. SD=standard deviation. 
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Table 6 Internal consistency (Cronbach’s alpha) and the mean inter-item correlation coefficient (MICC) of 
the Neuromuscular Disease Impact Profile (NMDIP) scales per neuromuscular diseases group 








 Alpha MICC Alpha MICC Alpha MICC Alpha MICC 
Muscle Functions 0.86 0.77 0.79 0.67 0.87 0.78 0.86 0.76 
Movement Functions 0.72 0.48 0.72 0.48 0.67 0.42 0.67 0.41 
Swallowing and Speech Functions 0.82 0.72 0.74 0.59 0.63 0.47 0.42 0.27 
Excretion and Reproductive Functions 0.71 0.47 0.54 0.30 0.63 0.36 0.68 0.45 
Mental Functions and Pain 0.69 0.34 0.77 0.40 0.73 0.36 0.72 0.33 
Activities of Moving around 0.90 0.62 0.90 0.60 0.85 0.50 0.90 0.59 
Self-care and Domestic Activities 0.95 0.69 0.93 0.63 0.83 0.43 0.88 0.47 
Participation in Life Situations 0.80 0.57 0.74 0.49 0.67 0.40 0.67 0.41 
 
Psychometric testing 
Table 7 provides evidence of convergent and discriminant validity for the NMDIP scales, reflecting 
the impact of a neuromuscular disease on physical, psychological, and social aspects of functioning. 
The predictions were consistent with the direction, magnitude, and patterns of correlations.  
Convergent validity was supported by a strong correlation between the NMDIP “Muscle 
Functions” scale and the SF-36 “Physical Functioning” scale, and a strong correlation between the 
NMDIP “Activities of Moving Around” and “Self-care and Domestic Activities” scales, and the 
GARS “Activities of Daily Living” and “Instrumental Activities of Daily Living” scales. The 
NMDIP “Participation in Life Situations” scale was moderately correlated with the IPAQ 
participation scales.  
Discriminant validity was supported by weak correlation values found, for example, between the 
NMDIP “Mental Functions and Pain” scale and the SF-36 “Physical Functioning” scale, and the 
GARS “Activities of Daily Living” and “Instrumental Activities of Daily Living” scales. Similarly, 
the NMDIP “Muscle Functions” scale correlated weakly with the SF-36 “Mental Health and “Role 
Emotional” scales, and the NMDIP “Participation in Life Situations” scale correlated weakly with 
the SF-36 “Mental Health” scale.  
 
 
Table 7 Results of convergent and divergent validity analyses of the Neuromuscular Disease Impact Profile 








NMDIP MUF MOF 
 
SSF ERF MFP AMA SDA PLS Alpha 
NMDIP          
 Muscle Functions (MuF) 1        0.87 
 Movement Functions (MoF) 0.57 1       0.72 
 Swallowing and Speech Functions (SSF) 0.26 0.23 1      0.69 
 Excretion and Reproductive Functions (ERF) 0.35 0.43 0.31 1     0.63 
 Mental Functions and Pain (MFP) 0.49 0.59 0.34 0.48 1    0.80 
 Activities of Moving around (AMA) 0.72 0.58 0.23 0.41 0.48 1   0.90 
 Self-care and Domestic Activities (SDA) 0.63 0.52 0.31 0.45 0.51 0.79 1  0.92 
 Participation in Life Situations (PLS) 0.54 0.46 0.26 0.38 0.53 0.68 0.61 1 0.72 
SF-36          
 Physical functioning -0.71 -0.52 -0.23 -0.40 -0.47 -0.85 -0.77 -0.61 0.94 
 Role physical -0.43 -0.42 -0.26 -0.37 -0.52 -0.43 -0.45 -0.40 0.88 
 Bodily pain -0.38 -0.51 -0.17 -0.32 -0.65 -0.42 -0.40 -0.38 0.91 
 General health -0.49 -0.49 -0.32 -0.44 -0.60 -0.49 -0.48 -0.46 0.78 
 Mental health -0.21 -0.33 -0.18 -0.18 -0.53 -0.21 -0.25 -0.32 0.83 
 Role emotional -0.18 -0.30 -0.20 -0.21 -0.39 -0.23 -0.26 -0.25 0.87 
 Social functioning -0.44 -0.46 -0.29 -0.40 -0.63 -0.46 -0.46 -0.51 0.77 
 Vitality -0.41 -0.42 -0.34 -0.33 -0.68 -0.35 -0.39 -0.39 0.81 
WHOQOL-BREF          
  Physical health and autonomy -0.29 -0.30 -0.22 -0.29 -0.49 -0.29 -0.29 -0.33 0.84 
  Psychological health -0.25 -0.33 -0.25 -0.23 -0.43 -0.29 -0.30 -0.35 0.80 
  Social relation -0.23 -0.22 -0.14 -0.40 -0.37 -0.26 -0.25 -0.33 0.60 
  Environment -0.34 -0.39 -0.24 -0.27 -0.51 -0.41 -0.39 -0.46 0.82 
GARS          
  Activities of daily living 0.64 0.54 0.26 0.45 0.44 0.81 0.81 0.62 0.95 
  Instrumental activities of daily living 0.67 0.49 0.30 0.44 0.49 0.78 0.84 0.62 0.93 
IPAQ          
  Autonomy indoors 0.54 0.52 0.25 0.43 0.50 0.66 0.65 0.56 0.94 
  Family role 0.53 0.52 0.30 0.41 0.59 0.61 0.61 0.53 0.92 
  Autonomy outdoors 0.57 0.50 0.34 0.48 0.63 0.68 0.66 0.66 0.84 
  Social relations 0.34 0.35 0.32 0.41 0.53 0.41 0.45 0.48 0.85 
NMDIP: n = 484–658; SF-36: n = 654–657; WHOQOL-BREF: n = 628–649; GARS: n = 655–658; IPAQ: n = 654–657. 
Bold correlations = expected convergent correlations. Italic correlations = expected discriminant correlations. 
MuF: Muscle functions; MoF: Movement functions; SSF: Swallowing and Speech functions; ERF: Excretion and 
Reproductive functions; MFP: Mental functions and Pain; AMA: “Activities of Moving around”; SDA: “Self-care and 
Domestic Activities”; PLS: Participation in life situations; GARS: Groningen Activity Restriction Scale; IPAQ: Impact 
on Participation and Autonomy Questionnaire..  
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NMDIP MUF MOF 
 
SSF ERF MFP AMA SDA PLS Alpha 
NMDIP          
 Muscle Functions (MuF) 1        0.87 
 Movement Functions (MoF) 0.57 1       0.72 
 Swallowing and Speech Functions (SSF) 0.26 0.23 1      0.69 
 Excretion and Reproductive Functions (ERF) 0.35 0.43 0.31 1     0.63 
 Mental Functions and Pain (MFP) 0.49 0.59 0.34 0.48 1    0.80 
 Activities of Moving around (AMA) 0.72 0.58 0.23 0.41 0.48 1   0.90 
 Self-care and Domestic Activities (SDA) 0.63 0.52 0.31 0.45 0.51 0.79 1  0.92 
 Participation in Life Situations (PLS) 0.54 0.46 0.26 0.38 0.53 0.68 0.61 1 0.72 
SF-36          
 Physical functioning -0.71 -0.52 -0.23 -0.40 -0.47 -0.85 -0.77 -0.61 0.94 
 Role physical -0.43 -0.42 -0.26 -0.37 -0.52 -0.43 -0.45 -0.40 0.88 
 Bodily pain -0.38 -0.51 -0.17 -0.32 -0.65 -0.42 -0.40 -0.38 0.91 
 General health -0.49 -0.49 -0.32 -0.44 -0.60 -0.49 -0.48 -0.46 0.78 
 Mental health -0.21 -0.33 -0.18 -0.18 -0.53 -0.21 -0.25 -0.32 0.83 
 Role emotional -0.18 -0.30 -0.20 -0.21 -0.39 -0.23 -0.26 -0.25 0.87 
 Social functioning -0.44 -0.46 -0.29 -0.40 -0.63 -0.46 -0.46 -0.51 0.77 
 Vitality -0.41 -0.42 -0.34 -0.33 -0.68 -0.35 -0.39 -0.39 0.81 
WHOQOL-BREF          
  Physical health and autonomy -0.29 -0.30 -0.22 -0.29 -0.49 -0.29 -0.29 -0.33 0.84 
  Psychological health -0.25 -0.33 -0.25 -0.23 -0.43 -0.29 -0.30 -0.35 0.80 
  Social relation -0.23 -0.22 -0.14 -0.40 -0.37 -0.26 -0.25 -0.33 0.60 
  Environment -0.34 -0.39 -0.24 -0.27 -0.51 -0.41 -0.39 -0.46 0.82 
GARS          
  Activities of daily living 0.64 0.54 0.26 0.45 0.44 0.81 0.81 0.62 0.95 
  Instrumental activities of daily living 0.67 0.49 0.30 0.44 0.49 0.78 0.84 0.62 0.93 
IPAQ          
  Autonomy indoors 0.54 0.52 0.25 0.43 0.50 0.66 0.65 0.56 0.94 
  Family role 0.53 0.52 0.30 0.41 0.59 0.61 0.61 0.53 0.92 
  Autonomy outdoors 0.57 0.50 0.34 0.48 0.63 0.68 0.66 0.66 0.84 
  Social relations 0.34 0.35 0.32 0.41 0.53 0.41 0.45 0.48 0.85 
NMDIP: n = 484–658; SF-36: n = 654–657; WHOQOL-BREF: n = 628–649; GARS: n = 655–658; IPAQ: n = 654–657. 
Bold correlations = expected convergent correlations. Italic correlations = expected discriminant correlations. 
MuF: Muscle functions; MoF: Movement functions; SSF: Swallowing and Speech functions; ERF: Excretion and 
Reproductive functions; MFP: Mental functions and Pain; AMA: “Activities of Moving around”; SDA: “Self-care and 
Domestic Activities”; PLS: Participation in life situations; GARS: Groningen Activity Restriction Scale; IPAQ: Impact 
on Participation and Autonomy Questionnaire..  
 




 Evidence of known-groups validity was obtained for all NMDIP scales by statistically significant 
group differences and clinically relevant effect sizes (Table 8). Patients classified as having a higher 
extent of limitation had statistically significant higher scores on all NMDIP scales compared with 
those classified as having a lower extent of limitation. Effect sizes were moderate for 2 scales, and 
large for 6 scales. 
 
 
Table 8 Results of known-groups validity analyses of the Neuromuscular Disease Impact Profile scales 
(n=702) 
 Low (1-4) versus high (5-10) Extent of limitations 








 Muscle Functions (MuF) 640 197.84 390.25 0.000 (-12.973) 0.51 
 Movement Functions (MoF) 577 201.52 342.52 0.000 (-9.994) 0.42 
  Swallowing and Speech Functions (SSF) 651 273.86 359.14 0.000 (-6.445) 0.25 
 Excretion and Reproductive Functions (ERF) 495 198.34 279.74 0.000 (-6.374) 0.29 
 Mental Functions and Pain (MFP) 581 201.45 346.38 0.000 (-10.170) 0.42 
 Activities of Moving  around (AMA) 683 210.67 422.72 0.000 (-13.704) 0.52 
 Self-care and Domestic Activities (SDA) 682 227.58 411.25 0.000 (-11.956) 0.46 
 Participation in Life Situations (PLS) 677 239.81 400.46 0.000 (-11.110) 0.43 
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The objective of this study was to develop a psychometrically sound ICF-based measure for 
estimating the prevalence and severity of a broad range of disabilities related to neuromuscular 
diseases using ICF features such as ICF terminology and ICF qualifiers. 
The results provide evidence to support the validity and reliability of the final version of the 
Neuromuscular Disease Impact Profile (NMDIP) as an instrument to measure the prevalence and 
severity of a broad spectrum of consequences of a neuromuscular disease including disabilities in 
Body Functions, Activities and Participation, and lack of support from Environmental Factors. The 
NMDIP can be used as a clinical and research instrument for the assessment of the impact of a 
neuromuscular disease. 
The original 45 items in the preliminary NMDIP could be reduced to 36 items: 32 items covering 
8 domains representing 3 ICF-components, and 4 clinically relevant items (1 Body Functions item 
and 3 Environmental Factors items), which were applied as single items in the questionnaire (See 
final version in Appendix).  
 Although the NMDIP used the same items as the initial MSIP14, results of the factor analysis 
showed some differences compared to the final MSIP scales. For example, the MSIP “Muscle and 
Movement functions” 4-item scale is represented in the NMDIP in 2 separate and recognizable 
scales “Muscle functions” with 2 items and “Movement functions”, also with 2 items.  Furthermore, 
the 3-item “Mental functions” MSIP scale appeared in the NMDIP as a 5-item version: new scale 
items were Fatigue and Pain. This can be explained by the fact that pain and fatigue are the direct 
result of (using) weakened muscles, which is a common symptom in neuromuscular diseases. 
Unlike neuromuscular diseases fatigue in multiple sclerosis is most likely related to the process of 
inflammation, while pain originates from spasticity and/or neuropathy. Furthermore, scale 
construction also identified a construct that was not present in the MSIP: “Swallowing and Speech 
Functions”. This can be explained by the fact that some myopathies and the myasthenia’s tend to 




affect bulbar musculature. Finally, analysis showed no consistent factor for the Environmental 
Factors items. 
Reliability of the NMDIP scales of the total sample was sufficient for 2 scales and good for 6 
scales. The scales per NMD group showed overall sufficient alpha’s and good MICC’s. Except for 
two scales the “Swallowing and Speech Functions” scale in the peripheral nerve disorder group and 
the “Excretion and Reproductive Functions” scale in the muscle disorder group. Some caution is 
advised in the interpretation of the results. Convergent and discriminant validity analysis indicated 
that the NMDIP measures the impact on physical, mental, and social functioning for people with a 
neuromuscular disease. 
The correlation between the NMDIP “Participation in Life Situations” scale and the SF-36 
“Physical Functioning” scale was unexpectedly higher. It is likely that the activity-related 
participation items in the NMDIP scale are responsible for this moderate correlation. 
Known-groups validity was supported for the 8 NMDIP scales. Scales discriminated sufficiently 
between groups of patients with a neuromuscular disease that differed in extent of limitations.  
An important strength of this study is the large and broad group of participating patients with a 
neuromuscular disease, and the sound conceptual basis in developing the NMDIP.3, 35 
A possible limitation in this study is the small sample size of the motor neuron disorder group, 
compared to the sample size of the 3 other NMD groups. However, in our opinion the disabilities in 
this group are sufficiently represented in the NMDIP because the basis of the NMDIP, the NMD 
ICF-Core set, covers all items of the disease-specific Amyotrophic Lateral Sclerosis Assessment 
Questionnaire-40.8 Another limitation could be the high floor effect of some scales that might affect 
the reliability of these scales.36 However, these floor effects match with the course of the slowly 
progressive nature in most NMDs. This means that some disabilities appear years after onset, such 
as speech and swallowing functions or upper extremity activities. 
Further research should focus on psychometric evaluation concerning stability and sensitivity to 
change of the NMDIP scales, and validation across other populations of neuromuscular disease 
 
 
patients in other cultures. It would also be interesting to examine the differences in prevalence and 
severity of disabilities between the 4 major NMD groups as defined by Rowland.15 Finally, it would 
be interesting to investigate the impact of the broad range of NMDIP related disabilities on HRQOL 
of neuromuscular disease patients. 
We considered the possibility to undertake the group invariance testing, however the sub groups 
are relative small and will affect the test of Differential Item Functioning. We therefore suggest 
further examination of the factor structure in a new sufficient sample. 
Clinical practice, especially in multidisciplinary rehabilitation teams, the NMDIP may contribute 
to better understanding the patients’ health problems when used as an assessment tool. Although 
positive results were found in the feasibility studies with the preliminary NMDIP and the MSIP, it 
is advisable to combine this application with research; for example, in order to investigate the 
effects on the health care plan when using the NMDIP.   
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   Neuromuscular Disease Impact Profile (NMDIP).  
NMDIP Body functioning questions 
Scale  Response options 
0 = no, not at all 
1 = yes, I have a slight impairment 
2 = yes, I have a moderate impairment 
3 = yes, I have a severe impairment 
4 = yes, I have a complete impairment 
MuF b1 Do you face loss of your muscle power functions? (b730) 
MuF b2 Do you face loss of muscle endurance functions? (b740) 
MoF b3 Do you face loss of control of voluntary movements? (b760) 
MoF b4 Do you face involuntary movements? (e.g., tremors or tics) (b765) 
MoF b5 Do you face muscle stiffness or muscle spasm? (b7800 / b7801) 
SSF b6 Do you face impairment in your speech functions? (b320)  
SSF b7 Do you face impairment in your swallowing functions? (b5105) 
ERF b8 Do you face impairment in your defecation functions? (e.g., changes in 
frequency, constipation, incontinence) (b525) 
ERF b9 Do you face impairment in your urination functions? (e.g., frequency of 
urination, incontinence, difficulties with urination) (b620) 
ERF b10 Do you face limitations in sexual functions? (b640) 
MFP b11 Do you face impairment in your sleep functions? (e.g., onset of sleep, the  
  maintenance of sleep or the quality of sleep) (b134) 
MFP b12 Do you experience fatigue? (b1300/b455)  
MFP b13 Do you face changes in your emotional functions? (e.g., fear, depression,  
  happiness) (b152) 
MFP b14 Do you face changes in your thought functions? (e.g., the ability to think  
  logically, the ability to memorize, the ability to concentrate) (b160) 
MFP b15 Do you experience sensation pain? (b280)  
single b16 Do you face impairment in your seeing functions? (With eyeglasses on or item   
 lenses in) (b210)  
NMDIP Activities questions 
Scale  Response options 
0 = No 
1 = Yes, but assistance devices and/or adaptations are not necessary 
2 = Yes, and assistance devices and/or adaptations are necessary 
3 = Yes, and assistance devices and/or adaptations and another person’s help  
are necessary 
 
AMA a1 Do you face limitations in changing your body position? (e.g., moving from 
lying down to standing up or from standing to sitting) (a410) 
AMA a2 Do you face limitations in maintaining your body position? (e.g., maintaining  
  kneeling, standing, and sitting postures) (a415) 
AMA a3 Do you face limitations in transferring yourself? (e.g., moving from a chair 
into bed; from a wheelchair into a car) (a420) 
AMA a4 Do you face limitations in walking? (a450) 
AMA a5 Do you face limitations in using transportation? (a470) 
AMA a6 Do you face limitations in activities you would like to undertake for recreation  
and leisure? (a920) 
SDA a7  Do you face limitations in your fine hand use? (e.g., picking up small objects;  
 
 
  manipulating a keyboard) (a440) 
SDA a8 Do you face limitations in your arm(s) and hand(s) use? (e.g., pulling or 
pushing objects; turning or twisting knobs or handles; reaching for kitchen 
cupboard) (a445) 
SDA a9 Do you face limitations in washing yourself? (a510) 
SDA a10 Do you face limitations in caring for body parts? (e.g., brushing teeth,  
  clipping your nails, combing your hair, shaving) (a520) 
SDA a11 Do you face limitations in toileting? (a530) 
SDA a12 Do you face limitations in dressing yourself? (a540) 
SDA a13 Do you face limitations in preparing meals? (a630) 
SDA a14 Do you face limitations in doing housework? (a640) 
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0 = no 
1 = Yes, as a consequence I have some trouble with …. 
2 = Yes, as a consequence I have trouble with... 
3 = Yes, as a consequence I have a lot of trouble with … 
4 = Yes, as a consequence …. is (nearly) impossible 
PLS p1 Are there obstacles in your environment that complicate your participation in 
community, recreation, and leisure? (e.g., accessibility of clubs or associations) 
(p910/p920) 
PLS p2 Are there obstacles in your environment that complicate the maintenance of  
your relationships with your closest family, friends, or relatives? (e.g., the travel distance, 
the attitude of others) (p740-p760) 
PLS p3 Are there obstacles in your environment that complicate your mobility inside 
or outside your home? (e.g., thresholds; curbs; absence of elevators) (p460 / 470) 
NMDIP Environmental factors questions 
Scale Response options 
 0 = Yes, very supportive;  
1 = Yes, somewhat supportive;  
2 = No, not supportive 
Single  
Item e1 
Is your relationship with your immediate family supportive for you? 
(e.g., partner, children, parents, brothers, sisters) (e310) 
Single  
Item e2 




Are the health services supportive for you? (e.g., medical and nursing care)  
(e580) 
MuF = Muscle Functions; MoF=Movement Functions; SSF = Swallowing and Speech Functions; ERF = 
Excretion and Reproductive Functions; MFP = Mental Functions and Pain; AMA = Activities of Moving 
Around; SDA = Self-care and Domestic Activities; PLS = Participation in Life Situations. 
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Background: The aim of this study was to examine the stability and relative validity (RV) of the 
Neuromuscular Disease Impact Profile (NMDIP) using criterion-related groups. In a previous study 
the NMDIP-scales showed good internal consistency, convergent and discriminant validity. Known-
groups analysis showed that the NMDIP discriminates between categories of extent of limitations.  
 Methods: A cross-sectional postal survey study was performed on patients diagnosed with a NMD 
and registered at the Department of Neurology, University Medical Center Groningen, the 
Netherlands. 
Participants were asked to complete the preliminary NMDIP, the Medical Outcome study Short 
Form Questionnaire (SF-36), the World Health Organization Quality Of Life-abbreviation version 
(WHOQOL-bref), and two generic domain specific measures: the Groningen Activity Restriction 
Scale (GARS) and the Impact on Participation and Autonomy Questionnaire (IPAQ). The variables 
‘Extent of Limitations’ and ‘Quality of Life’ were used to create criterion-related groups. Stability 
over time was tested using the Wilcoxon Signed Rank Test for paired samples and the intraclass 
correlation coefficients for repeated measures. RV was examined by comparing the ability of 
NMDIP with generic multidimensional health impact measures, and domain specific measures in 
discriminating between criterion-related subgroups using the Kruskal-Wallis H-test.  
Results: Response rate was 70% (n=702). The NMDIP-scales showed sufficient stability over time, 
and satisfactory or strong RV. In general, the NMDIP scales performed as well as or better than the 
concurrent measurement instruments.   
Conclusions: The NMDIP proved to be a valid and reliable disease-targeted measure with a broad 
scope on physical, psychological and social functioning. 
 
Keywords  





Neuromuscular Diseases (NMDs) may be caused by an abnormality of the anterior horn cells, 
sensory ganglion cells (neuronopathy), the peripheral nerves (neuropathy), neuromuscular junctions 
(myasthenia), or muscle (myopathy). Common symptoms and signs of NMD include muscle 
weakness, impairment in muscle endurance, involuntary muscle activity (stiffness, myotonia, 
cramps, and fasciculations), sensory loss, autonomic dysfunction and impairment in control of 
voluntary movements. Sensations of pain and fatigue are common consequences of muscle and 
nerve pathology.1,2 Easy to apply NMD-specific reliable and validated self-report assessment tools  
are essential for obtaining insight into the prevalence and severity of the broad range of patient 
perceived health-related problems in NMDs. This is important for research and for clinical practise 
as well, in order to narrow the gap between the clinician’s and patient’s view on the actual health 
situation and to help to tailor care plans to the patient’s need and preferences.3 We therefore 
developed the disability-severity Neuromuscular Disease Impact Profile (NMDIP) based on the 
ICF-Core set for NMDs, a set of categories selected from the International Classification of 
Functioning, Disability and Health (ICF).2,4 
The NMDIP consists of 36 items that cover all ICF-components and are divided into eight 
scales and four single items. The NMDIP-scales showed moderate to good Cronbach’s alpha and 
mean inter-item correlation coefficients. Convergent and discriminant validity analysis indicated 
that the NMDIP measures the impact of neuromuscular disease on physical, psychological and 
social functioning. The NMDIP discriminates between groups of patients who differ in ‘Extent of 
limitations’. The four single items represent the Environmental Factors component (three items) and 
one Body Functions item (Seeing function).4 
The objective of this study was to further examine the psychometric properties of the 
NMDIP and to build on previous studies on this measurement instrument.2,4 We examined its 
stability over time by assessing the test-retest reliability of the NMDIP-scales. We furthermore 
compared the ability of the NMDIP scales to discriminate between criterion related subgroups with 
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this ability of four established concurrent measurement instruments, by assessing the Relative 
Validity (RV).5,6 The RV coefficient indicates how much more or less valid each outcome measure 
is related to the best outcome measure. 
 
Methods 
Sample and procedure 
A cross sectional study, using a postal survey, was administered to patients diagnosed with a NMD 
who were registered at the Department of Neurology of the University Medical Center Groningen, 
University of Groningen, the Netherlands. Inclusion criteria for this study were: diagnosis with a 
NMD and representing one of Rowland’s NMD classification groups: motor-neuron disorders, 
muscle disorders, junction disorders and peripheral nerve disorders7; being aged 18 or older; being 
able to read and write in Dutch; and being able to give informed consent. No exclusion criteria were 
formulated.  
A total of 1003 eligible patients were selected from the hospital patient records system. To avoid 
inappropriately sending the questionnaires, we crosschecked for deceased patients using the 
national population register. Patients received information about the study and were invited to 
participate.  
Respondents completed demographic and disease specific questions, the NMDIP, two criterion 
variables to measure the ‘Extent of Limitations’ and ‘Quality of Life’. Also, concurrent measures 
were completed: two generic multidimensional health impact measures (the Medical Outcome study 
Short Form Questionnaire (SF-36)8 and the World Health Organization Quality Of Life-
abbreviation version (WHOQOL-bref)9, and two generic domain specific measures the Groningen 
Activity Restriction Scale (GARS)10 and the Impact on Participation and Autonomy Questionnaire 
(IPAQ).11 To assess stability over time, the NMDIP was administered on two occasions to patients 
who agreed to fill in the questionnaire twice. We, arbitrary, selected a time frame from eight to ten 
 
 
weeks to be sure that patients could not remember their answers on the first questionnaire, and the 
likelihood of changes in the health situation was minimal. 
  
Measurement instruments  
The NMDIP includes 36 items and consists of eight scales and four additional items. The 36 items 
were divided over the four ICF components. For the Body Functions component items and for the 
Participation component items scoring options ranged from 0 (no disability) to 4 (complete 
disability); for the Activities component items scoring options ranged from 0 (no disability) to 3 
(complete disability); and for the Environmental Factors component items scoring options ranged 
from 0 (no support) to 2 (full support).4 Item scores were summed into a scale with higher scores 
indicating more disability. To evaluate the RV, we used the ‘Physical Functioning’ construct as 
represented by the ‘Activities of Moving around’ and ‘Self-care and Domestic Activities’ scales, the 
‘Psychological Functioning’ construct as represented by the ‘Mental Functions and Pain’ scale, and 
the ‘Social Functioning’ construct as represented by the ‘Participation in Life Situations’ scale. 
These scales were selected because items in these scales are closely associated with the scales in the 
concurrent measures.      
 The SF-36 was selected as a well-known reliable and valid generic multidimensional health-
impact measure used for NMD.12,13 The SF-368 comprises 36 items with eight functional 
dimensions. Three scales were used to examine the RV: ‘Physical Functioning’, ‘Mental Health’ 
and ‘Social Functioning’. Item scores were coded, summed and transformed to a score of 0 (worst 
health) to 100 (best health) for each scale. The overall Cronbach’s alpha for these scales was 0.79 in 
a study of Amyotrophic Lateral Sclerosis patients.14 In our previous study the Cronbach’s alpha for 
the selected scales ranged from 0.77 and 0.94.4 
The WHOQOL-bref9 was selected as a generic measurement instrument for a broad 
evaluation of quality of life. It consists of 28 items in four constructs and two separate questions. 
Three scales were used to examine the RV: ‘Physical Health and Autonomy’, ‘Psychological 
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Health’, and ‘Social Relations’. Item scores from each scale were coded, summed and transformed 
to a score of 0 (worst health) to 20 (best health). The Cronbach’s alpha ranged from 0.63 to 0.81 in 
a study of Multiple Sclerosis patients.15 In our previous study the Cronbach’s alpha for the selected 
scales ranged from 0.60 to 0.84.4 
The GARS10 is a domain specific generic measurement instrument for assessing disability in 
‘Activities of daily living’ (ADL) and ‘Instrumental activities of daily living’ (IADL). It consists of 
eleven ADL items and seven IADL items. A four-category response format was used, and ranged 
from 1 (no problem in performing without help) to 4 (impossible to perform). The scores were 
summed for each subscale. The Cronbach’s alpha ranged from 0.95 to 0.97 in a study of Multiple 
Sclerosis patients.15 In our previous study the Cronbach’s alpha ranged from 0.93 to 0.95.4 
The IPAQ11,16 is a domain specific generic measurement instrument for assessing 
participation. It consists of fifteen items focusing on person-perceived participation and autonomy. 
The instrument assesses two aspects of participation: perceived participation and the perceived 
problems with participation. In this study the perceived participation aspect was used since this 
construct is closely associated with the ‘Participation in Life Situations’ construct in the NMDIP 
questionnaire. The sub-domains were ‘Autonomy Indoors’, ‘Family Role’, ‘Autonomy Outdoors’, 
and ‘Social Relations’. The response options ranged from 1 (very good) to 5 (very poor). Scores 
were summed for each domain. The Cronbach’s alpha ranged from 0.86 and 0.94 in a study of 
Multiple Sclerosis patients.15 In our previous study the Cronbach’s alpha ranged from 0.84 to 0.94.4 
 
Criterion variables  
Two questions were selected as criterion variables: ‘Extent of limitations’ and ‘Quality of life’.  
To evaluate the ‘Extent of Limitations’ respondents were asked to answer the question: ‘To 
what extent are you limited due to your NMD?’ Responses were on a ten-point scale ranging from 1 
(not limited at all) to 10 (completely limited). Respondents were classified into one of four groups: 
Group A with a ‘very low extent of limitation’ (score 1-2), Group B with a ‘moderate extent of 
 
 
limitation’ (score 3-5), Group C with a ‘high extent of limitation’ (score 6-8) and, Group D with a 
‘very high extent of limitation’ (score 9-10).  
The second criterion variable for evaluation of quality of life was one of the two single items 
adapted from the WHOQOL-bref. Respondents were asked: ‘How would you rate your quality of 
life?’. Response options were: 1=very poor, 2=poor, 3=neither poor nor good, 4=good and 5=very 
good. Respondents were classified into three groups: Group A– ’very poor or poor quality of life’, 
Group B– ‘neither poor nor good’, and Group C– ‘good or very good quality of life’. 
 
Analysis 
Descriptive statistics were used to characterize the total sample and the test-retest sample. 
Differences between both samples were examined using the difference in proportions test, the two-
sample t-test, and if data are not normally distributed a non-parametric test for independent samples 
were used. 
Test-retest reliability or stability over time was examined using the Wilcoxon Signed Test 
and the one-way random intraclass correlation coefficients (ICCs).17 
Relative Validity was examined in several steps. First, the Chi-square was computed for 
each scale by calculating the Kruskal-Wallis H-test. Second, the RV of each scale was computed by 
dividing each H-statistic by the H-statistic for the scale with the highest H-statistic, and multiplied 
by one hundred. The resulting RV-estimate indicates the extent to which a scale or construct is able 
to discriminate between two groups compared to the measure with the highest H-statistic.18,19 
Finally, the clinical relevance of the differences between respondent subgroups, and the 
nonparametric effect size (coefficient r) for unrelated samples, was calculated for statistically 
significant group differences (α=0.05) with post hoc tests (Bonferroni correction).20 Effect sizes 
where estimated through coefficient r, which was calculated by dividing the z-statistic (obtained 
from the Mann-Whitney U test) by the root of the sample size (n). To interpret this nonparametric 
effect sizes (coefficient r), Cohen suggested the following thresholds: an r of < 0.10 indicates a 
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limitation’ (score 3-5), Group C with a ‘high extent of limitation’ (score 6-8) and, Group D with a 
‘very high extent of limitation’ (score 9-10).  
The second criterion variable for evaluation of quality of life was one of the two single items 
adapted from the WHOQOL-bref. Respondents were asked: ‘How would you rate your quality of 
life?’. Response options were: 1=very poor, 2=poor, 3=neither poor nor good, 4=good and 5=very 
good. Respondents were classified into three groups: Group A– ’very poor or poor quality of life’, 
Group B– ‘neither poor nor good’, and Group C– ‘good or very good quality of life’. 
 
Analysis 
Descriptive statistics were used to characterize the total sample and the test-retest sample. 
Differences between both samples were examined using the difference in proportions test, the two-
sample t-test, and if data are not normally distributed a non-parametric test for independent samples 
were used. 
Test-retest reliability or stability over time was examined using the Wilcoxon Signed Test 
and the one-way random intraclass correlation coefficients (ICCs).17 
Relative Validity was examined in several steps. First, the Chi-square was computed for 
each scale by calculating the Kruskal-Wallis H-test. Second, the RV of each scale was computed by 
dividing each H-statistic by the H-statistic for the scale with the highest H-statistic, and multiplied 
by one hundred. The resulting RV-estimate indicates the extent to which a scale or construct is able 
to discriminate between two groups compared to the measure with the highest H-statistic.18,19 
Finally, the clinical relevance of the differences between respondent subgroups, and the 
nonparametric effect size (coefficient r) for unrelated samples, was calculated for statistically 
significant group differences (α=0.05) with post hoc tests (Bonferroni correction).20 Effect sizes 
where estimated through coefficient r, which was calculated by dividing the z-statistic (obtained 
from the Mann-Whitney U test) by the root of the sample size (n). To interpret this nonparametric 
effect sizes (coefficient r), Cohen suggested the following thresholds: an r of < 0.10 indicates a 




trivial effect, an r of ≥ 0.10 to < 0.24 a small effect, a r of ≥ 0.24 to < 0.37 a moderate effect, and an 
r ≥ 0.37 a large effect. A r ≥ 0.10 reflects a clinically relevant difference between groups.20,21 
IBM SPSS statistics version 22 was used.  
 
Results 
 A total of 702 participants (70% response rate) completed the questionnaires. Of the 202 patients 
who agreed to complete the NMDIP twice 185 participants (92% response rate) actually returned 
the questionnaire.  
The non-respondents from the 1003 eligible patients did not differ from respondents in terms 
of gender, but non-responders were significantly younger than respondents (p-value<0.001 not in 
table). 
 The total sample (n=702) and the test-retest sample (n=185) differed in Age, Years since 
diagnosis. Participants in the total sample were older and were diagnosed more recently with a 
NMD compared to the test-retest sample. Also a significant larger proportion of respondents in the 
total sample was ‘Retired due to age’ compared to test-retest sample (p-value=0.007) (Table 1). 
Finally the NMD category distribution differed significantly between the samples with less patients 
with Motor-neuron disorders and Muscle disorders and more patients with Peripheral nerve 
disorders in the total sample compared to the test-retest sample. 
  
Test-retest reliability 
Wilcoxon Signed Rank Test (Table 2) showed no significant score differences between time points 
for most of the NMDIP scales, indicating stability over time, except for the ‘Mental Functions and 
Pain’ scale. However this difference was not clinically relevant (ES 0.18, not shown in table). The 
ICC of all scales showed sufficient agreement and ranged from 0.79 to 0.97, indicating good 




Table 1 Patient characteristics of total sample and test-retest sample 






    
Gender (%)    
 Female 350 (50) 105 (57) 0.095^ 
 Male 352 (50) 80 (43) 0.095^ 
    
Age    0.024
##
 
 Median (IQR) 61 (21) 57 (18)  
 Range 19-92 19-92  
 
Year since diagnosis 




 Median (IQR)  7 (11) 10 (14)  
 Range   0-65 1-64  
    
Extent of limitations   0.329
##
 
 Median (IQR)  5 (4) 6 (4)  
 Range 1-10 1-10  
    
Quality of life (WHOQOL-bref)   0.129
##
 
  Median (IQR) 4 (1) 4 (1)  
  Range  1-5 1-5  
    
Relationship status (%)    
  Relationship (married/partnership) 515 (73) 135 (76) 0.910^ 
  Single (unmarried/widowed/divorced) 186 (27) 45 (24) 0.549^ 
    
Educational level (%)    
  Primary school/vocational training  235 (33) 57 (31) 0.492^ 
  Secondary school/vocational training  270 (38) 81 (44) 0.188^ 
  Higher education /vocational training  161 (23) 37 (20) 0.394^ 
  University  28 (4) 8 (4) 0.837^ 
    
Employment status (more answers possible) (%)    
  Following a training or study 36 (5) 12 (7) 0.468^ 
  Employment (part-time or full time) 173 (25) 43 (23) 0.693^ 
  Voluntary work (part-time or full time) 42 (6) 15 (8) 0.294^ 
  (Partially) retired due to NMD 213 (30) 67 (36) 0.126^ 
  Housewife/househusband 171 (24) 55 (30) 0.136^ 
  Retired due to age 244 (35) 45 (24) 0.007^ 
    
NMD category (%)    
   Motor neuron disorder (MND) 43 (6) 20 (11) 0.027^ 
   Muscle disorder (MD) 154 (22) 69 (37) <0.001^ 
   Junction disorder (JD) 234 (33) 66 (36) 0.549^ 
   Peripheral nerve disorder (PND) 271 (39) 30 (16) <0.001^ 
^Difference in proportions test, ## Mann-Whitney U test. Interquartile range (IQR)=Q3-Q1.   
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Table 2 Test-retest reliability for the NMDIP scales (n=185). 

















Muscle Functions  177 4 (2) 179 4 (2) -2.08 0.037 0.85 
Movement Functions 161 2 (3) 153 2 (2) -.006 0.995 0.88 
Excretion and Reproductive 
Functions  
135 2 (3) 144 1 (3) -1.00 0.318 0.85 
Swallowing and Speech 
Function  
172 0 (2) 180 0 (2) -0.23 0.818 0.91 
Mental Functions and Pain 164 4 (4) 162 4 (3) -3.39 0.001 0.90 
Activities of Moving around  185 4 (6) 185 4 (6) -1.23 0.219 0.96 
Self-care and Domestic 
Activities  
185 3 (9) 185 3 (7) -0.41 0.683 0.97 
Participation in Life Situations  180 1 (2) 182 0 (2) -1.70  0.090 0.79 
* Wilcoxon Signed Rank Test, 2-tailed. Interquartile range (IQR)=Q3-Q1.   
 
Criterion-related relative validity 
Median scores of patients with a low ‘Extent of limitation’ (Table 3) or very poor or poor ‘Quality 
of life’ level (Table 4) were significantly different in the hypothesized direction when compared to 
the next higher group mean. 
 
Extent of limitations 
About 16% (n=110) of the respondents reported ‘low extent of limitations’ (Group A) due to NMD, 
while 36% (n=250) reported a ’moderate extent of limitation’ (Group B), and 39% (n=270) reported 
a ‘high extent of limitation’ (Group C). About 8% (n=58) of the respondents reported a ‘very high 
extent of limitations’ (Group D).  
Comparisons of the RV coefficients, as summarized in Table 3, revealed that the NMDIP 
‘Activities of Moving around’ scale and SF-36 ‘Physical Functioning’ scale were the most valid in 
discriminating between groups with an increasing extent of limitation.  
We then examined the performance of the NMDIP-scales in indicating the differences between 
extreme groups (A-D) and subgroups (A-B, B-C, C-D) regarding the physical-, psychological- and 
social functioning constructs, as they relate to similar constructs in the concurrent measurement 
instruments. Regarding physical functioning, we found that both NMDIP activity scales turned out 
to be the most sensitive (followed by the ‘Muscle Functions’ scale) for measuring differences 
 
 
between extreme groups and subgroups. However, the performance of the concurrent SF-36 
‘Physical functioning’ scale and both GARS scales were almost identical. Regarding the 
psychological functioning construct we found that the NMDIP ‘Mental Functions and Pain’ scale 
was the best performing scale compared to the SF-36 ‘Mental Health’ scale and the WHOQOL-bref 
‘Psychological Health’ scale, showing the highest extreme group and subgroup differences. 
Regarding the social functioning construct the NMDIP ‘Participation in Life Situations’ scale 
performed better than the SF-36 ‘Social Functioning’ and the WHOQOL-bref ‘Social Relations’ 
scales, and roughly as well as the same as the comparable constructs in the domain-specific IPAQ. 
In summary, the NMDIP scales performed sufficient to good in discriminating between 
(sub) groups with an increasing extent of limitations compared to similar constructs in concurrent 
measures regarding physical functioning, psychological functioning and social functioning 
constructs.  
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Quality of life 
Eight percent (n=53) of the respondents reported poor or very poor quality of life (Group A), 
while 25% (n=175) experienced their quality of life as neither poor nor good (Group B) and 
67 % (n=474) reported a good or very good quality of life’ (Group C). 
 Comparisons of the RV-coefficients, as summarized in Table 4, revealed that the SF-
36 ‘Psychological Health’ scale and IPAQ ‘Autonomy outdoors’ scales were the most valid in 
discriminating between groups with differences in quality of life. The ‘Mental Functions and 
Pain’ NMDIP scale was the third most valid scale. 
 When examining the performance of the NMDIP-scales in indicating the differences 
between extreme and subgroups for quality of life, we found about the same extreme group 
differences for the physical functioning scales for all concurrent constructs with moderate 
Effect Sizes (ESs). The same goes for the subgroup differences, although the NMDIP ‘Mental 
Functions and Pain’ scale, and the WHOQOL-bref ‘Psychological Health’ scale performed 
slightly better than the SF-36 ‘Mental Health’ scale. Finally, when examining the social 
functioning scales we found that the comparable NMDIP ‘Participation in Life Situations’ 
scale performed about as well as the SF-36 ‘Social Functioning’ scale and the IPAQ scales 
with a moderate to large ESs for extreme group differences. The NMDIP ‘Participation in 
Life Situations’ scale also performed better compared to the social functioning construct of 
the WHOQOL-bref, the ‘Social Relations’ scale. The same goes for the subgroup differences. 
In summary, the NMDIP scales performed well in discriminating between subgroups 
with differences in quality of life compared to similar constructs in concurrent measures 








In this study the NMDIP, that was developed to reflect the prevalence and severity of a broad 
range of NMD-related disabilities(4), showed stability and performed well in the criterion-
related subgroups of NMD-patients who differed in the extent of limitation and quality of life.  
The results of the test-retest reliability analysis were sufficient indicating stability in 
the eight NMDIP scales. Although the results showed a difference for ‘Mental Functions and 
Pain’ scale while the effect size was trivial, the intraclass correlation showed sufficient 
agreement for all NMDIP scales between the two measurement moments.  
In general, the NMDIP scales performed well in discriminating between relevant 
subgroups with increasing extent of limitation. This was the case for constructs evaluating 
physical, psychological, and social functioning. The NMDIP scales showed satisfactory 
relative validity and moderate to strong ESs indicating the strength of the differences between 
subgroups. The NMDIP showed satisfactory performance in discriminating between relevant 
subgroups with decreasing Quality of Life. This was the case for constructs evaluating 
physical, psychological and social functioning.   
Strength of this study is the inclusion of a large population of patients diagnosed with 
a NMD. Some potential study limitations should be mentioned. First, RV was examined as 
criterion-related validity value in this study. Because of the absence of a widely accepted 
criterion measure we chose to use self-report measures, which turned out to be a useful 
method. Secondly, the (relatively) small group sizes for ‘very high extent of limitations’ 
(Group D) and ‘very poor or poor quality of life’ (Group A) might have a negative impact on 
detecting group differences, though the difference between these subgroups and the adjacent 
groups showed sufficient ESs.  
The results in this study permit us to recommend that researchers consider Relative 
Validity as a useful method to select a valid and ‘with caution’ a sensitive measure, especially 
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when data from longitudinal studies or intervention studies are lacking. At the same time, we 
want to stress that RV is not a substitute for the sensitivity-to-change test. The findings in this 
study cannot be generalized to longitudinal studies. We recommend further research to 
evaluate the sensitivity to change of the NMDIP scales.  
Furthermore generic health measures have some disadvantages against disease-
specific health measures in addressing topics of a particular relevance to patients with a 
specific disease. Therefore it is recommended that the individual items in a scale be examined 
to estimate the suitability of the scale for a particular patient population.13 
 
Conclusions 
The results in this study confirmed the stability of the NMDIP over time, and showed good 
relative validity compared to generic QOL and domain-specific measures. In combination 
with the findings in our previous study4, the NMDIP proved to be a valid and reliable disease-
targeted measure with a broad scope on physical, psychological and social functioning. 
Further research should examine the responsiveness of the NMDIP scales. 
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Objective: People with a Neuromuscular Disease (NMD) experience lower quality of life 
levels than people from the general population. We examined the prevalence and severity of a 
broad range of NMD-related disabilities and their impact on quality of life (QoL). 
Design: Cross-sectional postal survey study. 
Setting: Outpatient clinic of the Department of Neurology, University Medical Center 
Groningen, the Netherlands. 
Participants: Adult out-patients diagnosed with an NMD 
Interventions: Not Applicable 
Main Outcome Measures: Patients completed the Neuromuscular Disease Impact Profile 
(NMDIP), a disease-related disability impact questionnaire, and two generic health-related 
QoL questionnaires: the Medical Outcome study Short Form Questionnaire (SF-36) and the 
World Health Organization Quality of Life-bref (WHOQoL-bref). The impact of disabilities 
on QoL was estimated using multiple regression analyses.  
Results: 662 patients (68% response rate) completed the questionnaires. There were no 
differences in QoL between diagnosis-based subgroups. ‘Impairments in Muscle Functions’ 
had the highest prevalence and severity scores in the total sample and diagnosis-based 
subgroups. NMD-related disabilities showed strong and independent associations with all 
aspects of QoL. ‘Impairments in Mental Functions and Pain’ was the most important predictor 
of QoL followed by ‘Restrictions in Participation in Life situations’. The assessed impact on 
QoL appeared to be dependent on the QoL measurement instrument applied.  
Conclusion: Although ‘impairment in Muscle Functions’ is the most prevalent and severe 
disability, the ‘impairments in Mental Functions and Pain’ have the largest impact on QoL in 
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Neuromuscular diseases (NMDs) can be caused by dysfunction of the anterior horn cell or 
sensory ganglion cell (neuronopathy), peripheral nerve (neuropathy), neuromuscular junction 
(myasthenia), or muscle (myopathy). Common impairments in functioning as a consequence 
of neuromuscular diseases include muscle weakness, impairment in muscle endurance, 
involuntary muscle activity (stiffness, myotonia, cramp and fasciculation), sensory loss, 
autonomic dysfunction and impairment in the control of voluntary movements. These 
impairments cause fatigue and pain in most people, which has a profound impact on their 
daily activities and participation in life situations.1-5 
Quality of Life (QoL) has become increasingly important in evaluating healthcare 
outcomes in recent decades. Studies of QoL in NMDs generally report that people with an 
NMD experience lower QoL compared to the general population4, which can be explained by 
NMD-related health problems such as poorer physical4,6 and social functioning7,8, pain9-11, 
fatigue12, cognitive impairments and impaired emotional functioning.13 
Although these studies have generated clinically important information, they are limited by 
their typical focus on the impact of individual disabilities on QoL. Little is known of the 
relative impact of aggregated NMD-related disabilities on QoL. Insight into this could 
facilitate our understanding of the impact of disease-related disabilities in NMDs on QoL.  
The aim of this study is therefore to examine the prevalence and severity of a large number 
of disease-related disabilities and their impact on QoL in a sample of patients diagnosed with 






Sample and procedure 
A cross-sectional postal survey was conducted among patients diagnosed with an NMD and 
registered at the Department of Neurology of the University Medical Center Groningen, the 
Netherlands. The inclusion criteria in addition to an NMD diagnosis were: being aged 18 or 
older, and being able to read and write in Dutch.  
A total of 980 eligible patients diagnosed with a neuromuscular disease were selected from 
the hospital patient record system. To avoid inappropriately sending questionnaires, we 
crosschecked for deceased patients using the national population register.  
Patients received information about the study and were invited to participate. Respondents 
completed the Neuromuscular Disease Impact Profile (NMDIP), two generic health-related 
QoL questionnaires and some demographic and disease-specific questions. Reminders were 
sent after two weeks if there was no response. 
 
Measurement instruments 
Disease-related disabilities were assessed using the NMDIP5 This measurement instrument is 
based on the International Classification of Functioning, Disability and Health (ICF)14 and 
consists of 36 items covering four ICF components. Its items are grouped into eight scales 
with four additional items. For the Body Functions and Participation component items, 
scoring options ranged from 0 (no disability) to 4 (complete disability); for the Activities 
component items, scoring options ranged from 0 (no disability) to 3 (complete disability); and 
for the Environmental Factors component items, scoring options ranged from 0 (no support) 
to 2 (full support). Scores are summed for each scale. To make the scores for each scale and 
the individual items comparable, the summed and individual scores were divided by the 
highest possible score and multiplied by 100 to obtain a result between 0 and 100. We 
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established in previous work that the NMDIP shows satisfactory levels of internal 
consistency: Cronbach’s alphas ranged from 0.63 to 0.92, while mean inter-item correlations 
ranged from 0.38 to 0.77.5 Test-retest reliability was good: Intraclass correlations ranged from 
0.79 to 0.97.15  
QoL was assessed using two generic health-related QoL measurement instruments, the 
Medical Outcome Study 36-item Short Form Health Survey (SF-36)16 and the World Health 
Organization Quality of Life (abbreviated version) (WHOQoL-bref).17 The SF-36 consists of 
eight scales and two separate questions covering physical, psychological and social aspects of 
health. Item scores were coded, summed and transformed to a scale ranging from 0 (worst 
QoL) to 100 (best QoL) for each dimension. The Cronbach’s alpha for a recent NMD study 
ranged from 0.77 to 0.94.5 The WHOQoL-bref consists of 26 items divided into four domains 
covering physical, psychological, social and environmental aspects and has two single-item 
questions. For each scale, item scores were coded, summed and transformed to a scale ranging 
from 0 (worst QoL) to 100 (best QoL). The Cronbach’s alpha for a recent study of NMD 
patients ranged from 0.60 to 0.84.5 
Contextual variables were assessed using three questions with a visual analogue scale: 
General health status was assessed using the EuroQol-visual analogue scale for the single 
question ‘How good or bad is your health today?’,18 with the endpoints ‘Best imaginable 
health state’ scoring 100, and ‘Worst imaginable health state’ scoring 0. The extent of 
limitations was assessed using the single question ‘To what extent are you limited due to your 
NMD?’ Response options are on a ten-point scale ranging from 1 (not limited at all) to 10 
(completely limited). And general QoL was assessed using the single question ‘How do you 
rate your QoL?’, with the endpoints ‘Best imaginable QoL’ scoring 10, and ‘Worst 






To examine the differences in the prevalence and severity of disabilities between the relevant 
NMD subgroup we used the categorisation according to Rowland19: motor-neuron disorders, 
muscle disorders, junction disorders, and peripheral nerve disorders. Furthermore, the 
peripheral nerve disorders group was split into primary motor and primary sensor subgroups 




Descriptive statistics were used to examine the patient characteristics. The prevalence of 
disabilities was calculated as the percentage of the patients who experience a disability (score 
>0). Severity scores were calculated as the mean score of the disability scores of all patients. 
To assess differences between diagnosis-based subgroups, Analysis of Variance and T-tests 
were performed for normally distributed continuous variables, a Chi-square test for 
categorical variables, and a Mann-Whitney U-test and Kruskal-Wallis test for not normally 
distributed variables.  
The impact of the disease-related disabilities on QoL was assessed using a series of 
multiple regression analyses with each of the QoL variables as dependent variable. We first 
analysed the impact of patient characteristics (age, gender, years since diagnosis, employment 
status, and educational level) on QoL in Model 1 to control for patient characteristics. We 
then analysed the impact of the disease-related disabilities overall in Model 2. Before being 
entered into the regression analysis, the ordinal and categorical variables – gender, 
educational level and employment status – were dichotomized. The expected direction of 
standardized ß weights is negative, meaning that less disability equates to better QoL. Special 
attention was given to examining the multicollinearity between variables.20 
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Of the 980 eligible patients, 662 participants completed the questionnaires (68% response 
rate). The distribution of NMD diagnoses across the various NMD subgroups is described in 
supplementary table S1. Non-respondents did not differ from respondents in terms of gender, 
but were significantly younger than respondents (mean=53, SD=19, p=0.000). 
 





















 (n=662) (n=62) (n=155) (n=177) (n=71) (n=197) p-value 
Gender n (%)       0.756 # 
 Female 335 (51) 31 (50) 77 (50) 115 (65) 32 ( 45) 80 (41)  
        
Age (years)       0.000 ### 
 Mean (SD) 59 (15.4)  60.8 (12.7) 51.6 (16.8) 58.7 (15.7) 55.7 (14.4) 65.3 (12.3)  
 Range 19-92 29-86 19-92 22-89 26-82 32-91  
        
Relationship status n (%)       0.000 # 
 Married/partnership 468 (71) 51 (82) 95 (61) 128 (72) 52 (73) 142 (72)  
 Unmarried/widowed/ 
 Divorced 
193 (29) 11 (18) 60 (39) 48 (27) 19 (27) 55 (28)  
        
Educational level n (%)       0.000 # 
 Lower level 480 (73) 41 (66) 114 (75) 131 (74) 51 (73) 143 (73)  
 Higher level 177 (27) 21 (34) 37 (25) 46 (26) 19 (27) 54 (27)  
        
Employment status n (%)       0.000 # 
 Employment 187 (28) 18 (29) 46 (30) 60 (34) 21 (30) 42 (21)  
 Unemployment 475 (72) 44 (71) 109 (70) 117 (66) 50 (70) 155 (79)  
 Range  0-65 1-64 1-62 0-65 0-55 0-61  
        
Health-state        
 EQ-VAS, median (IQR) 67 (30) 65 (23) 65 (25) 70 (25) 70 (30) 65 (30) 0.058 ## 
        
Extent of limitations 






6 (5)  
 







        
Quality of Life        
 QoL-rate, median (IQR) 7 (2) 7 (2) 7 (2) 7 (2) 7 (1) 7 (2) 0.129 ## 





The mean age of respondents was 59 years and their mean disease duration was eleven 
years (Table 1). Most respondents were married or in a relationship, were of low education 
level and were retired. There was no significant difference in QoL between the NMD 
subgroups.  
Respondents categorized in the NMD subgroups showed statistically significant 
differences in age, relationship status, education level, employment status, years since 
diagnosis and extent of limitations (Table 1).  
 
Prevalence and severity of disease-related disabilities 
The most prevalent disability reported in the total sample (Table 2) was ‘impairments in 
Muscle Functions’, followed by ‘limitations in Activities of Moving Around’ and 
‘impairments in Mental Functions and Pain’. The Peripheral nerve disorders subgroup, 
primary sensor group, had the highest prevalence for ‘impairments in Mental Functions and 
Pain’ and for ‘impairments in Excretion and Reproductive Functions’ compared to the other 
disorders. The most severe disability in the total sample was ‘impairments in Muscle 
Functions’ followed by ‘lack of support from Social security services’ and ‘Health services’, 
and ‘limitations in Activities of Moving Around’. Disability severity differed statistically 
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 (n=662) (n=62) (n=155) (n=177) (n=71) (n=197) p-value 
Gender n (%)       0.756 # 
 Female 335 (51) 31 (50) 77 (50) 115 (65) 32 ( 45) 80 (41)  
        
Age (years)       0.000 ### 
 Mean (SD) 59 (15.4)  60.8 (12.7) 51.6 (16.8) 58.7 (15.7) 55.7 (14.4) 65.3 (12.3)  
 Range 19-92 29-86 19-92 22-89 26-82 32-91  
        
Relationship status n (%)       0.000 # 
 Married/partnership 468 (71) 51 (82) 95 (61) 128 (72) 52 (73) 142 (72)  
 Unmarried/widowed/ 
 Divorced 
193 (29) 11 (18) 60 (39) 48 (27) 19 (27) 55 (28)  
        
Educational level n (%)       0.000 # 
 Lower level 480 (73) 41 (66) 114 (75) 131 (74) 51 (73) 143 (73)  
 Higher level 177 (27) 21 (34) 37 (25) 46 (26) 19 (27) 54 (27)  
        
Employment status n (%)       0.000 # 
 Employment 187 (28) 18 (29) 46 (30) 60 (34) 21 (30) 42 (21)  
 Unemployment 475 (72) 44 (71) 109 (70) 117 (66) 50 (70) 155 (79)  
 Range  0-65 1-64 1-62 0-65 0-55 0-61  
        
Health-state        
 EQ-VAS, median (IQR) 67 (30) 65 (23) 65 (25) 70 (25) 70 (30) 65 (30) 0.058 ## 
        
Extent of limitations 






6 (5)  
 







        
Quality of Life        
 QoL-rate, median (IQR) 7 (2) 7 (2) 7 (2) 7 (2) 7 (1) 7 (2) 0.129 ## 





The mean age of respondents was 59 years and their mean disease duration was eleven 
years (Table 1). Most respondents were married or in a relationship, were of low education 
level and were retired. There was no significant difference in QoL between the NMD 
subgroups.  
Respondents categorized in the NMD subgroups showed statistically significant 
differences in age, relationship status, education level, employment status, years since 
diagnosis and extent of limitations (Table 1).  
 
Prevalence and severity of disease-related disabilities 
The most prevalent disability reported in the total sample (Table 2) was ‘impairments in 
Muscle Functions’, followed by ‘limitations in Activities of Moving Around’ and 
‘impairments in Mental Functions and Pain’. The Peripheral nerve disorders subgroup, 
primary sensor group, had the highest prevalence for ‘impairments in Mental Functions and 
Pain’ and for ‘impairments in Excretion and Reproductive Functions’ compared to the other 
disorders. The most severe disability in the total sample was ‘impairments in Muscle 
Functions’ followed by ‘lack of support from Social security services’ and ‘Health services’, 
and ‘limitations in Activities of Moving Around’. Disability severity differed statistically 
significantly for most disabilities between NMD subgroups. 
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Impact of disease-related disabilities on QoL  
We obtained satisfactory results, and there was no multicollinearity: the variance inflation 
factor (VIF) for ‘Activities of Moving Around’ was 5.6 and the average VIF was 2.0. The 
mean tolerance was 0.59 and the range was from 0.20 to 0.85 and was never below the critical 
value of 0.2. 
Disease-related disability variables contributed significantly and considerably to an 
important segment of the variance for all SF-36 and WHOQoL-bref domains. The significant 
standardized β weights were in the expected direction, meaning that patients who reported 
more disability experienced less QoL. The low significant positive direction of the β weight 
for the variable ‘Seeing Functions’ in relation to the SF-36 variable Bodily pain was 
somewhat unexpected.  
The disabilities which were strong predictors for QoL evaluated using the SF-36 (Table 3) 
were: 
- ‘Impairments in Mental Functions and Pain’ (impairments in sleep functions, fatigue, 
emotional functions, thought functions, and sensation of pain) was a significant 
predictor for six out of eight QoL variables 
- ‘Impairments in Muscle Functions’ (impairments in muscle power functions and 
muscle endurance functions) and ‘Limitations in Activities of Moving Around’ 
(limitations in changing body position, maintaining body position, transferring 
oneself, walking, using transportation, and recreation and leisure) were important 
predictors in the ‘Physical Functioning’ QoL domain 
- ‘Restrictions in Participation in Life Situations’ (restrictions in mobility, relationships 
and recreation and leisure) was an important predictor in the ‘Role Physical’ and 
‘Social Functioning’ QoL domains 
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Impact of disease-related disabilities on QoL  
We obtained satisfactory results, and there was no multicollinearity: the variance inflation 
factor (VIF) for ‘Activities of Moving Around’ was 5.6 and the average VIF was 2.0. The 
mean tolerance was 0.59 and the range was from 0.20 to 0.85 and was never below the critical 
value of 0.2. 
Disease-related disability variables contributed significantly and considerably to an 
important segment of the variance for all SF-36 and WHOQoL-bref domains. The significant 
standardized β weights were in the expected direction, meaning that patients who reported 
more disability experienced less QoL. The low significant positive direction of the β weight 
for the variable ‘Seeing Functions’ in relation to the SF-36 variable Bodily pain was 
somewhat unexpected.  
The disabilities which were strong predictors for QoL evaluated using the SF-36 (Table 3) 
were: 
- ‘Impairments in Mental Functions and Pain’ (impairments in sleep functions, fatigue, 
emotional functions, thought functions, and sensation of pain) was a significant 
predictor for six out of eight QoL variables 
- ‘Impairments in Muscle Functions’ (impairments in muscle power functions and 
muscle endurance functions) and ‘Limitations in Activities of Moving Around’ 
(limitations in changing body position, maintaining body position, transferring 
oneself, walking, using transportation, and recreation and leisure) were important 
predictors in the ‘Physical Functioning’ QoL domain 
- ‘Restrictions in Participation in Life Situations’ (restrictions in mobility, relationships 
and recreation and leisure) was an important predictor in the ‘Role Physical’ and 
‘Social Functioning’ QoL domains 





- ‘Limitations in Self-care and Domestic Activities’ (limitations in fine hand use, hand 
and arm use, washing oneself, caring for body parts, going to the toilet, dressing, 
preparing meals, and doing housework) and ‘Restrictions in Mental Functions and 
Pain’ were important predictors in the ‘Role Emotional’ QoL domain.  
 

























NMDIP          
Impairments in …..         
 Muscle Functions  -0.20** -0.06  0.12 -0.14 -0.07  0.21 -0.02 -0.08 
 Movement Functions  0.09 -0.01 -0.06  0.14 -0.06 -0.02 -0.10 -0.10 
 Excretion and Reproductive 
Functions 
-0.00 -0.11  0.04 -0.04 -0.11 -0.06  0.11 -0.14 
 Swallowing and Speech Functions  0.04 -0.01 -0.10 -0.11  0.11  0.08 -0.13 -0.02 
 Mental Functions and Pain -0.08 -0.16   -0.59***   -0.53***   -0.36***   -0.40**   -0.34**   -0.36** 
 Seeing Functions  0.09 -0.00  0.11* 0.09 -0.09 -0.02 -0.00 -0.01 
         
Limitations in …..         
 Activities of Moving Around   -0.57*** 0.20 -0.08 0.02  0.24  0.29  0.15  0.19 
 Self-care and Domestic Activities -0.11 0.15 -0.04 0.13 -0.17  -0.42** -0.03 -0.10 
         
Restrictions in …..         
 Participation in Life Situations -0.10   -0.46*** -0.09 -0.08  -0.32** -0.07 -0.12 -0.15 
         
Lack of support from…..         
 Immediate family  0.04  0.04  0.02  0.04  0.01  0.01 -0.13 0.03 
 Social security services -0.06  0.00 -0.05 -0.02  0.05 -0.12 -0.03 0.03 
 Health services  0.02  0.03 -0.05 -0.01 -0.07  0.04 -0.01 0.01 
         
 R2 0.73 0.31 0.52  0.51 0.49 0.27 0.29 0.43 
 ΔR2 # 0.66 0.22  0.41 0.33 0.38 0.19 0.24 0.31 
 F  20.7***  3.5***   8.35***   7.92***   7.33***   2.92***   3.23***   5.83 *** 
 F Change# 
 
  26.78***   3.47***   9.35***   7.26***   8.01***  2.91**   3.69***   5.91 *** 
* =p<.05; **=p<.01; ***=p<.001. In bold: statistically significant ß values.  
#  = compares Model 2 (disabilities) vs. Model 1 (patient characteristics) 
 
 
The disabilities which were strong predictors for QoL evaluated using the WHOQoL-bref 
(Table 4) were: 
- ‘Restrictions in Participation in Life Situations’ was a significant predictor for three 
out of four QoL variables 
- ‘Impairments in Mental Functions and Pain’ was an important predictor in the 

















NMDIP     
Impairments in …..     
 Muscle Functions -0.09 -0.03  0.02 -0.01 
 Movement Functions 0.06  0.10  0.20  0.21* 
 Excretion and Reproductive Functions -0.05 -0.13   -0.41*** -0.03 
 Swallowing and Speech Functions -0.06 -0.05  0.14 -0.06 
 Mental Functions and Pain   -0.54***  -0.28* -0.21 -0.21 
 Seeing Functions 0.09 -0.11 -0.08 -0.05 
     
Limitations in …..     
 Activities of Moving Around -0.04  0.19  0.00 -0.13 
 Self-care and Domestic Activities  0.07 -0.04  -0.13 -0.13 
     
Restrictions in …..     
 Participation in Life Situations  -0.21* -0.25*  -0.14  -0.27* 
     
Lack of support from …..     
 Immediate family  0.01  0.00  -0.20**  -0.24** 
 Social security services -0.12 -0.07  -0.21* -0.07 
 Health services  0.09 -0.05  0.09 -0.07 
     
 R2 0.70 0.30 0.38 0.43 
 ΔR2 # 0.46 0.23 0.34 0.36 
 F   17.94***   3.33***   4.76***   5.86*** 
 F Change#   16.60***   3.58***   5.99***   6.86*** 
 * =p<.05; **=p<.01; ***=p<.001. In bold: statistically significant ß values. 
 #  = compares Model 2 (disabilities) vs. Model 1 (patient characteristics) 
 
 
- ‘Impairments in Excretion and Reproductive Functions’ (impairments in defecation 
functions, urination functions, and sexual functions) was an important predictor in the 
‘Social Relations’ QoL domain 
-  ‘Lack of support from Immediate Family’ and ‘Lack of support from Social Security 
Services’ showed significant contributions in the ‘Social Relationships’ QoL domain 
- ‘Lack of support from Immediate Family’ showed a significant contribution in the 
‘Environment’ QoL domain.  
 
Discussion 
This study examined the prevalence, severity and impact of a broad range of disease-related 
disabilities on QoL in a large sample of NMD patients. The study’s most important finding is 
that disease-related disabilities have a strong and independent impact on all aspects of health-






- ‘Limitations in Self-care and Domestic Activities’ (limitations in fine hand use, hand 
and arm use, washing oneself, caring for body parts, going to the toilet, dressing, 
preparing meals, and doing housework) and ‘Restrictions in Mental Functions and 
Pain’ were important predictors in the ‘Role Emotional’ QoL domain.  
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The disabilities which were strong predictors for QoL evaluated using the WHOQoL-bref 
(Table 4) were: 
- ‘Restrictions in Participation in Life Situations’ was a significant predictor for three 
out of four QoL variables 
- ‘Impairments in Mental Functions and Pain’ was an important predictor in the 
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 * =p<.05; **=p<.01; ***=p<.001. In bold: statistically significant ß values. 
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- ‘Impairments in Excretion and Reproductive Functions’ (impairments in defecation 
functions, urination functions, and sexual functions) was an important predictor in the 
‘Social Relations’ QoL domain 
-  ‘Lack of support from Immediate Family’ and ‘Lack of support from Social Security 
Services’ showed significant contributions in the ‘Social Relationships’ QoL domain 
- ‘Lack of support from Immediate Family’ showed a significant contribution in the 
‘Environment’ QoL domain.  
 
Discussion 
This study examined the prevalence, severity and impact of a broad range of disease-related 
disabilities on QoL in a large sample of NMD patients. The study’s most important finding is 
that disease-related disabilities have a strong and independent impact on all aspects of health-





related QoL. Although ‘Impairments in Muscle Functions’ was the most severe disability with 
the highest prevalence in all diagnosis-based subgroups, the ‘Impairments in Mental 
Functions and Pain’ was the most important predictor of health-related QoL, followed by 
‘Restrictions in Participation in Life Situations’.  
Our finding that ‘Impairments in Mental Functions and Pain’ was an important 
predictor for QoL confirms previous studies.4,21 The same applies to ‘Restrictions in 
Participation in Life Situations’.7,8  
Our finding that the most prevalent and severe disability ‘Impairments in Muscle 
Functions’ was not a strong predictor for QoL is also interesting. In contrast, the strongest 
predictor, ‘Impairment in Mental Functions and Pain’ that yielded relatively little impairment. 
Other studies also reported this phenomenon.22,23 Graham et al.4 reviewed the literature on 
how disabilities in Muscle Disorders affects QoL and noted this phenomenon. Awareness of 
this phenomenon can help support professionals aiming to improve patients’ QoL.  
We found no differences in QoL between diagnosis-based subgroups, which indicates 
the relatively minor contribution that medical diagnosis make to predicting QoL. We found 
that disease-related disabilities are important indicators of QoL. These findings underline the 
importance of attention to the broad spectrum of consequences of NMDs.  
The positive impact of increased ‘Impairments in Seeing Functions’ on perceived QoL 
in the ‘Bodily Pain’ domain (SF-36), which means that worsening sight has a relatively small 
but positive impact on a patient’s experienced pain, was an unexpected finding. Given the 
number of relationships under investigation, this could be a chance finding, but on the other 
hand, worsening sight could causes a decrease in activity and thereby a decrease in 
experienced activity-related muscle pain. A comparable unexpected finding is the relatively 
small positive impact of increased ‘Impairments in Movement Functions’ on quality of 




effects of adaptations in the environment and the use of assist devices such as mobility 
scooters. 
We also found that the impact of disabilities on QoL was dependent on the QoL 
measurement instrument used. For example, when using the WHOQoL-bref, we found that 
limitations in activities did not affect one of the four domains of QoL. However, when using 
the SF-36, these limitations did affect QoL in the ‘Physical Functioning’ and ‘Role 
Emotional’ domains. Conversely, we found that environmental aspects had no impact on QoL 
when using the SF-36, while ‘Lack of support from Immediate Family or Social Security 
Services’ affected one or two of the four WHOQoL-bref domains. This finding indicates that 
QoL continues to be an evolving concept, which should be borne in mind when choosing a 
QoL measurement instrument and interpreting results. 
We examined our expectation of differences in disability prevalence and severity 
between the peripheral nerve disorders subgroups. We found differences in ‘impairments in 
Mental Functions and Pain’ (difference of proportion test p<0.01, Mann Whitney U-test, 
p=0.013) and ‘impairments in Excretion and Reproductive Functions’ (difference of 
proportion test p<0.01, Mann Whitney U-test, p=0.007). The prevalence and severity of pain, 
and impairments in reproductive functions were higher in the primary sensor group, probably 
because the autonomous nervous system is more involved compared to the motor sensor 
group.  
We did not expect a prevalence of more than 50% for ‘impairments of Swallowing and 
Speech Functions’ in our muscle group, but it should be realized that swallowing is a complex 
process not only comprising pharyngeal sphincters but also facial, lingual and chewing 
muscles. Self-evidently swallowing is an important factor for patients’ prognosis and 
QOL.24,25  
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Our study might be limited concerning the representativeness for the population of 
NMD patients, because all patients in our study are adults and from the northeast part of the 
Netherlands. 
Our study has some important strengths. First is the fact that we examined the impact 
on QoL of a broad range of disease-related disabilities, separately and in relation to each 
other, while most studies examined only one or some disabilities in one or some NMDs. As a 
result, this study offers a unique insight into the consequences of NMD. Second, this study 
examined the consequences of a large sample of NMDs representing all acknowledged 
diagnosis-based subgroups and not just one disease or a few diseases as is usually the case. 
Combined with our finding that it is the disease-related disabilities rather than the medical 
diagnosis which are relevant to predicting QoL, our findings are relevant to a broad 
population and could have important implications for the treatment of patients with chronic 
diseases such as NMD. Insight into the prevalence, severity and relative impact of a large 
number of disease-related disabilities could contribute to medical and non-medical support of 
NMD patients. Furthermore, if the focus of support is shifted from medical diagnoses to 
disabilities, the professionals who support patients with a chronic disease might exchange 
knowledge and experiences, or could integrate their activities. This ‘joining forces’ could 
contribute to the QoL of the chronically ill.    
Conclusions: Although impairment of muscle function is the most prevalent and 
severe disability, impairment of mental function and pain have the greatest impact on QoL of 
NMD patients.  
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Objective: To adapt and to combine the self-report Upper Extremity Functional Index and 
Lower Extremity Function Scale, for the assessment of disability-severity in patients with a 
neuromuscular disease and to examine its psychometric properties in order to make it suitable 
for indicating disease-severity in neuromuscular diseases.  
Design: A cross-sectional postal-survey study was performed among patients diagnosed with 
a neuromuscular disease.  
Methods: Patients completed both adapted extremity function scales, questionnaires for 
psychometric evaluation, and disease-specific questions. Confirmatory factor analysis was 
performed, and reliability and validity were examined.  
Results: Response rate was 70% (n=702). The Extremity Function Index model with a two-
factor structure – for upper and lower extremities – showed an acceptable fit. The Extremity 
Function Index-scales showed good internal consistency (alphas: 0.97-0.98). The known-
groups validity test confirmed that Extremity Function Index scales discriminate between 
categories of ‘Extent of limitations’ and ‘Quality of Life’. Convergent and divergent validity 
tests confirmed that Extremity Function Index scales measure the physical impact of 
neuromuscular diseases. Relative Validity tests showed that the Extremity Function Index 
scales performed well in discriminating between subgroups of patients with increasing ‘Extent 
of limitations’ compared to concurrent measurement instruments. 
Conclusion: The Extremity Function Index proved to be a sound and easy to apply self-report 
disability-severity measurement instrument in neuromuscular diseases. 
 
Key words: disability; disability-severity; disease-severity; neuromuscular disease; 
psychometric evaluation; extremity function; questionnaire; activities; extent of limitations; 






Neuromuscular diseases (NMDs) generally lead to progressive impairment in body functions 
and therefore have a profound impact on physical and psychosocial life, with loss of mobility 
as one of the main problems.1, 2 Research into therapeutic approaches to neuromuscular 
disorders has progressed rapidly over the past decade and shows great promise for the future.3 
Therefore easy to apply and psychometrically sound assessment tools for evaluating disease-
severity or impairments in body functions, are of growing importance.  
Currently, the evaluation of disease-severity in NMDs is mainly achieved by assessing 
muscle power functioning using electromyography, measuring muscle strength using 
handheld dynamometry or by manual muscle tests. However, such tests can be experienced as 
harmful and time consuming, and do not reflect the subject’s functional abilities.4 In addition, 
there are observation-based measurements for NMD -as for example the Motor Function 
Measure scale4, and the disease-specific Muscular Dystrophy Functional Rating Scale5 but 
these measurements require patient exercise, a physiotherapy room and trained investigators. 
In order to overcome these disadvantages, self-report measuring instruments were developed, 
for example the disease specific Amyotrophic Lateral Sclerosis Functional Rating Scale6, 7, 
measuring instruments administered by trained evaluators such as the Muscular Dystrophy 
Functional Rating Scale5, and a measurement of activity limitations the ACTIVLIM8, a 
combination questionnaire for children and adults. However, some of these instruments are 
disease specific, evaluator dependent or limited in feasibility. Also generic health related 
quality of life (QoL) measurements – the SF-36, for example – are used to measure the impact 
of disabilities on QoL.2 Unfortunately, these generic measurements do not have specific items 
relevant for patients with a NMD, and therefore lacking sensitivity to change, while some of 
these items will be redundant when applied to NMDs.1 
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A well-known and commonly used disability-severity score, in clinical practice often used 
as indicator for disease-severity, is the Expanded Disability Scale (EDSS) developed for 
patients with Multiple Sclerosis9. This disability-severity score is based on limitations in 
mobility. The biggest advantages of the self-report version of the EDSS are that: 1) it is an 
easy instrument to administer in clinical practice and research, and 2) it expresses disability-
severity in terms of a number, so that a change in disability-severity can easily be evaluated.10 
For these reasons we opted for limitations in mobility as a starting point for the development 
of a disability-severity measurement in NMDs that can serve as an indicator for disease-
severity. This seems to be appropriate as it is known that muscle function related limitations 
in activities in NMDs are regarded as indicators of disease-severity.11, 12  
In summary, a valid and reliable, easy to apply, self-report disability-severity measurement 
instrument for adults, reflecting the functioning of muscles in the upper and lower extremities 
involved in activities of daily living covering NMDs is not available yet. Therefore, the aim of 
this study was to adapt and to combine two validated self-report questionnaires, the Upper 
Extremity Functional Index13 (UEFI) and the Lower Extremity Functional Scale14(LEFS) as a 






Patients and Methods 
Sample  
A cross-sectional postal-survey study was conducted among patients diagnosed with an NMD 
(n=1003). These patients were registered at the Department of Neurology of the University 
Medical Center Groningen, the Netherlands. The sample comprised patients from the four 
major NMD groups according to Rowland: motor neuron disorders, muscle disorders, 
junction disorders, and peripheral nerve disorders.15 Patients were included if they could be 
assigned to one of these four NMD groups. Furthermore, patients also had to be aged 18 years 
or older, be able to read and write in Dutch, and able to provide informed consent.  
 
Procedure 
Patients received information about the study and were invited to participate. Patient’s 
informed consent was achieved by returning the completed questionnaire. Respondents 
completed both (adjusted) extremity function scales, questionnaires for psychometric 
evaluation, and answered demographic and disease specific questions. Reminders were sent 
after two weeks. After the questionnaires had been returned, they were checked for 
completeness. If a page had not been completed, a copy was returned with a request to 
complete the missing questions or, if this only concerned one or a few questions, patients 
were interviewed by telephone.  
The Medical Ethical Committee of the University Medical Center of Groningen has assessed 
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Extremity Functioning Index 
The self-report Upper Extremity Functional Index (UEFI) and Lower Extremity Functional 
Scale (LEFS) were used as a basis for the disability-severity measure, the Extremity 
Functioning Index. Both scales were developed and validated for easy assessment of 
(limitations in) functioning. Each scale consists of twenty items assessing functional 
problems. Items were scored on a 5-point scale with discrete responses ranging from 0 
(extremely difficult or unable to perform activity) to 4 (no difficulty). Items for both scales 
were summed for a total score ranging from 0 to 80 points, with higher scores representing 
higher levels of functioning. In previous studies both scales showed good internal consistency 
(Cronbach’s alphas: 0.9016 and 0.9614 for the LEFS, and 0.9513 for the UEFI), and stability 
(ICCs: 0.8817 and 0.9718 for the LEFS, and 0.8519 for the UEFI).  
For the purpose of this study the LEFS and the UEFI were translated into Dutch following 
the procedure proposed by Guillemin and colleagues.20 First, the original Canadian English 
version was translated into Dutch by three researchers (IB, KvdB and HB) who have a 
working command of Dutch and English at academic level and who worked independently of 
each other. Secondly, the most satisfactory translation was chosen by consensus among the 
researchers. Thirdly, this Dutch translation was translated back into English by a native 
English speaker. Finally, the resulting English version was compared to the original English 
version, and all discrepancies were discussed by the three researchers. Any remaining 
discrepancies were discussed with the native English speaker.  
The translated version of the LEFS and UEFI was reviewed by three medical specialists in 
NMDs (JBMK, GD and IB) and a methodologist (BM) on clarity, applicability and patient 
burden. As a result, six questions in the LEFS were adjusted for reasons of applicability in 
NMD-patients concerning disease specific limitations to walking distance (questions 11 and 





These questions were adjusted to shorter distances (questions 11 and 12), shorter duration 
(question 14), walking (questions 16 and 17) and jumping (question 19). Because of these 
disease specific adjustments we have renamed the LEFS into the Lower Extremity Functional 
Index (LEFI). Next, the feasibility of the UEFI and LEFI was examined by pre-testing in a 
sample of twenty randomly selected NMD-patients. No barriers or unclear and ambiguous 
items were found. For the UEFI, the LEFI and the combination of both scales, the EFI, item 
scores were transformed for both subscales (score range from 0 to 80) and the total scale 




To examine the psychometric properties of the EFI the following measurement instruments were 
applied:  
The Neuromuscular Disease Impact Profile (NMDIP), a broad and generic ICF-based 
disease impact measurement instrument that includes 36 items and consists of eight scales and 
four additional items.21 The 36 items represent the four ICF components. For the Body 
Functions component items and for the Participation component items scoring options ranged 
from 0 (no disability) to 4 (complete disability); for the Activities component items scoring 
options ranged from 0 (no disability) to 3 (complete disability); and for the Environmental 
Factors component items scoring options ranged from 0 (no support) to 2 (full support). Item 
scores were summed into a scale, with higher scores indicating more disability. In a previous 
study among Dutch NMD patients, the NMDIP domains showed satisfactory levels of internal 
consistency: Cronbach’s alpha ranged from 0.63 to 0.92 and Mean Inter-item Correlation 
Coefficient from 0.47 to 0.77.21  
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The Medical Outcome Study 36-item Short Form Health Survey (SF-36) is a broad and 
generic Health Related Quality Of Life (HRQoL) measurement and consists of 36 items 
divided over eight domains.22 For each domain, item scores were coded, summed, and 
transformed on a scale from 0 (worst health) to 100 (best health). In a previous study among 
Dutch multiple sclerosis patients, the SF-36 domains showed satisfactory levels of internal 
consistency: Cronbach’s alpha ranged from 0.81 to 0.94.21  
The Groningen Activity Restriction Survey (GARS) is a domain-specific instrument for 
measuring Limitation in activities and consists of 18 items divided over two scales.23 A four-
category response format was used, ranging from 1 (no problem in performing without help) 
to 4 (impossible to perform). Scores were summed for each subscale. The GARS showed 
strong levels of internal consistency in a study among Dutch NMD patients: Cronbach’s 
alphas were 0.93 and 0.95.21  
 
Single item variables 
The first variable ‘Extent of Limitations’ was evaluated with the Extent of Limitations Visual 
Analogue Scale (VAS)24 Respondents were asked to answer the question: ‘To what extent are 
you limited due to your NMD?’ Scoring options ranged from 0 (no limitation at all) to 10 
(most severely limited). The second variable ‘Quality of Life’ (QoL) was adapted from the 
WHOQOL-bref.25 Respondents were asked to answer the question: ‘How would you rate your 
quality of life?’ Response options were: 1=very poor, 2=poor, 3=neither poor nor good, 
4=good and 5=very good.  
 
Analysis 





To construct the EFI, we hypothesized a two-factor model in which extremity functioning 
is measured within domains for upper extremity functioning (using items from the UEFI)13 
and lower extremity functioning (using items from the LEFI).14 Before testing the two-factor 
model the data were examined for the presence of univariate (standardized scores: |z| ≥ 3.30) 
and multivariate outliers (Mahalanobis Distance: p < 0.001).26, 27 Next, to test the two-factor 
model a confirmatory factor analysis (CFA) was conducted using M-Plus 7.1.28  The CFA 
methods used in this software are suitable for not normally distributed ordinal items, and are 
based on polychoric correlations between standardized observed ordinal items.29 Factor 
loadings of > 0.40 were considered sufficient.30 Model fit was examined using multiple 
criteria: 1) as a measure of overall fit, the root means squared error of approximation 
(RMSEA): ≤ 0.05 indicate a close fit, whereas values up to 0.08 indicate an adequate fit; and 
2) as descriptive measures: a Comparative Fit Index (CFI) ≥ 0.95 and a Tucker-Lewis Index 
(TLI) ≥ 0.95 indicate an adequate fit.31 To merge the two domains into one disability-severity 
measurement, a strong correlation as expected (Spearman’s correlation coefficient ≥ 0.70). 
For scale construction, the maximum number of missing items allowed to be replaced by the 
mean scale score was determined by a sufficient Cronbach’s alpha in relation to the number of 
scale items.32  
Next the EFI scale features were examined. The internal consistency was examined using 
Cronbach’s alpha. Alpha was considered sufficient if ≥ .70.33, 34 The distribution of scale 
scores was evaluated by calculating the median, mean, standard deviation, and the observed 
score range. Floor and ceiling effects were examined by calculating the proportions of 
patients with worst and best possible scores. Proportions ≤ 20% were considered acceptable.35  
For examining psychometric properties the Kruskal-Wallis test and the Mann-Whitney U 
test were used for not normally distributed variables (Shapiro-Wilk test, p < 0.05). 
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Regarding known-groups validity36, 37 we hypothesized that the EFI scales should 
discriminate between respondent subgroups known to differ on relevant clinical 
characteristics. The variables ‘Extent of Limitations’ and ‘Quality of Life’ were used to create 
such relevant respondent subgroups. Respondents were divided into two groups of ‘Extend of 
Limitations’: those with a lower ‘Extent of Limitations’ (score 0-4) and those with a higher 
‘Extent of Limitations’ (score 5-10). Respondents were divided into two groups of ‘Quality of 
Life’: those with a poor Quality of Life’ (response options 1-3) and those with good Quality 
of Life (response options 4-5).  
Convergent and divergent validity was performed by examining the extent to which 
correlation values between EFI scales and concurrent measures were consistent with 
hypotheses. The Spearman rank order correlation coefficient (Rho, p, 2-tailed) was calculated 
between the EFI scales and concurrent scales. To support convergent validity, the EFI scales 
needed to have strong correlations (≥ 0.70), with scales covering the same domain in 
concurrent measurements (physical functioning scale and activity scales).38 To support the 
divergent validity, the EFI scales should correlate weakly (≤ 0.40) with scales covering 
different domains (mental health scale) in concurrent measurements.38 
Relative Validity (RV) indicates the extent to which a scale or construct is able to 
discriminate between groups compared to the concurrent measures.22, 39 Respondents were 
divided into four groups of ‘Extent of Limitations’: Group A with a ‘No to low extent of 
limitation’ (score 0-4), Group B with a ‘moderate extent of limitation’ (score 5-6), Group C 
with a ‘high extent of limitation’ (score 7-8) and, Group D with a ‘very high extent of 
limitation’ (score 9-10). Next, RV of scales was examined in several steps. First, the Chi-
square was computed for each scale by calculating the Kruskal-Wallis H-test. Second, the RV 
of each scale was computed by dividing each H-ratio by the H-ratio for the scale with the 





To estimate the magnitude of the clinical relevance of statistically significant group 
differences the nonparametric effect size (coefficient r) for unrelated samples was 
calculated.38 The coefficient r was calculated by dividing the Z-statistic (obtained from the 
Mann-Whitney U test) by the root of the sample size (n). To interpret these nonparametric 
effect sizes, Cohen suggests the following thresholds for interpretation: r < 0.10 indicates a 
trivial effect; r ≥ 0.10 to < 0.24 a small effect; r ≥ 0.24 to < 0.37 a moderate effect; and r ≥ 
0.37 a large effect. An r ≥ 0.10 reflects a clinically relevant difference between groups.38, 40 
Statistical analyses were performed using SPSS 23.0 for Windows and CFA was 




In sum, 702 patients (70% response rate) completed the questionnaires. The participants’ 
demographic and disease specific characteristics are described in table 1. Mean age of 
participants was 59 years (SD=15,7), the mean number of years since diagnosis was 12 years, 
and about 30 percent of the respondents had retired due to an NMD. The motor neuron 
disorder group was relatively small compared to the other NMD subgroups (Rowland 
classification). 
Non-respondents did not differ from respondents in terms of gender but were statistically 
significant younger (p-value: 0.000, 2-sided) than respondents. 
 
Extremity Function index (EFI) structure 
CFA confirmed the expected two-factor model with good loadings (Table 2). Each observed 
aspect in terms of use of lower or upper extremities, loaded sufficiently on the expected 
factor. Model fit indicators were sufficient with RMSEA 0.086 (90% confidence interval: 
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0.084 - 0.089), CFI 0.96, and TLI 0.96, and confirmed a good fit of the two-factor model 
using the Upper Extremity Functional Index (UEFI) and the Lower Extremity Functional 
Index (LEFI). As expected, the correlation between the UEFI and LEFI was strong (0.87), 
such that both functioning domains can be merged into one disability-severity measure. 
 
Table 1 Sample characteristics (n = 702) 
Variable Total sample 
Gender (%)  
 Female 350 (50.1) 
Age  
 Median  
 IQR 
 Mean (SD) 
61 
21 
58.9 (15.7)  
 Range 19-92 
Year since diagnosis  
 Median  
 IQR 




 Range  0-65 
Relationship status (%)  
 Married/partnership 497 (70.8) 
 Unmarried/widowed/divorced 186 (26.5) 
 Missing 19 (2.7) 
Educational level (%)  
 Primary school/vocational training  235 (33) 
 Secondary school/vocational training  270 (38) 
 Higher education /vocational training  161 (23) 
 University  28 (4) 
Employment status (more answers possible) (%)  
 Enrolled in a training program or educational course 36 (5.1) 
 Employment (part-time or full-time) 173 (24.6) 
 Voluntary work (part-time or full-time) 42 (6.0) 
 (Partially) retired due to NMD 213 (30.3) 
 Housewife/househusband 171 (24.4) 
 Retired due to age 243 (34.6) 
NMD category (%)  
  Motor neuron disorder  43 (6.1) 
  Muscle disorder  154 (22.1) 
  Junction disorder  234 (33.3) 
  Peripheral nerve disorder  271 (38.5) 








Table 2 Factor loadings of the Extremity Function Index (EFI) model 
  
Upper Extremity Function Index 
 
Factor  
1  Any of the activities involved in your usual work, housework, or schoolwork 0.860 
2  Your usual hobbies, and recreational or sporting activities 0.766 
3  Lifting a bag of groceries to waist level 0.928 
4  Lifting a bag of groceries above your head 0.900 
5  Grooming your hair 0.829 
6  Pushing up on your hands (e.g., from bathtub or chair) 0.855 
7  Preparing food (e.g., peeling, cutting) 0.861 
8  Driving 0.755 
9  Vacuuming, sweeping, or raking 0.920 
10  Dressing 0.915 
11  Buttoning your clothing 0.839 
12  Using tools or appliances 0.871 
13  Opening doors 0.867 
14  Cleaning 0.919 
15  Tying or lacing shoes 0.883 
16  Sleeping 0.494 
17  Laundering clothes (e.g., washing, ironing, folding) 0.884 
18  Opening a jar 0.810 
19  Throwing a ball 0.846 
20  Carrying a small suitcase (with your affected limb) 0.889 
   
  
Lower Extremity Function Index 
 
Factor  
1  Any of the activities involved in your usual work, housework, or schoolwork 0.897 
2  Your usual hobbies, and recreational or sporting activities 0.809 
3  Getting into or out of the bathtub 0.889 
4  Walking between rooms 0.924 
5  Putting on your shoes or socks 0.894 
6  Squatting 0.886 
7  Lifting an object, like a bag of groceries from the floor 0.914 
8  Performing light activities around your home 0.928 
9  Performing intensive activities around your home 0.927 
10  Getting into or out of a car 0.873 
11  Walking 10 yards 0.924 
12  Walking 200 yards 0.897 
13  Going up or down 10 stairs (about 1 flight of stairs) 0.897 
14  Standing for 1 hour 0.859 
15  Sitting for 1 hour 0.623 
16  Running on even ground 0.886 
17  Running on uneven ground 0.905 
18  Making sharp turns while running fast 0.933 
19  Jumping  0.943 
20  Rolling over in bed 0.828 
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Table 3 shows the scale features for the Extremity Function Index (EFI) total scale and EFI 
subscales for the total sample and for the four major NMD groups. Internal consistency for 
the EFI and both of the subscales was good. Cronbach’s alphas ranged from 0.97 to 0.98. No 
negative floor and ceiling effects were found. 
The final version of the EFI scale consists of two subscales each with twenty items, and 
also a total scale score can be calculated. (See appendix), 
 
Table 3 Scale features of the EFI total scale and subscales UEFI and LEFI (n=702) 
 
 

















Median  IQR Mean SD Alpha  
Total              
 EFI 702 40 0-160 0-159 5.6 0.0 37 41 37.8 25.8 0.98  
  UEFI 701 20 0-80 0-79 9.1 0.0 31 42 33.9 25.7 0.97  
  LEFI 700 20 0-80 0-80 8.4 0.6 41 48 41.7 28.2 0.97  
Motor neuron disorder             
 EFI 43 40 0-160 0-158 2.3 0.0 54 49 55.1 28.2 0.98  
  UEFI 43 20 0-80 0-79 2.3 0.0 49 47 52.4 27.9 0.97  
  LEFI 43 20 0-80 0-80 4.7 4.7 61 50 57.4 32.1 0.98  
Muscle disorder             
 EFI 155 40 0-160 0-159 1.3 0.0 49 67 50.8 25.7 0.98  
  UEFI 154 20 0-80 0-79 3.2 0.0 44 40 46.1 26.4 0.97  
  LEFI 153 20 0-80 0-80 1.9 1.3 56 42 55.6 27.4 0.97  
Junction disorder             
 EFI 234 40 0-160 0-143 11.5 0.0 23 37 26.9 22.4 0.98  
  UEFI 234 20 0-80 0-72 14.1 0.0 25 36 26.8 22.3 0.96  
  LEFI 234 20 0-80 0-71 17.1 0.0 23 40 27.0 24.1 0.97  
Peripheral nerve 
disorder 
          
  
 EFI 270 40 0-160 0-152 3.7 0.0 36 37 37.1 23.3 0.98  
  UEFI 270 20 0-80 0-76 9.3 0.0 27 40 30.2 23.9 0.96  
  LEFI 270 20 0-80 0-76 5.2 0.0 44 38 44.0 25.2 0.97  
EFI=Extremity Function Index; UEFI=Upper Extremity Functional Index; LEFI =Lower Extremity Functional 









Known-groups validity  
The known-groups validity of the EFI scales was confirmed by the expected group differences 
(Table 4). Patients classified as having greater ‘Extent of Limitations’ or higher ‘Quality of 
Life’ had significantly higher scores on the EFI scales compared with those classified as 
having lower ‘Extent of Limitations’ or lower reported ‘Quality of Life’. Effect sizes were 
very large for ‘Extent of Limitations’ and moderate for ‘Quality of Life’ and confirmed 
clinical relevance.  
 
Table 4 Known groups validity of the Extremity Function Index (n=702) 
 Low (0-4) versus High (5-10)  
Extent of Limitations 
Poor (1-3) versus Good (4-5)  































Extremity Function Index 278/424 216.4 440.1 0.000 (-14.3) 0.54 228/474 453.8 302.3 0.000 (-9.3) 0.35 
 Lower Extremity Function Index 278/422 215.3 439.6 0.000 (-14.4) 0.54 228/472 443.1 305.8 0.000 (-8.4) 0.32 
 Upper Extremity Function Index 278/423 230.5 430.3 0.000 (-12.8) 0.48 228/473 453.1 301.8 0.000 (-9.3) 0.35 
*Mann-Whitney U test, 2-sided. 
 
 
Convergent and divergent validity 
Table 5 summarizes our findings on the convergent and divergent test of EFI scales. The 
direction, strength and pattern of correlations are as hypothesized. We found the expected 
high correlations for most of the similar constructs (bold figures in the table) confirming 
convergent validity. Unexpected was the moderate correlation with the NMDIP ‘Muscle 
Functions’ variable. We found the expected low correlations (italic figures in the table) 
supporting divergent validity. Unexpected were the moderate correlations with the NMDIP 
‘Mental Functions and Pain’ variable.  
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convergent validity. Unexpected was the moderate correlation with the NMDIP ‘Muscle 
Functions’ variable. We found the expected low correlations (italic figures in the table) 
supporting divergent validity. Unexpected were the moderate correlations with the NMDIP 
‘Mental Functions and Pain’ variable.  
 
 






Table 5 Results of convergent and divergent validity of EFI total and subscales (n=702). 
 
 
EFI# UEFI# LEFI# 
NMDIP    
 Muscle Functions 0.73 0.63 0.74 
 Movement Functions 0.59 0.50 0.59 
 Swallowing and Speech Functions 0.31 0.35 0.25 
 Excretion and reproductive Functions 0.46 0.44 0.42 
 Mental Functions and Pain 0.58 0.56 0.53 
 Activities of Moving around 0.82 0.69 0.86 
 Self-care and Domestic Activities 0.85 0.83 0.80 
 Participation in Life Situations 0.64 0.56 0.64 
SF-36    
 Physical functioning -0.89 -0.76 -0.92 
  Social Functioning -0.53 -0.52 -0.49 
 Role Physical -0.51 -0.49 -0.47 
 Bodily Pain -0.48 -0.44 -0.48 
 General Health -0.58 -0.55 -0.53 
 Mental health -0.29 -0.32 -0.25 
 Role Emotional -0.32 -0.33 -0.28 
 Vitality -0.49 -0.52 -0.42 
GARS    
  Instrumental activities of daily living  0.89 0.83 0.86 
  Activities of daily living  0.86 0.77 0.87 
#=Spearman rank order correlation coefficient, all correlations are significant at the 0.01 level (2-tailed); 
EFI=Extremity Function Index; UEFI=Upper Extremity Functional Index; LEFI =Lower Extremity Functional 
Index; NMDIP= Neuromuscular Disease Impact Profile; SF-36= Medical Outcome Study Short Form 
Questionnaire; GARS=Groningen Activity Restriction Scale.  
Expected convergent validity scores (higher correlations >.70) in bold and expected divergent validity scores 
(lower correlations <.40) in italic. Relative Validity (RV) 
 
About 40% (n=278) of the respondents reported ‘low extent of limitations’ (Group A) due to 
NMD, while 24% (n=169) reported a ’moderate extent of limitation’ (Group B), and 28% 
(n=197) reported a ‘high extent of limitation’ (Group C). About 8% (n=58) of the respondents 
reported a ‘very high extent of limitations’ (Group D).  
Comparisons of the RV coefficients, as summarized in table 6, revealed that the EFI 
‘Lower Extremity Function Index’ subscale and the Extremity Function Index total scale were 
the most valid in discriminating between groups with an increasing ‘Extent of Limitation’. 
 We then examined the performance of the EFI in indicating the differences between 
extreme groups (A-D) and subgroups (A-B, B-C, C-D) regarding the physical functioning 
construct, as it relates to the similar constructs in the concurrent measurement instruments. 
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Regarding physical functioning, we found that the NMDIP ‘Muscle Functions’ performed 
slightly better compared to the ‘Lower Extremity Function Index’. Subgroup differences (A-
B, B-C and C-D) were statistically significant and clinically relevant for all EFI scales.  
In summary, the EFI scales showed one small, and furthermore large effect sizes in 
discriminating between (sub) groups with an increasing ‘Extent of Limitations’ compared to 
similar physical functioning constructs in concurrent measures. 
 
Discussion 
The Extremity Function Index (EFI) appears to be a valid and reliable instrument for 
evaluating disability-severity in adult patients with an NMD. The confirmed model for the 
EFI included a two-factor structure with two one-dimensional scales with twenty indicators in 
the upper extremity function domain and twenty indicators in the lower extremity function 
domain. The reliability of the EFI and both subscales was good. Known-groups validity was 
supported by statistically significant and clinically relevant differences between groups of 
patients with a NMD that differed in terms of ‘Extent of Limitations’ and ‘Quality of Life’. 
Expectations regarding the direction and strengths of the convergent and divergent 
correlations were confirmed for most correlations. Unexpected was the moderate correlation 
with the ‘Muscle Functions’ variable. Apparently loss of muscle strength is more obvious in 
lower extremity function than in upper extremity function. Also unexpected were the 
moderate correlations with the NMDIP ‘Mental Functions and Pain’ variable. Probably the 
aspect of pain in this variable caused this stronger correlation with the EFI (sub)scales than 
expected. Finally, compared to concurrent domain specific and generic QOL measurement 
instruments the EFI performed well in discriminating between groups of NMD patients with 
an increasing ‘Extent of Limitations’ as indicated on the visual analogue scale. 
A major strength of this study lies in the large and representative study population 





generalizability of the study results. As such the EFI may be considered applicable to the 
broad range of NMD patients that are encountered in clinical practice 
 A possible study limitation should be noted: the relatively small sample size of the motor 
neuron disorder group compared to the sample size of the other NMD groups. However, the 
complete study sample showed good representation of functional limitations in NMDs in 
terms of the use of upper and lower extremities in daily activities.  
The EFI can have important implications for multidisciplinary care, research and for 
patients. Clinicians now have an easy to apply and patient-friendly disability-severity 
measurement instrument to evaluate the differences in disability-severity between relevant 
subgroups of NMD-patients. These differences can be seen as an indicator for the ability of 
this measurement instrument for detecting changes in disability over time. Researchers also 
can compare disability-severity between groups of NMD-patients. EFI could also have 
implications for patient self-management. For instance, EFI can offer patients a voice in 
making future decisions about assistive equipment and environmental adjustments. 
Further research should focus on examining the relationship between objective and 
subjective disease-severity, psychometric evaluation concerning stability and sensitivity to 
change of the EFI, and validation across other populations of neuromuscular disease patients 
in other cultures.   
In conclusion, this study showed that the Extremity Function Index (EFI) appears to be a 
reliable and valid disability-severity measurement instrument for NMDs. Moreover, the 
measure is an easy to apply and patient-friendly instrument for clinical practice, and can also 
support clinical trials and epidemiological studies.  
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The 40-item Extremity Function Index 
Response options 
0 = not difficult 
1 = slightly difficult 
2 = moderately difficult 
3 = quite difficult 
4 = extremely difficult or impossible  
Upper Extremity Function Index (UEFI) 
We are interested in whether the upper-limb problem for 
which you are seeking help is causing you any difficulty with 
the activities listed below. Please indicate how difficult each 
of the following activities is or would be for you today: 
 Lower Extremity Function Index (LEFI) 
We are interested in whether the lower-limb problem for 
which you are seeking help is causing you any difficulty with 
the activities listed below. Please indicate how difficult each 
of the following activities is or would be for you today: 
1 Any of the activities involved in your 
usual work, housework, or schoolwork 
 1 Any of the activities involved in your 
usual work, housework, or schoolwork 
2 Your usual hobbies, recreational or 
sporting activities 
 2 Your usual hobbies, recreational or 
sporting activities 
3 Lifting a bag of groceries to waist level  3 Getting into or out of the bathtub 
4 Lifting a bag of groceries above your head  4 Walking between rooms 
5 Grooming your hair  5 Putting on your shoes or socks 
6 Pushing up on your hands (e.g., from a 
bathtub or chair) 
 6 Squatting 
7 Preparing food (e.g., peeling, cutting)  7 Lifting an object (e.g., a bag of groceries) 
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Background: To examine the influence of stigma on the quality of life of patients with a 
neuromuscular disease. 
Design: Cross-sectional postal survey. 
Setting: Outpatient clinic of the Department of Neurology, University Hospital Groningen, 
the Netherlands. 
Subjects: Patients diagnosed with a neuromuscular disease. 
Measures: The Stigma Scale for Chronic Illness, the World Health Organization Quality of 
Life – abbreviated version questionnaires and some background and disease-related questions. 
The Stigma Scale for Chronic Illness was translated into Dutch according to international 
guidelines. The impact of stigma on quality of life was estimated using hierarchical multiple 
regression analysis after controlling for the extent of limitations and patient characteristics. 
Results: In total 235 patients (75% response rate) were diagnosed with neuromuscular disease 
and represented all four categories of the approximately 600 neuromuscular diseases. Most 
patients (86%) reported self-stigma, while 64% reported to experience enacted stigma. 
Experienced quality of life was moderate to good. Stigma contributed to a unique and 
substantial extent to all domains of quality of life: explained variance for the impact of stigma 
on quality ranged from 0.13 (social relations) to 0.34 (physical functioning) for self-stigma 
and from 0.09 (social relations) to 0.11 (physical and psychological health, and quality of the 
environment). 
Conclusion: Self stigma was a stronger predictor for poorer quality of life compared with 
enacted stigma. In other words: patients suffered more from shame and fear for discrimination 
(self-stigma) than from the really experienced discrimination and exclusion (enacted stigma). 
 
Keywords  






Goffman (1963) was the first to define stigma as ‘an undesired differentness’.1 Since then, 
many scientists have studied stigma.2–5 A recent and broad definition of stigma came from 
Scambler:4 ‘Stigma is typically a social process, experienced or anticipated, characterized by 
exclusion, rejection, blame or devaluation that results from experience, perception or 
reasonable anticipation of an adverse social judgement about a person or group’. 
Health-related stigma is typically characterized by social disqualification of 
individuals and populations who are identified with particular health problems.5 For better 
understanding stigma in (chronic) diseases, Scambler and Hopkins introduced a recognizable 
and generally accepted distinction between ‘felt’ and ‘enacted’ stigma.6,7 In this dichotomy, 
enacted stigma refers to actually experiencing discrimination or exclusion, whereas felt 
stigma refers to shame of being deviant and the feeling that discrimination or exclusion will 
happen.7–9 Van Brakel3 identified similarities in the perceived consequences of health-related 
stigma across diseases such as social avoidance, concealment of the condition, marital 
problems, shame and embarrassment, and reduced employment opportunities. 
Experiences and negative feelings related to stigma are likely to increase 
psychological distress such as depression7,10 and to decrease wellbeing and quality of life. 
Various studies reported a negative influence of stigma on the quality of life of patients with 
different kinds of chronic diseases, such as irritable bowel syndrome,11 epilepsy,12 mental 
illnesses13,14 and hepatitis.15 
Neuromuscular diseases comprises chronic neurological disorders that affect any part 
of the nerve and muscle with impact on sensation or movement.16 There are approximately 
600 neuromuscular diagnoses that can be classified in four major categories: motor neuron 
disorders, for example amyotrophic lateral sclerosis (ALS); muscle disorders, for example 
Duchenne muscular dystrophy; junction disorders, for example myasthenia gravis; and 
peripheral nerve disorders, for example Polyneuropathy.17 Many of these neuromuscular 
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diseases have a genetic basis, are progressive and incurable.16,18 Patients with a 
neuromuscular disease can have difficulties with speech or writing, can be wheelchair 
dependent or may need assistance with activities of daily living.19 
Quality of life of neuromuscular disease patients has great potential to become 
negatively affected by the combination of a chronic and often progressive disease, and it 
seems plausible that stigma is a relevant variable in explaining quality of life of patients with 
a neuromuscular disease. We think that these patients can be at risk for stigmatization because 
of the eventually developed limitations, and dependency from assistance devices. However, 
the prevalence of stigma, and consequently the impact of stigma on quality of life among 
patients with a neuromuscular disease are, to our opinion, not investigated. 
Therefore, the objective of this study was to examine the prevalence and seriousness 
of stigma in patients with a neuromuscular disease, and the effect of stigma on quality of life. 
We controlled for the extent of limitations when analysing the impact of stigma on quality of 






A cross-sectional postal survey was carried out among a sample of patients diagnosed with a 
neuromuscular disease (n = 315) attending the Department of Neurology of the University 
Hospital in Groningen, the Netherlands. The sample comprised patients from the four major 
neuromuscular disease categories, namely: motor neuron disorders, muscle disorders, junction 
disorders and peripheral nerve disorders. In total, 235 patients (75% response rate) completed 
the questionnaire. 
Patients were included if they, according to the pre-specified clinical disease 
characteristics, without any doubt could be assigned to one of these four neuromuscular 
disease categories. After inclusion, patients received a mailed questionnaire. After the 
questionnaires were returned, they were checked for completeness. If a page had not been 
filled in, a copy was sent with a request to complete the questions or, if it concerned one or 
only a few questions, patients were interviewed by telephone. 
Ethical approval was obtained from the local ethics committee. 
 
Measures 
Patient characteristics, including age, gender, marital status, educational level and 
employment status were derived from patients’ questionnaires. For application of the ordinal 
variables marital status, educational level and employment status in the regression analyses, 
they were dichotomized to (so-called) dummy variables. 
Clinical variables, such as neuromuscular diagnosis of the patient’s neuromuscular disease, 
were retrieved from medical records. For determining the disease severity, patients were 
asked to appraise their extent of limitations with the question “To what extent are you limited 
due to your neuromuscular disease?” on a visual analogue scale ranging from 0 (not limited at 
all) to 10 (severely limited).20 
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Subjective quality of life was assessed using the World Health Organization Quality of Life 
(WHOQOL) - BREF.21 The WHOQOL-BREF consists of 26 items divided into four domains 
covering: physical health (for example ‘‘How well are you able to get around?’’), 
psychological health (for example ‘‘How much do you enjoy life?’’), social relations (for 
example ‘‘How satisfied are you with your personal relationships?’’) and environmental 
aspects (for example ‘‘How satisfied are you with your access to health services?’’) and two 
generic single-item questions (not considered in the scoring). For each scale, item scores were 
coded, summed and transformed to a scale ranging from 0 (worst health) to 20 (best health). 
In a previous Dutch study the WHOQOL-BREF showed satisfactory levels of internal 
consistency: Cronbach’s alpha ranged between 0.63 and 0.81.20 
The Stigma Scale for Chronic Illness is a recently developed generic stigmatization measure 
in chronic neurological diseases.22 The Stigma Scale for Chronic Illness consists of 24 items 
that can be examined as one overall stigma scale or as two subscales: one scale for enacted 
stigma and one for self or internalized stigma. The enacted-stigma scale measures the 
experienced discrimination or exclusion, and consists of 11 items (for example “Because of 
my illness, some people avoided me”). The self-stigma scale measures shame and the fear for 
discrimination or exclusion, and consists of 13 items (for example “Because of my illness, I 
felt embarrassed in social situations”). Response options range between 0 (never) and 4 
(always). For each scale, item scores were summed and transformed to a scale ranging 
between 0 and 52 for the self-stigma scale, and between 0 and 40 for the enacted-stigma scale. 
Higher scores indicate more stigmatization. The American–English language version of the 
Stigma Scale for Chronic Illness showed satisfactory levels of internal consistency among 
patients with neurological disorders.22 Cronbach’s alpha was 0.97 for the overall scale, while 
both subscales correlated considerably (r = 0.81). To avoid a biased estimate of reliability by 





related stigma we assumed that a patient should report at least one symptom of enacted stigma 
or self-stigma, respectively. 
For this study the Stigma Scale for Chronic Illness was translated into the Dutch language 
following the procedure proposed by Guillemin et al.23 First, the original American–English 
version of the questionnaire was translated into Dutch by three researchers who had the 
command of the Dutch and English languages at academic level, working independently of 
each other. Second, the most satisfactory translation was chosen in consensus among the 
researchers. Third, this Dutch translation was translated back into the English language 
version by a native English speaker. Finally, the resulting American–English version was 
compared with the original American–English version and all discrepancies were discussed 




First, descriptive statistics were used to examine the patient characteristics, perceived stigma 
and quality of life scores. Continuous variables of self-stigma, enacted stigma and quality of 
life domains were not normally distributed (Shapiro-Wilk test, p < 0.05). Therefore, 
differences between the neuromuscular disease categories were analysed using the Kruskal–
Wallis test with a post hoc Bonferroni correction to adjust for multiple comparisons with 
critical level of significance p = 0.01 (p = 0.05/5). 
Reliability of all scales was examined with the internal consistency coefficient Cronbach’s 
alpha and mean interitem correlation coefficient. According to the guidelines of Briggs and 
Cheek,24 an mean interitem correlation coefficient of ≥ 0.25 seems reasonable. For acceptable 
reliability of the scales we used the following criteria: Cronbach’s alpha ≥ 0.70 and ≤ 0.90; 
and mean interitem correlation coefficient ≥ 0.25.24,25 
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Second, a series of hierarchical regression analyses (the enter method) were employed to 
examine the impact of stigma on physical health, psychological health, social relations and 
environmental aspects, yielding standardized regression coefficients (beta). We used three 
models to explore the effect of stigma: Model 1 tested the crude effect of stigma on physical, 
psychological, social and environmental quality of life, respectively. Model 2 tested the effect 
of stigma on the quality of life variables when controlling for the extent of limitations by the 
neuromuscular disease, and finally in Model 3, patient characteristics (gender, age, marital 
status, educational level and employment status) were added. Ordinal variables were 
dichotomized (see Table 1) – for using them as so-called dummy variables – before entering 
them in the regression analysis: marital status – living without a partner (score 0) and living 
with a partner (score 1); employment status – employment without payment (score 0) and no 
employment with payment (score 1); educational level – lower level (score 0) and higher level 
(score 1). 
In order to assume that our conclusions are true for a wider population of neuromuscular 
patients we tested the following assumptions. First, the risk for multicollinearity between the 
predictor variables (Type II error) was diagnosed by calculating the variance inflation factor 
and the tolerance statistic for all predictor variables in the regression model. Estimated beta-
coefficients in the regression analysis are inflated when a predictor has a strong linear 
relationship with the other predictor(s) in case the variance inflation factors exceed four. 
Moreover, if the average variance inflation factor is substantially greater than one the 
regression may be biased by multicollinearity. Tolerance estimates below 0.1 (1/variance 
inflation factor) indicates a serious problem and tolerance estimates below 0.2 are worthy of 
concern or indicate a potential problem.26,27 Furthermore (second assumption), the error terms 
or residuals should be uncorrelated or independent: the lack of autocorrelation was tested with 
the Durban–Watson test and finally (third assumption) the distribution of residuals should 









In sum 235 patients (75% response rate) completed the questionnaire. 
Proportions of males and females in the study sample did not differ from the proportions 
among non-responders (n = 80). Although non-respondents were on average younger (mean 
age 50 years, SD 18.5) compared with participating patients (mean age 56 years, SD 15.5), 
this difference was not statistically significant (p = 0.97). 
 
Table 1 Patient characteristics (n=235) 
Variable Sample 
Gender  
  Female (%) 





  Mean (SD) 




Marital status (%) 
  Married / partner(ship) 
  Unmarried / widowed / divorced 
 
173 (74) 
62  (26) 
Educational level (highest level) (%) 
  Primary or secondary school / vocational  training 




Employment status (%)  
 Employment for payment 71 (30) 
 No employment for payment 164 (70) 
Neuromuscular disease category (%) 
  Motor neuron disorder 
  Muscle disorder 
  Junction disorder 






Extent of limitations (0-10)* 
  Mean (SD)  
 
5.3 (2.5) 
* A higher score indicates a higher extent of limitations 
 
All participating patients were diagnosed in one of the four neuromuscular disease 
categories (Table 1). Most patients had a muscle disorder or a junction disorder. Respondents 
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reported to be moderately limited owing to their neuromuscular disease. There were more 
women than men (p = 0.09). The average age was 56 years (SD 15.5) while 72% was younger 
than 65 years. About one-third of the respondents were retired owing to the disease, and about 
one-third was employed for payment. About three-quarters had a lower or secondary 
educational or vocational level. 
Reliability of the quality of life and stigma scales was good. Cronbach’s alpha for the 
WHOQOL-BREF scales ranged between 0.70 and 0.81, while the homogeneity of the scales 
was confirmed by the mean interitem correlation coefficients that ranged between 0.35 and 
0.50. Cronbach’s alpha for the self-stigma scale was 0.91 and for the enacted-stigma scale 
0.89. Mean interitem correlation coefficients were 0.41 (self-stigma) and 0.45 (enacted 
stigma). Scale scores for both stigma scales were moderately correlated (Spearman’s 
correlation coefficient: Rho = 0.63, p < 0.01), and explained variance (R²) was 0.40 indicating 
that these scales measured related but distinct constructs. 
Most respondents reported to experience self-stigma while two-thirds of the patients 
reported to experience enacted stigma. There were no differences between the neuromuscular 
disease categories when it comes to self-stigma (not in table); however patients with a 
peripheral nerve disorder experienced a lower level of enacted stigma than patients with 
muscle disorders (not in table: p > 0.01 Kruskal–Wallis post hoc analysis with Bonferroni 
correction). 
Patients reported moderate to good levels of quality of life (Table 2), while there were no 










Table 2 Stigma and quality of life (n=235) 
Variable Sample 
Stigma* 
Self-stigma (0-52)  
    Prevalence (> 0) (%) 
    Mean (SD)** 
  Enacted stigma (0-40) 
      Prevalence (> 0) (%) 








Quality of Life* (0-20) mean (SD) 
Physical health  
  Psychological health 
  Social relations 






* a higher score indicates more stigma or better QOL, **Score among all respondents. 
 
In analysing the impact of self-stigma and enacted stigma, indices of variance inflation 
factor were all close to 1.0 with an average variance inflation factor values that ranged from 
1.08 to 1.09 and from 1.13 to 1.14 for the enacted-stigma and self-stigma models, 
respectively. As all variance inflation factor values were close to 1.0 and consequently, 
tolerance statistics (1/variance inflation factor value) were close to 1.0 as well and were not 
below the critical value of 0.2. Furthermore, in each of the four regression analysis the 
Durbin–Watson test was close to 2.0, and varied from 2.056 to 2.147 and from 1.996 to 2.055 
for enacted and self-stigma, respectively. All residuals were tested against the normal 
distribution and each Kolmogorov–Smirnov test was non-significant indicating that the 
deviation from the normal distribution were owing to random variation (in other words: it is 
probably normal). 
The results of the regression analysis to determine the effect of stigma on health-related 
quality of life are presented in Tables 3 and 4. Self-stigma, as well as enacted stigma, 
contributed to a unique segment of the variance for all quality of life domains. The 
standardized β weights were in the expected direction, meaning that patients who reported 
more stigmatization experienced less quality of life. 
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    Mean (SD)** 
  Enacted stigma (0-40) 
      Prevalence (> 0) (%) 








Quality of Life* (0-20) mean (SD) 
Physical health  
  Psychological health 
  Social relations 






* a higher score indicates more stigma or better QOL, **Score among all respondents. 
 
In analysing the impact of self-stigma and enacted stigma, indices of variance inflation 
factor were all close to 1.0 with an average variance inflation factor values that ranged from 
1.08 to 1.09 and from 1.13 to 1.14 for the enacted-stigma and self-stigma models, 
respectively. As all variance inflation factor values were close to 1.0 and consequently, 
tolerance statistics (1/variance inflation factor value) were close to 1.0 as well and were not 
below the critical value of 0.2. Furthermore, in each of the four regression analysis the 
Durbin–Watson test was close to 2.0, and varied from 2.056 to 2.147 and from 1.996 to 2.055 
for enacted and self-stigma, respectively. All residuals were tested against the normal 
distribution and each Kolmogorov–Smirnov test was non-significant indicating that the 
deviation from the normal distribution were owing to random variation (in other words: it is 
probably normal). 
The results of the regression analysis to determine the effect of stigma on health-related 
quality of life are presented in Tables 3 and 4. Self-stigma, as well as enacted stigma, 
contributed to a unique segment of the variance for all quality of life domains. The 
standardized β weights were in the expected direction, meaning that patients who reported 
more stigmatization experienced less quality of life. 
 






Table 3 Impact of self-stigma on WHOQOL-BREF variables: hierarchical multiple regression 
analysis (n = 235). 








Model 1  
Self-stigma   –0.59***   –0.55***   –0.36***   –0.50*** 
  ssmc   










Self-stigma   –0.49***   –0.56***   –0.37***   –0.44*** 
Extent of 
limitations 
  –0.24*** 0.04 0.03   –0.16** 
  ssmc  
  R2  














Self-stigma   –0.56***   –0.60***    –0.46***   –0.46*** 
Extent of 
limitations 
  –0.22*** 0.06 –0.07 –0.15* 
Gender –0.00  0.04  0.14* –0.05 
Age    –0.25*** –0.10 –0.18*   –0.13* 
Marital status 0.04  0.06    0.18**   0.08 
Educational level 0.05  0.11 0.04     0.16** 
Employment status 0.04  0.04 0.02  0.02 
  ssmc  
  R2  













*p < 0.05; **p < 0.01; ***p < 0.001. 
ssmc: statistical significance of model change for the added variables. 
 
 
Adjusting the impact of stigma for potential confounders (Models 2 and 3) did not affect the 
impact of stigma on the quality of psychological health. The impact of stigma on the quality 
of physical health was weakened when adjusted for the influence of extent of limitations and 
age, and (only for enacted stigma) gender. The impact of stigma on the quality of social 
relations was weakened by age, but strengthened by marital status (self-stigma) and gender 
(self-stigma).The impact of stigma on the quality of the environment was weakened by gender 









Table 4 Impact of enacted stigma on WHOQOL-BREF variables: hierarchical multiple regression 
analysis (n = 235). 
 Physical health Psychological health Social relations Environment  
 β β β β 
Model 1 











Model 2  
Enacted-stigma –0.252*** –0.30*** –0.29*** –0.27*** 
Extent of 
limitations 
















Model 3  
Enacted-stigma –0.31*** –0.32*** –0.33*** –0.30*** 
Extent of 
limitations 
–0.34*** –0.07 –0.04 –0.26*** 
Gender –0.13* –0.08 0.07 –0.13* 
Age –0.23*** –0.08 –0.16* –0.12 
Marital Status –0.02 –0.01 0.12 0.03 
Educational level 0.01 0.05 0.00 0.13* 
Employment 
status 
















*p < 0.05; **p < 0.01; ***p < 0.001. 




In this study, the prevalence and impact of stigma on quality of life was examined among 
patients with a neuromuscular disease and represented the four categories of the 
approximately 600 neuromuscular diseases. The most important finding is that both self-
stigma and enacted stigma have strong and independent associations with physical, 
psychological, social and environmental quality of life, both crude and after adjustment for 
the extent of limitation and patient characteristic variables. In other words, this study gives 
evidence that patients suffering from a neuromuscular disease who experienced stronger 
feelings of being stigmatized reported poorer quality of life. Furthermore, the patterns of 
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impact of self-stigma and enacted stigma on domains of quality of life, and the influence of 
confounding variables were similar (Tables 3 and 4). 
We found evidence that self-stigma was a stronger predictor in all domains of quality of 
life compared with enacted stigma, meaning that neuromuscular disease patients suffered 
more from shame and their fear for discrimination, than from the really experienced 
discrimination and exclusion. As the saying goes ‘people suffer most by the suffering that is 
feared’. We also found that the extent of limitations, which can be seen as a risk for stigma, 
had no impact on perceived quality of psychological health and quality social relations. This 
means that self-stigma, or the fear for discrimination and exclusion, was a stronger predictor 
of these quality of life variables than the actual risk for stigma, the extent of limitations, is. 
Thus, taking these findings into account, the conclusion could be that fear for stigma is a more 
important issue for health care professionals than (the risk for) actual discrimination is. 
We also may conclude that the outcomes from the regression analyses were not biased by 
multicollinearity, correlated residuals or non-normally distributed errors and we assume that 
our conclusions are likely to be true for a wider population of patients with a neuromuscular 
disease. 
As expected, the prevalence and severity of self-stigma was higher than of enacted stigma. 
Scambler and Hopkins6 also reported that about 90% of the epilepsy patients admitted to 
experience felt stigma that is closely related to self-stigma, while only a third of these patients 
could recall ever having encountered enacted stigma. Rao et al.,22 who examined stigma 
among a sample of 511 patients with different chronic neurological disorders, found 
considerably higher stigma scores (total score range: 0–92, mean 42.2, SD 19.7) compared 
with results in our sample (mean 14.0, SD 12.4). An explanation could be found in the 
difference in the composition of the samples. The sample in the study of Rao et al.22 mainly 
consisted of stroke (38%) and epilepsy (33%) patients. Maybe the consequences of these 





explanation could be found in cultural differences between the more individualistic oriented 
culture in the United States of America and the generally more social-oriented culture in the 
Netherlands. 
Most of the respondents in our study perceived a good quality of life. Comparable results 
were found among people in the general population: the WHOQOL-group found relatively 
similar mean scores in 23 countries.28 Probably the impact of a neuromuscular disease on the 
perceived quality of life is negligible. The same could be said for other chronic conditions 
because comparable findings for quality of life were also found among Multiple Sclerosis 
patients29 and Sickle Cell disease patients,30 while patients with HIV infection perceived a 
moderate quality of life.31 
There are some possible limitations in our study. First, our sample is a convenience sample 
based on the patients attending the university hospital in the northeast part of the Netherlands. 
Therefore our sample might be limited concerning the representativeness for the population of 
neuromuscular disease patients. Second, there might be questions about the motivation of 
patients to participate in a study evaluating stigma and its impact on the findings, and 
therefore threaten the representativeness of the sample. However, this survey was part of a 
larger study in which a large number of questionnaires was administered, so we think the 
influence of this possible limitation is trivial. Third, despite our well-considered selection of 
confounding variables we might have overlooked relevant variables. We considered including 
stigma and quality of life-related variables like depression,32 but had to decide against it 
considering the large number of questionnaires already administered. Finally, a possible, but 
acceptable, limitation in our study is our choice for a less well known quality of life measure, 
the WHOQOL-BREF. Therefore, the results concerning quality of life in neuromuscular 
disease are less comparable than when a well-known measure, such as the SF-36, was used. 
However, the relative validity of the WHOQOL-BREF seemed better compared with the SF-
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36.33 Furthermore, the WHOQOL-BREF is based on a more recent and broader definition of 
quality of life34 than the SF-36 is,35 including also environmental aspects. 
In our opinion, this is the first time that the impact of stigma on health-related quality of 
life was investigated among patients with a neuromuscular disease. The recently developed 
Stigma Scale for Chronic Illness performed well within our sample. However, unlike Rao et 
al.,22 we found a moderate correlation (Spearman’s correlation coefficient: Rho = 0.63, p < 
0.01) and explained variance (R² = 0.40) between the two subscales self-stigma and enacted 
stigma, indicating that these scales measured related but distinct constructs. Probably, the 
difference between self-stigma and enacted stigma is larger than in patients with stroke or 
epilepsy. Considering the relative low prevalence and severity of enacted stigma in our study, 
in combination with the more visible consequences of stroke and epilepsy, it seems 
reasonable to assume that this difference in findings is owing to the scores on the enacted 
stigma scale in our study. 
Further psychometric evaluation of the Stigma Scale for Chronic Illness will strengthen the 
validation of this instrument, and comparisons across other neurological and non-neurological 
conditions will help to evaluate the generalizability of the Stigma Scale for Chronic Illness to 
other chronic conditions. However, cautiousness is desired in the merging of both subscales to 
one overall stigma scale. Furthermore, it would be valuable when the sensitivity for change of 
the Stigma Scale for Chronic Illness is examined, because the effectiveness from many stigma 
reduction interventions is often not known.36 
Considering the findings in this study it is appropriate for scientist and healthcare 
professionals to pay attention to stigma and to apply (preventive) interventions targeted on 
decreasing the impact of stigma in patients with a neuromuscular disease to improve quality 









 • Patients suffering from a NMD who experienced stronger feelings of being   
   stigmatized reported poorer quality of life. 
 • Fear for stigma is a more important issue than (the risk for) actual discrimination is. 
 • The extent of limitations owing to the NMD has no impact on perceived quality of 
   psychological health and quality of social relations. 
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The objective of this thesis was to provide insight into the consequences of having an NMD. 
Therefore the main focus of this thesis was to identify the most relevant NMD-related 
disabilities, to develop a psychometrically sound measurement instrument based on these 
disabilities and to evaluate the impact of these disabilities on perceived quality of life. A 
second objective was to adapt and combine two known extremity functioning scales, so that 
they can serve as an easy to apply indicator for disease-severity in NMDs. The third objective 
was to examine the prevalence and severity of stigmatization in persons diagnosed with an 
NMD and its impact on QoL.  
This chapter provides an overview of the main findings, including methodological 
considerations, and explains implications for practice and research. 
 
Main findings 
Research question 1 (Chapter 2): What is the content validity of the initial ICF Core Set 
for NMDs?  
This study examined the content validity of the initial ICF Core Set for NMDs. This initial 
ICF Core Set was developed for three neurological diseases. Concepts in three established 
disease-specific health-related QoL questionnaires were linked with ICF categories. Next, 
these selected ICF categories were linked to the ICF categories in the initial ICF Core Set. 
The final ICF Core Set for NMDs is a valid selection of ‘very relevant’ categories, 
belonging to the four ICF components reflecting a broad range of functioning and disabilities 
related to NMDs. This ICF Core Set provides a solid basis for the development of a 
measurement instrument reflecting the most relevant aspects of functioning and health for 







Research question 2 (Chapter 3 and 4): How should the prevalence and severity of NMD- 
related disabilities, using the ICF Core Set for NMDs, be assessed? 
To answer this question we developed the Neuromuscular Disease Impact Profile (NMDIP), a 
self-report measurement instrument based on the ICF categories in the Core Set for NMD. 
The NMDIP reflects the disease-related disabilities in adult patients diagnosed with an NMD. 
We found that the NMDIP has a good fit for an eight-factor model within three ICF 
components with good reliability (internal reliability within disease-related subgroups and 
stability over time) and convergent, discriminant and known-groups validity. The NMDIP is 
sensitive to clinically important differences between the relevant subgroups and performed as 
well as or better than the concurrent measurement instruments. We may therefore conclude 
that the NMDIP is a psychometrically sound measurement instrument for the evaluation of a 
broad range of disease-related disabilities. 
 
Research question 3 (Chapter 5): What is the impact of a broad range of NMD-related 
disabilities on QoL? 
To answer this question, we first compared the diagnosis-related subgroups and found no 
differences in QoL between subgroups. We then performed multiple regression analysis and 
found that all NMD-related disabilities showed strong and independent associations with all 
aspects of QoL. ‘Impairments in Mental Functions and Pain’ was the most important predictor 
of QoL, followed by ‘Restrictions in Participation in Life situations’. Although ‘Impairments 
in Muscle Functions’ showed the highest prevalence and severity scores, its impact on QoL 
was relatively limited.  
 
Research question 4 (Chapter 6): How should disability severity be assessed when focusing 
on extremity functioning in patients with an NMD? 
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To answer this question we first translated, adapted and combined the self-report Upper 
Extremity Functional Index and Lower Extremity Function Scale, calling it the Extremity 
Function Index (EFI). The EFI represents all relevant upper and lower activity items 
reflecting NMD-related disability-severities in extremity function. We then examined the 
psychometric properties of the EFI and found good internal consistency, and convergent, 
divergent and known-groups validity. Relative Validity tests showed that the EFI scales 
performed well in discriminating between patients subgroups compared to concurrent 
measurement instruments. We may therefore conclude that the EFI is a sound and easy to 
apply self-report disability-severity measurement instrument in neuromuscular diseases. 
 
Research question 5 (Chapter 7): What is the impact of stigma on the QoL of patients with 
an NMD? 
To answer this question, we first translated the Stigma Scale for Chronic Illness and then 
examined the impact of stigma on QoL using a hierarchical multiple regression analysis after 
controlling for the extent of limitation and patient characteristics. Most patients (86%) 
reported self-stigma, while 64% reported experiencing enacted stigma. Stigma contributed to 
a unique and substantial extent to all QoL domains. Self-stigma was a stronger predictor for 
poorer QoL compared to enacted stigma, meaning that patients suffered more from shame and 






Reflection on the main findings 
The following themes arise from the findings in this thesis. The overall theme was the 
consequences of having an NMD. This main theme can be specified into three subthemes: 1) 
measuring the consequences of an NMD, 2) the consequences of an NMD for functioning, 
and 3) the consequences of an NMD on QoL. These themes will be discussed below.  
 
Measuring the consequences of an NMD on functioning 
The main challenge in this study was to develop disease-specific measurement instruments to 
evaluate the consequences for functioning for all NMDs. We succeeded in developing two 
such instruments. The two instruments share ease of administration as self-report disability-
severity measurement instruments, and differ in terms of goals, scope and use.  
The NMDIP was primarily developed for organizing person-centred care and support 
for persons diagnosed with an NMD. Therefore, the International Classification for 
Functioning and Health (ICF) was chosen as the basis for developing the questionnaire. 
Furthermore, NMD patients and their representatives were given a lot of influence in the 
selection of relevant categories from the ICF. As a result, The NMDIP is a measurement 
instrument for assessing of a broad spectrum of specific consequences of NMDs on human 
functioning, representing categories from the ICF components ‘Body Functions’, ‘Activities 
and Participation’ and ‘Environmental Factors’. The EFI was primarily developed as a 
disability-severity measure capable of indicating disease severity. Therefore, two valid and 
reliable extremity function measurement instruments were translated into Dutch and adapted 
for people with an NMD to assess their daily activities, reflecting upper and lower extremity 
muscle function. As a result, the EFI is an instrument for the measurement of the specific 
consequences of NMDs for a broad spectrum of upper and lower extremity muscle function. 
 We also translated an instrument for the measurement of the prevalence and severity 
of stigma, the Stigma Scale for Chronic Illness. Stigma among NMD patients and the impact 
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of stigma on QoL are relevant but were not investigated. As a result, the two subscales of the 
translated Stigma Scale for Chronic Illness showed good internal consistency and performed 
well within our sample. 
 
The NMDIP reflects disease-specific characteristics of NMDs  
We were also able to demonstrate that the NMDIP reflects disease-specific characteristics by 
comparing results on disease-specific disabilities between NMDs and Multiple Sclerosis. We 
found differences between the two diseases, which underlines the strength of both 
measurement instruments, the NMDIP and the Multiple Sclerosis Impact Profile (MSIP).1 
The same ICF Core Set was used as the basis for the development of both measurement 
instruments, but we had to add the ‘Endurance function’ ICF category to improve the validity 
of the ICF Core Set for NMDs (Chapter 2). ‘Endurance function’ is strongly related to 
‘Muscle weakness’ which is a characteristic aspect of NMDs. Two important differences 
between diseases became clear during the scale construction for the NMDIP (Chapter 3) and 
the MSIP.1 First, the categories for ‘Muscle Functions’ and ‘Movement Functions’ were 
related within MS and formed a single scale, but the two categories were not related within 
the NMDs and formed separate scales. This could be because of the strong relationship 
between muscle endurance and muscle strength within NMDs, based on the etiological 
difference with MS: NMDs mainly cause muscle weakness, while MS is primarily a 
neurological disease. We also found a strong relationship between the disabilities Pain and 
Fatigue (Chapter 3) within NMDs, while this relationship was not found in MS. This can be 
explained by the fact that pain and fatigue are the direct result of having and using weakened 
muscles, which is a common symptom in NMDs. Unlike with NMDs, fatigue in MS is most 
likely connected to the process of inflammation, while pain originates from spasticity and/or 





present in the MSIP: ‘Swallowing and Speech Functions’. This can be explained by the fact 
that some myopathies and myasthenias tend to affect bulbar musculature. 
 
The consequences of NMD on functioning  
We succeeded in obtaining unique insight into the prevalence and severity of a broad range of 
NMD-related disabilities covering a large sample of NMDs. These findings underlined the 
multidimensionality of the health-related problems related to having an NMD. We also found 
evidence of the differences in severity of disease-related disabilities among NMD subgroups. 
To the best of our knowledge, this is the first time that such an insight was obtained. 
 The most prevalent disability reported in the overall sample was ‘impairments in 
muscle functions’, followed by ‘limitations in activities of moving around’ and ‘impairments 
in mental functions and pain’ (Chapter 5). The most severe disability in the overall sample 
was also ‘impairments in muscle functions’ followed by ‘lack of support from social security 
services’ and ‘lack of support from health services’ and ‘limitations in activities of moving 
around’. Disability severity differed statistically significantly for most disabilities among 
NMD-subgroups. 
 We were able to develop a valid and reliable instrument for the measurement of 
extremity functions and their limitations. We therefore had to translate and adapt two known 
extremity function measurement instruments to make them suitable for use in NMDs. It was 
particularly important that the measurement of the lower extremity functions was applicable 
to the evaluation in NMD patients of disease-specific limitations in terms of the ability to 
walk a certain distance, sit for a particular length of time, run and hop. These adjustments 
underline the disease-specific consequences of an NMD. 
When comparing outcomes of the two measurement instruments, the NMDIP and the 
EFI (Chapters 3 and 6), we found that ‘loss of muscle strength’ is more obvious in lower 
extremity function than in the upper extremity function in the context of the impact of NMDs. 
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We also found that the pain aspect had a stronger relationship with extremity function than 
expected. These findings underline the importance of the combination of the two 
measurement instruments. 
Concerning stigma, we found that most respondents reported experiencing self-stigma, 
while two-thirds of the patients reported experiencing enacted stigma. There were no 
differences between the NMD subgroup categories for self-stigma (shame and fear of 
discrimination). However, patients with a peripheral nerve disorder experienced a lower level 
of enacted stigma (actually experienced discrimination and exclusion) than patients with 
muscle disorders. The consequences of peripheral nerve disorders are probably less visible for 
others than the consequences of muscle disorders. This knowledge is important, as it is also 
known that stigmata associated with disability and assistive technology (AT) use are 
integrally related and have the potential to affect AT decision-making processes 
substantively.2 
 
The consequences of NMDs on QoL  
An important challenge in this thesis was to provide a detailed insight into the consequences 
of having an NMD on perceived QoL. Although it is known that having an NMD can 
seriously affect a person’s QoL, little is known about the impact of the individual disease-
specific disabilities. We succeeded in examining the relative impact of a broad range of 
NMD-related disabilities and their relative impact on QoL.  
Most of the respondents in our study reported having a good quality of life. 
Comparable results were found in the general population (Chapter 7). Despite this finding, we 
also found that the disease-related disability variables contributed significantly and 
considerably to the variance for all QoL domains, meaning that patients who reported more 
disability experienced less QoL. Our most important finding was that although ‘impairments 





‘impairments in mental functions and pain’ and ‘restrictions in participation in life situations’ 
showed the most significant impact on QoL (Chapter 5). Of interest in this context is our 
finding that there are no differences in perceived QoL among NMD subgroups, indicating the 
relatively small contribution made by the medical diagnosis in predicting QoL (Chapter 5). 
Finally, we found that that most patients reported stigma, and that stigma contributed 
to a unique and substantial extent to all QoL domains. We also found that patients suffered 
more from shame and fear of discrimination (self-stigma) than from actually experienced 
discrimination and exclusion (enacted stigma). These findings were also found in epilepsy 
patients by Jacobi.3,4 
 
Methodological considerations  
The main strengths of this study are the large and broad sample of NMD patients obtained, 
and the carefully selected and applied methods in the various studies. Nevertheless, some 
possible limitations should also be taken into account.  
 
Sample 
A major strength of this thesis is the large and varied sample of adult NMD patients used, 
representing all NMD subgroups – rather than just drawing from patients of only one disease 
or a few diseases as is usually the case – which improves the generalizability of the study 
results. The measurement instruments developed and validated in the various studies may be 
considered applicable to the broad range of NMD patients encountered in clinical practice. 
Another strength is the classification5 we used, which offered a valid insight into the broad 
representation of NMDs in our sample. 
A possible limitation is the relatively small sample size of the motor neuron disorder 
subgroup compared to the sample size of the other NMD subgroups. However, in our opinion 
the disabilities in this group are sufficiently represented in the NMDIP and EFI, because the 







We also found that the pain aspect had a stronger relationship with extremity function than 
expected. These findings underline the importance of the combination of the two 
measurement instruments. 
Concerning stigma, we found that most respondents reported experiencing self-stigma, 
while two-thirds of the patients reported experiencing enacted stigma. There were no 
differences between the NMD subgroup categories for self-stigma (shame and fear of 
discrimination). However, patients with a peripheral nerve disorder experienced a lower level 
of enacted stigma (actually experienced discrimination and exclusion) than patients with 
muscle disorders. The consequences of peripheral nerve disorders are probably less visible for 
others than the consequences of muscle disorders. This knowledge is important, as it is also 
known that stigmata associated with disability and assistive technology (AT) use are 
integrally related and have the potential to affect AT decision-making processes 
substantively.2 
 
The consequences of NMDs on QoL  
An important challenge in this thesis was to provide a detailed insight into the consequences 
of having an NMD on perceived QoL. Although it is known that having an NMD can 
seriously affect a person’s QoL, little is known about the impact of the individual disease-
specific disabilities. We succeeded in examining the relative impact of a broad range of 
NMD-related disabilities and their relative impact on QoL.  
Most of the respondents in our study reported having a good quality of life. 
Comparable results were found in the general population (Chapter 7). Despite this finding, we 
also found that the disease-related disability variables contributed significantly and 
considerably to the variance for all QoL domains, meaning that patients who reported more 
disability experienced less QoL. Our most important finding was that although ‘impairments 





‘impairments in mental functions and pain’ and ‘restrictions in participation in life situations’ 
showed the most significant impact on QoL (Chapter 5). Of interest in this context is our 
finding that there are no differences in perceived QoL among NMD subgroups, indicating the 
relatively small contribution made by the medical diagnosis in predicting QoL (Chapter 5). 
Finally, we found that that most patients reported stigma, and that stigma contributed 
to a unique and substantial extent to all QoL domains. We also found that patients suffered 
more from shame and fear of discrimination (self-stigma) than from actually experienced 
discrimination and exclusion (enacted stigma). These findings were also found in epilepsy 
patients by Jacobi.3,4 
 
Methodological considerations  
The main strengths of this study are the large and broad sample of NMD patients obtained, 
and the carefully selected and applied methods in the various studies. Nevertheless, some 
possible limitations should also be taken into account.  
 
Sample 
A major strength of this thesis is the large and varied sample of adult NMD patients used, 
representing all NMD subgroups – rather than just drawing from patients of only one disease 
or a few diseases as is usually the case – which improves the generalizability of the study 
results. The measurement instruments developed and validated in the various studies may be 
considered applicable to the broad range of NMD patients encountered in clinical practice. 
Another strength is the classification5 we used, which offered a valid insight into the broad 
representation of NMDs in our sample. 
A possible limitation is the relatively small sample size of the motor neuron disorder 
subgroup compared to the sample size of the other NMD subgroups. However, in our opinion 
the disabilities in this group are sufficiently represented in the NMDIP and EFI, because the 






basis of the two instruments covers all the disabilities in this subgroup sufficiently. Another 
limitation could be the high floor effect of some NMDIP scales, which might affect the 
reliability of these scales.6 However, these floor effects match the course of the slowly 
progressive nature of most NMDs. This means that some disabilities appear years after onset, 
such as impairments in speech and swallowing functions or limitations in upper extremity 
function.  
 
ICF and methods applied 
An important strength in the development of the NMDIP was the application of the ICF 
alongside strong methodologies. This permitted us to develop a valid and reliable 
measurement instrument which could provide a detailed insight into a broad spectrum of the 
impact of NMDs.  
We first used the ICF to reach a valid selection of the most important and relevant ICF 
categories. We therefore validated the initial ICF Core Set, which was meticulously 
developed in a Delphi study,6 in which relevant ICF categories were selected by a varied and 
extensive Delphi panel. It is important to mention the relative great influence of the NMD 
patients and their representatives in this selection. Second, we applied a proven method to 
evaluate the content validity of this initial ICF Core Set by linking concepts from established 
disease-specific measurement instruments, representing three of the four NMD subgroups 
according to Rowland,5 to the items in the initial ICF Core Set. Finally, a reliable linking 
procedure was carried out by experts in NMDs and ICF so that all the relevant expertise was 
present.  
We then used the ICF qualifiers to operationalize the selected ICF categories. These 
qualifiers were specified for each ICF component to record the presence and severity of a 
problem in functioning and were applied to each question. The preliminary questionnaire with 





pre-tested with a random sample of clinicians and patients. The questionnaire was then 
evaluated psychometrically, and rigorous statistical tests were conducted.  
 
Implications for clinical practice  
When used as an assessment tool, the NMDIP may contribute to understanding patients’ 
health problems better, especially in multidisciplinary rehabilitation teams. Clinicians now 
have a valid and reliable assessment tool to assess a broad spectrum of disease-related 
disabilities (Chapter 2). The insight into the prevalence, severity and relative impact of a large 
number of disease-related disabilities could also contribute to medical and non-medical 
support of NMD patients. Furthermore, by shifting the focus of support from medical 
diagnoses to disabilities, the professionals who support patients with chronic diseases can 
exchange knowledge and experiences, or integrate their activities. This jointed up care could 
contribute to the QoL of the chronically ill.  
The EFI could also have important implications for multidisciplinary care and for 
patients. Clinicians now have an easy to apply and patient-friendly instrument to evaluate 
changes in disability-severity over time (Chapter 6).  
The NMDIP and the EFI could also have implications for patient self-management. 
For instance, the results of the combination of the two tools could give patients a say in future 
decisions concerning their healthcare. 
 
Implications for further research 
Future research could focus on the further psychometric evaluation of the measurement 
instruments we developed, adapted or translated for application in NMD patients. For 
example, we recommend further research to evaluate the sensitivity to change of the NMDIP 
scales. Examining and validating the subjective dimension of the NMDIP (Chapter 3) is also 
of interest because we learned from the psychometric evaluation of the MSIP7 (for MS 
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patients) that the subjective dimension of functioning and health operationalized in disability 
perception is relevant to explaining QoL. 
Further research using the EFI (Chapter 6) should focus on the applicability of this 
disability-severity measurement instrument. Psychometric evaluation of the EFI’s stability 
and sensitivity to change, and validation across other NMD patient populations in other 
cultures could further strengthen the quality of the EFI. Finally, researchers could explore 
how the EFI can be used to compare disability severity between NMD patient groups.  
We suggested that both the NMDIP and the EFI could also have clinical implications 
for patient self-management. Although positive results were found in the feasibility studies 
with the preliminary NMDIP and the MSIP, we recommend combining this application with 
research: for example, to investigate the effects on a healthcare plan when using the NMDIP.  
Concerning the Stigma Scale for Chronic Illness (Chapter 7), we recommend further 
psychometric evaluation of this scale to strengthen the validation of this instrument. 
Comparisons across other neurological and non-neurological conditions will help evaluate the 
generalizability of the Stigma Scale for Chronic Illness to other chronic conditions. This 
would also be valuable when examining the sensitivity to change of the Stigma Scale for 




In conclusion, this thesis yielded three easy-to-apply, valid and reliable measurement 
instruments which are applicable across the range of NMD diagnoses. These measurement 
instruments offered a broad and unique insight into the consequences of NMD on the 
functioning of patients, and the impact of these consequences on their perceived QoL. 
This insight may have great implications for multidisciplinary care and support for 
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Neuromuscular diseases (NMDs) encompass many diseases which impair muscle function, 
either directly through pathologies of the muscles, or indirectly through pathologies of the 
nerves or neuromuscular junctions. NMDs are progressive diseases which can cause muscle 
weakness or spasticity, and increased and increasing need for supportive devices and medical 
and non-medical support. We developed two self-report instruments to measure disability in 
NMDs and examined the consequences of NMDs on functioning and quality of life. We also 
examined the prevalence and severity of stigmatization among NMD patients and the impact 
on quality of life.  
 
In the introduction in Chapter 1, we described the central concepts in this thesis: the 
pathophysiology and epidemiology of the broad and extensive group of NMDs, and the 
consequences of NMDs on physical, mental and social functioning. We then introduced the 
International Classification of Functioning, Disability and Health (ICF) as a suitable 
classification method for the development of a measurement instrument for the assessment of 
disease-related functioning and disability. Stigmatization was introduced as a relevant 
consequence of physical, mental and social disabilities in NMDs. We then described the 
broad concept of quality of life (QoL) and what is known about the impact of having an NMD 
on QoL. Finally, we described the characteristics and importance of patient reported outcome 
measurements (PROMs) and how to examine their psychometric properties. 
We concluded with the following research questions: 
1 What is the content validity of the initial ICF Core Set for NMDs?  
2 How should the prevalence and severity of NMD-related disabilities, using the ICF 
Core Set for NMDs, be assessed? 





4 How should disability severity be assessed when focusing on extremity functioning in 
patients with an NMD?  
5 What is the impact of stigma on the QoL of patients with an NMD? 
 
In Chapter 2 we described the validation of the initial ICF Core Set for NMDs. This initial 
Core Set was originally developed for three neurological diagnoses: Multiple Sclerosis, 
Parkinson’s disease and Neuromuscular diseases. To examine the content validity of this 
initial ICF Core Set for NMDs, concepts in established and validated NMD quality of life 
measurement instruments were used. Concepts were linked to relevant ICF categories. Next 
these categories were compared with the ICF categories in the initial Core Set. The final 
NMD-ICF Core Set reflects a broad scope of NMD-related problems in functioning. In 
Chapter 3 we described the development of the Neuromuscular Disease Impact Profile 
(NMDIP). The first step was to develop an initial questionnaire based on the NMD-ICF Core 
Set. The second step was to carry out a cross-sectional postal survey on NMD patients. We 
then constructed robust scales and examined the psychometric properties of these scales. The 
final NMDIP consists of 36 items divided into eight scales with satisfactory psychometric 
properties, and four single items. In Chapter 4 we examined the stability over time and the 
Relative Validity of the NMDIP scales. The NMDIP is sensitive to detecting clinically 
important differences between relevant subgroups, and performed as well as or better than the 
concurrent measurement instruments.  
In Chapter 5 we reported on the prevalence and severity of a broad range of NMD-
related disabilities and the impact of these disabilities on QoL. We found no differences in 
QoL between diagnosis-based subgroups. ‘Impairments in muscle functions’ had the highest 
prevalence and severity scores in the overall sample and diagnosis-based subgroups, while 
‘impairments in mental functions and pain’ was the most important predictor of QoL, 
followed by ‘restrictions in participation in life situations’. In Chapter 6 we described the 
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adaptation and combination of two self-report measurement instruments for the assessment of 
disability-severity in NMD patients and examined the psychometric properties of this 
measurement instrument. The Extremity Functioning Index (EFI) proved to be a sound and 
easy to apply self-report disability-severity measurement instrument that was able to detect 
clinically important differences between relevant disability-severity subgroups.  
In Chapter 7 we reported on the influence of stigma on the QoL of patients with an 
NMD. We performed a postal survey among NMD patients and found that most patients 
(86%) reported self-stigma, while 64% reported enacted stigma. Self-stigma was a stronger 
predictor of poorer QoL compared with enacted stigma. In other words, patients suffered 
more from shame and fear of discrimination (self-stigma) than from actually experienced 
discrimination and exclusion (enacted stigma). 
In Chapter 8 we summarized and reflected on the thesis’s main findings, including 
methodological considerations and implications for clinical practice and further research.  
The aim of this thesis was to provide insight into the consequences of having an NMD 
on functioning and QoL. The main challenge in this study was to develop disease-specific 
measurement instruments for the evaluation of the consequences on functioning for all 
NMDs. We succeeded in developing two such measurement instruments. The NMDIP was 
primarily developed for organizing person-centred care and support for persons diagnosed 
with an NMD. The EFI was primarily developed as a disability-severity measure capable of 
discerning disease severity. We also translated a measurement instrument for the evaluation 
of the prevalence and severity of stigmatization, the Stigma Scale for Chronic Illness. We 
succeeded in providing a unique insight into the prevalence and severity of a broad range of 
NMD-related disabilities covering the large sample of NMDs. These findings underline the 
multidimensionality of the problems in functioning as a consequence of an NMD. We also 
found evidence of the differences in the severity of disease-related disabilities between NMD 





When comparing outcomes regarding the impact of an NMD on functioning between the two 
measurement instruments, the NMDIP and EFI, we found that ‘loss of muscle strength’ is 
more obvious in lower extremity function than in upper extremity function. We also found 
that the pain aspect had a stronger relationship with extremity function than expected. These 
findings underline the importance of the combination of both measurement instruments.  
Another important challenge in this thesis was to provide a detailed insight into the 
consequences of having an NMD on perceived QoL. We succeeded in examining the relative 
impact of a broad range of NMD-related disabilities and their relative impact on QoL.  
The main strength of this study is its large and broad sample of adult NMD patients, 
representing a large sample of NMDs, and the methods carefully selected and applied in the 
various studies. An important strength in the development of the NMDIP was the application 
of the ICF. This offered the opportunity to develop a measurement instrument which could 
provide a detailed insight into a broad spectrum of consequences of NMDs.  
The NMDIP could contribute to a better understanding of patient problems in 
functioning when used as an assessment tool, especially in multidisciplinary rehabilitation 
teams. The EFI could also have important implications for clinical care and for patients. 
Clinicians now have an easy to apply and patient-friendly disability-severity instrument to 
measure changes in disability-severity over time. Both the NMDIP and the EFI could also 
have clinical implications for patient self-management. 
We recommend further research to confirm the results found in this thesis, to assess its 
generalizability to other age-groups or cultural and social settings, and to explore further the 
psychometric properties of the EFI. Further research using the EFI should also focus on the 
applicability of this disability-severity measurement instrument. 
To conclude, this thesis resulted in three easy to apply, valid and reliable measurement 
instruments which are applicable to a broad range of NMD diagnoses. These measurement 
instruments offer a broad and unique insight into the consequences of NMDs in adults in 
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functioning and QoL. This insight could have important implications for multidisciplinary 
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Neuromusculaire aandoeningen (NMAs) omvatten vele aandoeningen die het functioneren 
van de spieren verstoren, hetzij direct door pathologie van de spieren, hetzij indirect door 
pathologie van de zenuwen of de neuromusculaire overgang. NMAs zijn progressieve 
aandoeningen die spierzwakte of spasticiteit kunnen veroorzaken en leiden tot een 
toenemende vraag naar ondersteunende hulpmiddelen en medische en niet-medische 
ondersteuning. We ontwikkelden twee zelfrapportage instrumenten voor het meten van 
functioneringsproblemen in NMAs en onderzochten de gevolgen van NMAs voor de kwaliteit 
van leven. Verder hebben we de prevalentie en ernst van stigmatisering onder mensen met een 
NMA onderzocht en het effect hiervan op de kwaliteit van leven. 
 
In de inleiding in Hoofdstuk 1, beschrijven we de centrale concepten in deze thesis. Eerst de 
pathofysiologie en epidemiologie van een brede en omvangrijke groep NMAs en de gevolgen 
van NMAs voor het fysiek, mentaal en sociaal functioneren. Dan introduceren we de 
Internationale Classificatie van het menselijk functioneren (ICF) als een geschikte 
classificatie methode voor het ontwikkelen van een meetinstrument voor het in kaart brengen 
van ziekte gerelateerd functioneren en functioneringsproblemen. Stigmatisering werd 
geïntroduceerd als een relevant gevolg van fysieke, mentale en sociale 
functioneringsproblemen in NMAs. Vervolgens beschrijven we het brede concept van 
kwaliteit van leven (KvL) en wat bekend is over het effect van het hebben van een NMA op 
KvL. Ten slotte, beschrijven we de kenmerken en het belang van de meetinstrumenten met 
door de patiënt gerapporteerde uitkomstmetingen en hoe de psychometrische eigenschappen 
van deze meetinstrumenten te onderzoeken.  
We besluiten met de volgende onderzoeksvragen: 
1 Wat is de inhoudsvaliditeit van de initiële ICF Core Set voor NMAs? 
2 Hoe moeten de prevalentie en ernst van NMA gerelateerde functioneringsproblemen 





3 Wat zijn de effecten van NMA-gerelateerde functioneringsproblemen op KvL? 
4 Hoe moet de ernst van functioneringsproblemen worden beoordeeld vanuit de focus op 
het functioneren van de extremiteiten bij patiënten met een NMA?  
5 Wat is de impact van stigma op de KvL van patiënten met een NMA? 
 
In Hoofdstuk 2 beschrijven we de validatie van de initiële ICF Core Set voor NMAs. Deze 
initiële Core Set werd oorspronkelijk ontwikkeld voor drie neurologische diagnosen: Multiple 
Sclerosis, Ziekte van Parkinson en Neuromusculaire aandoeningen. Voor het onderzoeken 
van de inhoudsvaliditeit van deze initiële ICF Core Set voor NMAs werden concepten in 
erkende en gevalideerde NMA specifieke kwaliteit van leven meetinstrumenten gebruikt. 
Concepten werden verbonden aan relevante ICF categorieën. Daarna werden deze categorieën 
vergeleken met de ICF-categorieën in de initiële Core Set. De definitieve NMA-ICF Core Set 
weerspiegelt een breed scala van NMA gerelateerde functioneringsproblemen. In hoofdstuk 3 
beschrijven we de ontwikkeling van de Neuromuscular Disease Impact Profile (NMDIP). De 
eerste stap was het ontwikkelen van een concept vragenlijst op basis van de NMA-ICF Core 
Set. De tweede stap was een transversaal onderzoek met deze vragenlijst (via de post) onder  
NMA patiënten. Vervolgens construeerden we robuuste schalen en onderzochten we de 
psychometrische eigenschappen van deze schalen. De definitieve NMDIP bestaat uit 36 items 
verdeeld over acht schalen met bevredigende psychometrische eigenschappen en vier 
afzonderlijke vragen. In Hoofdstuk 4 hebben we de stabiliteit en de relatieve validiteit van de 
NMDIP-schalen onderzocht. De NMDIP is gevoelig voor het signaleren van klinisch 
belangrijke verschillen tussen relevante subgroepen en presteerde net zo goed, of beter, dan 
vergelijkbare meetinstrumenten. 
In hoofdstuk 5 rapporteren we over de prevalentie en ernst van de breed scala aan 
NMA-gerelateerde functioneringsproblemen en de impact van deze functioneringsproblemen 
op KvL. We vonden geen verschillen in KvL tussen diagnose gebaseerde subgroepen. 
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pathofysiologie en epidemiologie van een brede en omvangrijke groep NMAs en de gevolgen 
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3 Wat zijn de effecten van NMA-gerelateerde functioneringsproblemen op KvL? 
4 Hoe moet de ernst van functioneringsproblemen worden beoordeeld vanuit de focus op 
het functioneren van de extremiteiten bij patiënten met een NMA?  
5 Wat is de impact van stigma op de KvL van patiënten met een NMA? 
 
In Hoofdstuk 2 beschrijven we de validatie van de initiële ICF Core Set voor NMAs. Deze 
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vergeleken met de ICF-categorieën in de initiële Core Set. De definitieve NMA-ICF Core Set 
weerspiegelt een breed scala van NMA gerelateerde functioneringsproblemen. In hoofdstuk 3 
beschrijven we de ontwikkeling van de Neuromuscular Disease Impact Profile (NMDIP). De 
eerste stap was het ontwikkelen van een concept vragenlijst op basis van de NMA-ICF Core 
Set. De tweede stap was een transversaal onderzoek met deze vragenlijst (via de post) onder  
NMA patiënten. Vervolgens construeerden we robuuste schalen en onderzochten we de 
psychometrische eigenschappen van deze schalen. De definitieve NMDIP bestaat uit 36 items 
verdeeld over acht schalen met bevredigende psychometrische eigenschappen en vier 
afzonderlijke vragen. In Hoofdstuk 4 hebben we de stabiliteit en de relatieve validiteit van de 
NMDIP-schalen onderzocht. De NMDIP is gevoelig voor het signaleren van klinisch 
belangrijke verschillen tussen relevante subgroepen en presteerde net zo goed, of beter, dan 
vergelijkbare meetinstrumenten. 
In hoofdstuk 5 rapporteren we over de prevalentie en ernst van de breed scala aan 
NMA-gerelateerde functioneringsproblemen en de impact van deze functioneringsproblemen 
op KvL. We vonden geen verschillen in KvL tussen diagnose gebaseerde subgroepen. 






‘Stoornissen in spierfuncties’ had de hoogste prevalentie en ernst score in de totale steekproef 
en diagnose gebaseerde subgroepen, terwijl 'Stoornissen in de mentale functies en pijn' de 
belangrijkste voorspeller van KvL was, gevolgd door ‘Belemmeringen in Participatie in 
maatschappelijke situaties’. In Hoofdstuk 6 beschrijven we de aanpassing en de combinatie 
van twee zelfrapportage meetschalen voor de beoordeling van de ernst van de 
functioneringsproblemen van patiënten met een NMA en onderzochten we de 
psychometrische eigenschappen van dit meetinstrument. De Extremity Function Index (EFI) 
bleek een goed en gemakkelijk toe te passen zelfrapportage meetinstrument voor de ernst van 
functioneringsproblemen dat in staat was klinisch belangrijke verschillen vast te stellentussen 
relevante subgroepen gebaseerd op ernst van functioneringsproblemen.  
In Hoofdstuk 7 rapporteren we over de invloed van stigma op de KvL van patiënten 
met een NMA. We hebben een onderzoek via de post uitgevoerd onder NMA patiënten en 
vonden dat de meeste patiënten (86%) zelfstigma rapporteerden, terwijl 64% interactioneel-
stigma rapporteerde. Zelfstigma was een sterkere voorspeller voor lagere KvL vergeleken met 
interactioneel-stigma. Met andere woorden: patiënten leden meer onder schaamte en angst 
voor discriminatie (zelfstigma) dan van de werkelijk ervaren discriminatie en uitsluiting 
(interactioneel-stigma). 
In Hoofdstuk 8 vatten we de belangrijkste bevindingen in dit proefschrift samen en 
reflecteren we hierop, met inbegrip van de methodologische overwegingen en de implicaties 
voor de klinische praktijk en verder onderzoek.   
Het doel van dit proefschrift was inzicht te bieden in de gevolgen van een NMA voor 
het functioneren en KvL. De belangrijkste uitdaging in deze studie was het ontwikkelen van 
ziekte specifieke meetinstrumenten voor de beoordeling van de gevolgen op het functioneren 
voor alle NMAs. We zijn erin geslaagd om twee dergelijke meetinstrumenten te ontwikkelen. 
De NMDIP is primair ontwikkeld voor het organiseren van persoonsgerichte zorg en 





als een meetinstrument voor het meten van de ernst van de functioneringsproblemen met de 
mogelijkheid om ziekte-ernst te verklaren. We hebben ook een meetinstrument vertaald voor 
de evaluatie van de prevalentie en de ernst van stigmatisering, de Stigma schaal voor 
Chronische Ziekte. We zijn erin geslaagd een uniek inzicht te geven in de prevalentie en ernst 
van een breed scala van NMA-gerelateerde functioneringsproblemen die relevant zijn voor 
het grote aantal NMAs. Deze bevindingen onderstrepen de veelzijdigheid van de 
functioneringsproblemen door een NMA.  
We vonden ook bewijs voor de verschillen in de ernst van de ziekte gerelateerde 
functioneringsproblemen tussen de NMA-subgroepen. Voor zover we weten is dit de eerste 
keer dat een dergelijk inzicht werd verkregen. Bij het vergelijken van de resultaten tussen 
beide meetinstrumenten, de NMDIP en de EFI, vonden we dat ’verlies van spierkracht’ 
duidelijker aanwezig is in de onderste extremiteiten dan in de bovenste extremiteiten. We 
vonden ook dat pijn een sterkere relatie had met het functioneren van de extremiteiten dan 
verwacht. Deze bevindingen onderstrepen het belang van de combinatie van beide 
meetinstrumenten. 
Een andere belangrijke uitdaging in dit proefschrift was het geven van een 
gedetailleerd inzicht in de gevolgen van een NMA op ervaren QoL. We zijn erin geslaagd de 
relatieve impact van een breed scala van NMA-gerelateerde functioneringsproblemen te 
onderzoeken en hun relatieve impact op KvL. De belangrijkste kracht van deze studie is de 
grote en brede steekproef van volwassen NMA-patiënten die een grote verzameling van 
NMAs vertegenwoordigen, en de zorgvuldig geselecteerde en toegepaste methoden in de 
verschillende studies. Een belangrijk sterk punt in de ontwikkeling van de NMDIP was de 
toepassing van de ICF. Dit bood de mogelijkheid een meetinstrument te ontwikkelen dat een 
gedetailleerd inzicht geeft in een breed scala aan gevolgen van NMAs. 
De NMDIP kan bijdragen aan een beter begrip van de functioneringsproblemen van 
een patiënt wanneer het wordt gebruikt als evaluatie-instrument, met name in 
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multidisciplinaire revalidatie teams. De EFI kan ook een belangrijke bijdrage leveren in de 
klinische zorg voor patiënten. Clinici hebben nu de beschikking over een gemakkelijk toe te 
passen en patiëntvriendelijk zelfrapportage meetinstrument voor het meten van de ernst van 
functioneringsproblemen en veranderingen in de tijd gezien. Zowel de NMDIP als de EFI 
kunnen klinische gevolgen hebben voor het zelfmanagement van patiënten. 
We adviseren verder onderzoek om de gevonden resultaten in dit proefschrift te 
bevestigen en naar de generaliseerbaarheid naar andere leeftijdsgroepen, culturele en sociale 
omgevingen. Verder onderzoek zou zich ook moeten richten op de toepasbaarheid van de EFI 
als ziekte-ernst schaal. 
Concluderend, resulteerde dit proefschrift in drie eenvoudig toe te passen, valide en 
betrouwbare meetinstrumenten die toepasbaar zijn voor de brede groep van NMAs. Deze 
meetinstrumenten bieden een breed en unieke inzicht in de gevolgen van NMAs bij 
volwassenen voor functioneren en QoL. Dit inzicht kan belangrijke gevolgen hebben voor de 
multidisciplinaire zorg en ondersteuning voor deze patiënten en hen helpen invloed uit te 
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Neuromuscular Disease Impact Profile (NMDIP) 
 
NMDIP Body functioning questions 
Scale  Response options 
0 = no, not at all 
1 = yes, I have a slight impairment 
2 = yes, I have a moderate impairment 
3 = yes, I have a severe impairment 
4 = yes, I have a complete impairment 
MuF B1 Do you face loss of your muscle power functions? (b730) 
MuF B2 Do you face loss of muscle endurance functions? (b740) 
MoF B3 Do you face loss of control of voluntary movements? (b760) 
MoF B4 Do you face involuntary movements? (e.g., tremors or tics) (b765) 
MoF B5 Do you face muscle stiffness or muscle spasm? (b7800 / b7801) 
SSF B6 Do you face impairment in your speech functions? (b320)  
SSF B7 Do you face impairment in your swallowing functions? (b5105) 
ERF B8 Do you face impairment in your defecation functions? (e.g., changes in frequency,  
               constipation, incontinence) (b525) 
ERF B9 Do you face impairment in your urination functions? (e.g., frequency of urination,  
  incontinence, difficulties with urination) (b620) 
ERF B10 Do you face limitations in sexual functions? (b640) 
MFP B11 Do you face impairment in your sleep functions? (e.g., onset of sleep, the maintenance of 
  sleep or the quality of sleep) (b134) 
MFP B12 Do you experience fatigue? (b1300/b455)  
MFP B13 Do you face changes in your emotional functions? (e.g., fear, depression, happiness) (b152) 
MFP B14 Do you face changes in your thought functions? (e.g., the ability to think  
  logically, the ability to memorize, the ability to concentrate) (b160) 
MFP B15 Do you experience sensation pain? (b280)  
single B16 Do you face impairment in your seeing functions? (With eyeglasses on or item lenses in)                                     
 (b210)  
NMDIP Activities questions 
Scale  Response options 
0 = No 
1 = Yes, but assistance devices and/or adaptations are not necessary 
2 = Yes, and assistance devices and/or adaptations are necessary 
3 = Yes, and assistance devices and/or adaptations and another person’s help  
are necessary 
 
AMA A1 Do you face limitations in changing your body position? (e.g., moving from 
lying down to standing up or from standing to sitting) (a410) 
AMA A2 Do you face limitations in maintaining your body position? (e.g., maintaining  
  kneeling, standing, and sitting postures) (a415) 
AMA A3 Do you face limitations in transferring yourself? (e.g., moving from a chair 
into bed; from a wheelchair into a car) (a420) 
AMA A4 Do you face limitations in walking? (a450) 
AMA A5 Do you face limitations in using transportation? (a470) 
AMA A6 Do you face limitations in activities you would like to undertake for recreation and leisure? 
  (a920) 
SDA A7  Do you face limitations in your fine hand use? (e.g., picking up small objects;  
  manipulating a keyboard) (a440) 
SDA A8 Do you face limitations in your arm(s) and hand(s) use? (e.g., pulling or pushing objects; 
  turning or twisting knobs or handles; reaching for kitchen cupboard) (a445) 





SDA A10 Do you face limitations in caring for body parts? (e.g., brushing teeth, clipping your nails, 
  combing your hair, shaving) (a520) 
SDA A11 Do you face limitations in toileting? (a530) 
SDA A12 Do you face limitations in dressing yourself? (a540) 
SDA A13 Do you face limitations in preparing meals? (a630) 
SDA A14 Do you face limitations in doing housework? (a640) 
NMDIP Participation questions 
Scale  Response options 
0 = no 
1 = Yes, as a consequence I have some trouble with …. 
2 = Yes, as a consequence I have trouble with... 
3 = Yes, as a consequence I have a lot of trouble with … 
4 = Yes, as a consequence …. is (nearly) impossible 
PLS P1 Are there obstacles in your environment that complicate your participation in 
community, recreation, and leisure? (e.g., accessibility of clubs or associations) (p910/p920) 
PLS P2 Are there obstacles in your environment that complicate the maintenance of  
your relationships with your closest family, friends, or relatives? (e.g., the travel distance, 
the attitude of others) (p740-p760) 
PLS P3 Are there obstacles in your environment that complicate your mobility inside 
or outside your home? (e.g., thresholds; curbs; absence of elevators) (p460 / 470) 
NMDIP Environmental factors questions 
Scale Response options 
 0 = Yes, very supportive;  
1 = Yes, somewhat supportive;  
2 = No, not supportive 
Single    E1 
item  
Is your relationship with your immediate family supportive for you? (e.g., partner, children, 
parents, brothers, sisters) (e310) 
Single    E2 
item  
Are the social security services supportive for you? (e.g., income support) (e570) 
Single    E3 
item  
Are the health services supportive for you? (e.g., medical and nursing care) (e580) 
MuF = Muscle Functions; MoF=Movement Functions; SSF = Swallowing and Speech Functions; ERF = 
Excretion and Reproductive Functions; MFP = Mental Functions and Pain; AMA = Activities of Moving 
Around; SDA = Self-care and Domestic Activities; PLS = Participation in Life Situations. 
  






Neuromuscular Disease Impact Profile (NMDIP) 
 
NMDIP Body functioning questions 
Scale  Response options 
0 = no, not at all 
1 = yes, I have a slight impairment 
2 = yes, I have a moderate impairment 
3 = yes, I have a severe impairment 
4 = yes, I have a complete impairment 
MuF B1 Do you face loss of your muscle power functions? (b730) 
MuF B2 Do you face loss of muscle endurance functions? (b740) 
MoF B3 Do you face loss of control of voluntary movements? (b760) 
MoF B4 Do you face involuntary movements? (e.g., tremors or tics) (b765) 
MoF B5 Do you face muscle stiffness or muscle spasm? (b7800 / b7801) 
SSF B6 Do you face impairment in your speech functions? (b320)  
SSF B7 Do you face impairment in your swallowing functions? (b5105) 
ERF B8 Do you face impairment in your defecation functions? (e.g., changes in frequency,  
               constipation, incontinence) (b525) 
ERF B9 Do you face impairment in your urination functions? (e.g., frequency of urination,  
  incontinence, difficulties with urination) (b620) 
ERF B10 Do you face limitations in sexual functions? (b640) 
MFP B11 Do you face impairment in your sleep functions? (e.g., onset of sleep, the maintenance of 
  sleep or the quality of sleep) (b134) 
MFP B12 Do you experience fatigue? (b1300/b455)  
MFP B13 Do you face changes in your emotional functions? (e.g., fear, depression, happiness) (b152) 
MFP B14 Do you face changes in your thought functions? (e.g., the ability to think  
  logically, the ability to memorize, the ability to concentrate) (b160) 
MFP B15 Do you experience sensation pain? (b280)  
single B16 Do you face impairment in your seeing functions? (With eyeglasses on or item lenses in)                                     
 (b210)  
NMDIP Activities questions 
Scale  Response options 
0 = No 
1 = Yes, but assistance devices and/or adaptations are not necessary 
2 = Yes, and assistance devices and/or adaptations are necessary 
3 = Yes, and assistance devices and/or adaptations and another person’s help  
are necessary 
 
AMA A1 Do you face limitations in changing your body position? (e.g., moving from 
lying down to standing up or from standing to sitting) (a410) 
AMA A2 Do you face limitations in maintaining your body position? (e.g., maintaining  
  kneeling, standing, and sitting postures) (a415) 
AMA A3 Do you face limitations in transferring yourself? (e.g., moving from a chair 
into bed; from a wheelchair into a car) (a420) 
AMA A4 Do you face limitations in walking? (a450) 
AMA A5 Do you face limitations in using transportation? (a470) 
AMA A6 Do you face limitations in activities you would like to undertake for recreation and leisure? 
  (a920) 
SDA A7  Do you face limitations in your fine hand use? (e.g., picking up small objects;  
  manipulating a keyboard) (a440) 
SDA A8 Do you face limitations in your arm(s) and hand(s) use? (e.g., pulling or pushing objects; 
  turning or twisting knobs or handles; reaching for kitchen cupboard) (a445) 





SDA A10 Do you face limitations in caring for body parts? (e.g., brushing teeth, clipping your nails, 
  combing your hair, shaving) (a520) 
SDA A11 Do you face limitations in toileting? (a530) 
SDA A12 Do you face limitations in dressing yourself? (a540) 
SDA A13 Do you face limitations in preparing meals? (a630) 
SDA A14 Do you face limitations in doing housework? (a640) 
NMDIP Participation questions 
Scale  Response options 
0 = no 
1 = Yes, as a consequence I have some trouble with …. 
2 = Yes, as a consequence I have trouble with... 
3 = Yes, as a consequence I have a lot of trouble with … 
4 = Yes, as a consequence …. is (nearly) impossible 
PLS P1 Are there obstacles in your environment that complicate your participation in 
community, recreation, and leisure? (e.g., accessibility of clubs or associations) (p910/p920) 
PLS P2 Are there obstacles in your environment that complicate the maintenance of  
your relationships with your closest family, friends, or relatives? (e.g., the travel distance, 
the attitude of others) (p740-p760) 
PLS P3 Are there obstacles in your environment that complicate your mobility inside 
or outside your home? (e.g., thresholds; curbs; absence of elevators) (p460 / 470) 
NMDIP Environmental factors questions 
Scale Response options 
 0 = Yes, very supportive;  
1 = Yes, somewhat supportive;  
2 = No, not supportive 
Single    E1 
item  
Is your relationship with your immediate family supportive for you? (e.g., partner, children, 
parents, brothers, sisters) (e310) 
Single    E2 
item  
Are the social security services supportive for you? (e.g., income support) (e570) 
Single    E3 
item  
Are the health services supportive for you? (e.g., medical and nursing care) (e580) 
MuF = Muscle Functions; MoF=Movement Functions; SSF = Swallowing and Speech Functions; ERF = 
Excretion and Reproductive Functions; MFP = Mental Functions and Pain; AMA = Activities of Moving 
Around; SDA = Self-care and Domestic Activities; PLS = Participation in Life Situations. 
  



































Neuromusculair Disease Impact Profile (NMDIP)  
 
 
NMDIP  functie vragen 
schaal  antwoord mogelijkheden 
0 = nee, helemaal niet 
1 = ja, een beetje 
2 = ja, behoorlijk 
3 = ja, ernstig 
4 = ja, zeer ernstig 
SF   F1 Is er bij u sprake van krachtsverlies in de spieren? (b730) 
SF   F2 Is er bij u sprake van verminderd uithoudingsvermogen van de spieren? (b740) 
BF  F3 Is er bij u sprake van een verminderde controle van willekeurige bewegingen? (b760) 
BF   F4 Is er bij u sprake van onwillekeurige bewegingen? (bijvoorbeeld tremoren of tics) (b765) 
BF    F5 Is er bij u sprake van spierstijfheid of spierspasmen? (b7800/7801) 
SSF  F6 Is er bij u sprake van een stoornis in het spreken?  (b320) 
SSF F7 Is er bij u sprake van een stoornis in het slikken? (b5105) 
URF  F8 Is er bij u sprake van een afwijkend ontlastingspatroon? (bijv. verandering in frequentie, obstipatie, 
 incontinentie) (b525) 
URF F9 Is er bij u sprake van een afwijkend patroon van urineren? (bijv. verandering in frequentie, incontinentie,  
moeilijk kunnen plassen) (b620) 
URF F10 Zijn er voor u beperkingen op seksueel gebied? (b640) 
MFP F11 Is er bij u sprake van een afwijkend slaappatroon? (bijv. het inslapen, doorslapen of de kwaliteit van de slaap) 
(b134) 
MFP F12 Is er bij u sprake van vermoeidheid? (bijv. verminderde energie en uithoudingsvermogen) (b1300/b455) 
MFP F13 Is er bij u sprake van een verandering in uw stemming? (bijv. angst, somberheid, vreugde) (b152) 
MFP F14 Is er bij u sprake van een verandering in uw verstandelijke vermogens? (bijv. in het logisch kunnen denken, 
het onthouden van dingen, het kunnen concentreren) (b160) 
MFP F15 Heeft u pijn? (b280) 
Single 
item 
F16 Is er bij u sprake van een stoornis in het zien? (met bril op of contactlenzen in) (b134) 
NMDIP  activiteiten vragen 
schaal  antwoord mogelijkheden 
0 = nee 
1 = ja, maar hulpmiddelen en/of aanpassingen zijn niet nodig 
2 = ja, hulpmiddelen en/of aanpassingen zijn wel nodig 
3 = ja, maar hulpmiddelen en/of aanpassingen én hulp van anderen zijn nodig. 
BBA A1 Zijn er voor u beperkingen in het veranderen van uw lichaamshouding? (bijv. van liggen gaan zitten 
of vanuit staan gaan zitten) (a410) 
BBA A2 Zijn er voor u beperkingen in het handhaven van uw lichaamshouding? (bijv. het kunnen blijven staan 
of zitten) (a415) 
BBA A3 Zijn er voor u beperkingen in het kunnen verplaatsen van uzelf? (bijv. van stoel naar bed of van 
rolstoel in de autostoel) (a420) 
BBA A4 Zijn er voor u beperkingen in het lopen? (a450) 
BBA A5 Zijn er voor u beperkingen in het gebruik kunnen maken van (openbaar) vervoermiddelen? (a470) 
BBA A6 Zijn er voor u beperkingen bij wat u in uw vrije tijd graag zou willen doen? (a920) 
ADL A7 Zijn er voor u beperkingen in het nauwkeurig kunnen gebruiken van uw hand(en)? (bijv. het oppakken 
van kleine voorwerpen of het gebruiken van een toetsenbord) (a440) 
ADL A8 Zijn er voor u beperkingen in het gebruiken van uw arm(en) én hand(en)? (bijv. trekken of duwen van 
voorwerpen, omhoog of omlaag drukken van knoppen, reiken naar keukenkastje) (a445) 
ADL A9 Zijn er voor u beperkingen in het wassen van uzelf? (a510) 
ADL A10 Zijn er voor u beperkingen in het verzorgen van lichaamsdelen? (bijv. tanden poetsen, nagels knippen, 





ADL A11 Zijn er voor u beperkingen in de toiletgang? (a530) 
ADL A12 Zijn er voor u beperkingen in het aan- en uitkleden? (a540) 
ADL A13 Zijn er voor u beperkingen in het bereiden van maaltijden? (a630) 
ADL A14 Zijn er voor u beperkingen in het doen van het huishouden? (a640) 
NMDIP  participatie vragen 
Schaal  antwoord mogelijkheden 
0 = nee 
1 = ja, hierdoor heb ik enige moeite met …. 
2 = ja, …. kost mij hierdoor moeite 
3 = ja, …. kost mij hierdoor veel moeite 
4 = ja, …. Is hierdoor (vrijwel) niet mogelijk. 
PML P1 Zijn er voor u belemmeringen in uw omgeving die vrijetijdsbesteding bemoeilijken? (bijv. 
bereikbaarheid van clubs of verenigingen) (p910/p920) 
PML P2 Zijn er belemmeringen in uw omgeving die het onderhouden van uw relaties met uw naaste familie, 
vrienden of bekenden bemoeilijken? (bijv. reisafstand, de houding van anderen) (p740-p760) 
PML P3 Zijn er belemmeringen in uw omgeving die uw mobiliteit binnen- en buitenshuis bemoeilijken? (bijv. 
drempels, stoepranden, afwezigheid van liften) (p460/p470) 
NMDIP  externe factoren vragen 
Scale   antwoord mogelijkheden 
0 = ja, (zeer) ondersteunend 
1 = ja, enigszins ondersteunend 
2 = nee, niet ondersteunend 
Single 
item 
E1 Is uw naaste familie ondersteunend voor u? (partner, kinderen, ouders, broers en zusters, enz.) (e310) 
Single 
item 
E2 Zijn de voorzieningen op het gebied van de sociale zekerheid ondersteunend voor u? (bijv. 
inkomenssteun, uitkeringen en uitkerende instanties) (e570) 
Single 
item 
E3 Zijn de gezondheidszorgvoorzieningen ondersteunend voor u? (bijv. medische en verpleegkundige 
zorg) (e580) 
SF = Spier functies;  BF = Bewegingsfuncties; URF = Uitscheidings- en Reproductie Functies; 
MFP = Mentale Functies en Pijn; BBA = Basale Bewegingsactiviteiten; ADL = Activiteiten van het Dagelijkse 
Leven; PML = Participatie aan het Maatschappelijke Leven; EF = Externe Factoren. 
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The Extremity Function Index (EFI) 
Response options 
0 = not difficult 
1 = slightly difficult 
2 = moderately difficult 
3 = quite difficult 
4 = extremely difficult or impossible 
 
Upper Extremity Function Index (UEFI) 
We are interested in whether the upper-limb problem for 
which you are seeking help is causing you any difficulty 
with the activities listed below.  
 
Please indicate how difficult each of the following 
activities is or would be for you today: 
 Lower Extremity Function Index (LEFI) 
We are interested in whether the lower-limb problem for which 
you are seeking help is causing you any difficulty with the 
activities listed below. 
  
Please indicate how difficult each of the following activities is 
or would be for you today: 
1 Any of the activities involved in your usual 
work, housework, or schoolwork 
 1 Any of the activities involved in your usual work, 
housework, or schoolwork 
2 Your usual hobbies, recreational or sporting 
activities 
 2 Your usual hobbies, recreational or sporting activities 
3 Lifting a bag of groceries to waist level  3 Getting into or out of the bathtub 
4 Lifting a bag of groceries above your head  4 Walking between rooms 
5 Grooming your hair  5 Putting on your shoes or socks 
6 Pushing up on your hands (e.g., from a bathtub 
or chair) 
 6 Squatting 
7 Preparing food (e.g., peeling, cutting)  7 Lifting an object (e.g., a bag of groceries) from the 
floor  
8 Driving  8 Performing light activities around your home 
9 Vacuuming, sweeping, or raking  9 Performing heavy activities around your home 
10 Dressing  10 Getting into or out of a car 
11 Buttoning your clothing   11 Walking 10 yards  
12 Using tools or appliances  12 Walking 200 yards 
13 Opening doors  13 Going up or down 10 steps (about 1 flight of stairs) 
14 Cleaning  14 Standing for 10 minutes  
15 Tying or lacing shoes  15 Sitting for 1 hour 
16 Sleeping  16 Walking on even ground 
17 Laundering clothes (e.g., washing, ironing, 
folding) 
 17 Walking on uneven ground 
18 Opening a jar  18 Making sharp turns while walking quickly 
19 Throwing a ball  19 Jumping 
20 Carrying a small suitcase (with your affected 
limb) 
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De Extremity Function Index (EFI) 
Antwoord opties 
0 = geen moeite 
1 = weinig moeite 
2 = matige moeite 
3 = veel moeite 
4 = extreme moeite/onmogelijk  
 
Upper Extremity Function Index (UEFI) 
We willen graag weten hoeveel moeite u door de NMA heeft met 
het uitvoeren van de hieronder genoemde activiteiten. Het zijn 
activiteiten waarbij u uw armen moet gebruiken.  
Wilt u bij elke activiteit het best passende hokje aankruisen? 
 
Had u vandaag en/of de afgelopen dagen moeite met de 
volgende activiteiten? 
 Lower Extremity Function Index (LEFI) 
We willen graag weten hoeveel moeite u door de NMA heeft met het 
uitvoeren van de hieronder genoemde activiteiten. Het zijn activiteiten 
waarbij u uw benen moet gebruiken.  
Wilt u bij elke activiteit het best passende hokje aankruisen? 
 




1 Uw dagelijkse werk, huishouden of schoolactiviteiten 
 
 1 Uw dagelijkse werk, huishouden of schoolactiviteiten 
 
2 Uw hobby’s, recreatieve of sport activiteiten 
 
 2 Uw hobby’s, recreatieve of sport activiteiten 
 
3 Optillen van een boodschappentas tot uw middel 
 
 3 In of uit bad gaan 
 
4 Optillen van een boodschappentas boven uw hoofd 
 
 4 Het lopen van de ene naar de andere kamer 
 
5 Verzorgen van uw haar 
 
 5 Uw schoenen of sokken aantrekken 
 
6 Uzelf omhoog duwen met de handen. 
(bv. uit het bad of de stoel) 
 6 Hurken 
 
7 Eten klaar maken (bv. schillen, snijden) 
 
 7 Een voorwerp optillen, bv. een boodschappentas van de 
vloer 
8 Autorijden  
 
 8 Uitvoeren van lichte activiteiten rondom uw huis 
 
9 Stofzuigen, vegen of harken 
 




 10 In of uitstappen van een auto 
 
11 Dichtknopen van kleding 
 
 11 10 meter lopen 
 
12 Gebruik van gereedschap of hulpmiddelen 
 
 12 200 meter lopen 
 
13 Openen van deuren 
 




 14 10 minuten staan 
 
15 Schoenveters strikken 
 




 16 Lopen over een vlakke ondergrond 
 
17 Kleding wassen (bv. wassen, strijken, vouwen) 
 
 17 Lopen over een oneffen ondergrond 
 
18 Een pot openmaken 
 
 18 Scherpe bochten maken terwijl u hard loopt 
 
19 Gooien van een bal 
 
 19 Springen 
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Stigma Scale for Chronic Illness 
Response options 
0 = never  
1 = rarely  
2 = often  
3 = sometimes  
4 = always 
 
Your experience of the consequences of your illness  
The following propositions are about possible consequences of your illness and your 
experience of it.   




1 Because of my illness, I felt emotionally distant from other people  
2 Because of my illness, I felt left out of things  
3 Because of my illness, I felt embarrassed in social situations  
4 Because of my illness, I worried about other people’s attitudes towards me  
5 I was unhappy about how my illness affected my appearance  
6 Because of my illness, it was hard for me to stay neat and clean  
7 Because of my illness, I worried that I was a burden to others  
8 I felt embarrassed about my illness  
9 I felt embarrassed because of my physical limitations  
10 I felt embarrassed about my speech  
11 Because of my illness, I felt different from others  
12 I tended to blame myself for my problems  
13 I avoided making new friends to avoid telling others about my illness  
14 Because of my illness, some people seemed uncomfortable with me  
15 Because of my illness, some people avoided me  
16 Because of my illness, people were unkind to me  
17 Because of my illness, people made fun of me  
18 Because of my illness, people avoided looking at me  
19 Because of my illness, strangers tended to stare at me  
20 Because of my illness, I was treated unfairly by others  
21 Because of my illness, people tended to ignore my good points  
22 Some people acted as though it was my fault I have this illness  
23 People with my illness lost their jobs when their employers found out about it  

















Stigma Scale for Chronic Illness 
Response options 
0 = never  
1 = rarely  
2 = often  
3 = sometimes  
4 = always 
 
Your experience of the consequences of your illness  
The following propositions are about possible consequences of your illness and your 
experience of it.   




1 Because of my illness, I felt emotionally distant from other people  
2 Because of my illness, I felt left out of things  
3 Because of my illness, I felt embarrassed in social situations  
4 Because of my illness, I worried about other people’s attitudes towards me  
5 I was unhappy about how my illness affected my appearance  
6 Because of my illness, it was hard for me to stay neat and clean  
7 Because of my illness, I worried that I was a burden to others  
8 I felt embarrassed about my illness  
9 I felt embarrassed because of my physical limitations  
10 I felt embarrassed about my speech  
11 Because of my illness, I felt different from others  
12 I tended to blame myself for my problems  
13 I avoided making new friends to avoid telling others about my illness  
14 Because of my illness, some people seemed uncomfortable with me  
15 Because of my illness, some people avoided me  
16 Because of my illness, people were unkind to me  
17 Because of my illness, people made fun of me  
18 Because of my illness, people avoided looking at me  
19 Because of my illness, strangers tended to stare at me  
20 Because of my illness, I was treated unfairly by others  
21 Because of my illness, people tended to ignore my good points  
22 Some people acted as though it was my fault I have this illness  
23 People with my illness lost their jobs when their employers found out about it  


















Stigma schaal voor chronische aandoeningen 
Antwoord opties 
0 = nooit 
1 = zelden 
2 = soms 
3 = vaak 
4 = altijd 
 
Uw beleving van de gevolgen van uw ziekte  
De volgende stellingen gaan over mogelijke gevolgen van uw ziekte en uw beleving daarvan. 
Wilt u de bij iedere stelling aankruisen hoe vaak deze voor u de afgelopen 7 dagen van 
toepassing was? 
 
1 Door mijn ziekte voelde ik een emotionele afstand tot andere mensen 
2 Door mijn ziekte voelde ik mij bij activiteiten buitengesloten 
3 Door mijn ziekte schaamde ik mij in sociale situaties 
4 Door mijn ziekte maakte ik mij zorgen over de houding van andere mensen naar mij toe  
5 Ik voelde mij ongelukkig over hoe mijn ziekte mijn uiterlijk veranderde  
6 Door mijn ziekte was het voor mij moeilijk schoon en verzorgd te blijven 
7 Door mijn ziekte was ik bezorgd dat ik anderen tot last zou zijn 
8 Ik schaamde mij voor mijn ziekte 
9 Ik schaamde mij voor mijn fysieke beperkingen 
10 Ik schaamde mij voor mijn spraak 
11 Door mijn ziekte voelde ik mij anders dan anderen 
12 Ik had de neiging mijzelf de schuld te geven voor mijn problemen 
13 Ik vermeed het aangaan van nieuwe vriendschappen om te voorkomen dat ik over mijn ziekte 
moest vertellen 
14 Door mijn ziekte leken sommige mensen zich niet op hun gemak te voelen bij mij  
15 Door mijn ziekte vermeden sommige mensen mij 
16 Door mijn ziekte waren mensen onvriendelijk tegen mij 
17 Door mijn ziekte maakten mensen grappen over mij 
18 Door mijn ziekte vermeden mensen het om naar mij te kijken 
19 Door mijn ziekte hadden vreemden de neiging om naar mij te staren 
20 Door mijn ziekte werd ik door anderen oneerlijk behandeld 
21 Door mijn ziekte neigden mensen ernaar mijn goede punten te negeren 
22 Sommige mensen deden alsof het mijn schuld was dat ik deze ziekte heb 
23 Mensen met dezelfde ziekte als ik verloren hun baan nadat hun werkgevers er achter kwamen 








Het is algemeen bekend dat een promotieonderzoek een samenwerkingstraject is en dat 
betekent ook dat meerdere mensen zich hiermee hebben bezig gehouden. Deze mensen wil ik 
in het bijzonder bedanken voor hun inbreng. 
 
Allereerst wil ik alle patiënten (en hun partners) bedanken die hebben deelgenomen aan het 
onderzoek. Zij hebben behoorlijk wat vragenlijsten ingevuld. Deze gegevens hebben 
belangrijke informatie opgeleverd waardoor het mogelijk werd dit proefschrift te schrijven. 
 
Graag wil ik mijn promotoren prof. dr. J.B.M. Kuks en prof. dr. H.P.H. Kremer bedanken. 
Beste Jan, ik wil je hartelijk danken voor het feit dat je mij al vroegtijdig uitdaagde tot het 
doen van onderzoek. Je gaf ook aan dat de onderzoekslijn die copromotor dr. K. Wynia had 
neergezet ook voor de neuromusculaire groep mensen interessant was. Dit heeft uiteindelijk 
geleid tot mijn promotietraject. Voor mij waren je betrokkenheid, kennis en begeleiding een 
zeer prettige basis voor het doen van onderzoek. 
Beste Berry, als hoofd van de afdeling Neurologie met een brede affiniteit in het doen van 
onderzoek, wil ik je bedanken voor de zeer plezierige en scherpe invulling van de begeleiding 
van mijn promotietraject. Aan beide promotoren mijn dank voor de faciliteiten die zo nodig 
zijn voor het doen van onderzoek.  
 
Veel dank gaat uit naar mijn copromotor dr. K. Wynia. Beste Klaske, ik wil je hartelijk 
bedanken voor je niet aflatende deskundige en creatieve inbreng, je hebt mij zo ver gebracht 
dat een promotie realiteit werd. Je bent het meest intensief betrokken geweest bij het vorm 
geven van dit onderzoek, het schrijven van de artikelen en het proefschrift. Je gelooft dat 
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iedereen een opdracht heeft in zijn leven. Jouw opdracht als copromotor en mijn opdracht als 
promovendus zijn mede daardoor goed op elkaar afgestemd. De basis van deze samenwerking 
was jaren geleden al begonnen op de Chirurgische Intensive Care en kreeg een vervolg binnen 
het ‘deelproject Neurologie’ (een van de tien deelprojecten in drie academische ziekenhuizen 
die de toepassingsmogelijkheden van de ICF, toen nog ICIDH-2, onderzochten) en het 
Coördinatie Centrum Chronisch Zieken-Noord Nederland met het speerpunt de aandacht en 
zorg voor de chronisch zieken te verbeteren. Daar hebben wij een mooi vervolg aan gegeven. 
 
De leden van de leescommissie, prof. dr. B.G.M. van Engelen, prof. dr. J.S. Rietman en prof. 
dr. S.A. Reijneveld, wil ik bedanken voor de tijd die ze vrijgemaakt hebben voor het kritisch 
doorlezen en beoordelen van mijn proefschrift. 
 
Graag wil ik de coauteurs dr. H.A. Stallinga, dr. J.A. Almansa en dr. G. Drost bedanken. 
Beste Gonda ook onze samenwerking is begonnen op de Intensive Care en bij het begin van 
het denken over eerst de ICIDH daarna de ICF, zo ongeveer in 1997. Ik wil je heel graag 
bedanken voor je enthousiasme en inzet van kennis van de ICF voor dit onderzoek, en het 
stimuleren van je dochters voor de invoer van de gegevens van de vragenlijsten. Beste Josué 
ik wil je bedanken voor je statistische bijdragen aan dit onderzoek. Je maakte de statistische 
beschrijvingen compacter en dat was erg welkom. Beste Gea, bedankt voor je heldere kijk op 
de inhoud en structuur van de artikelen waar je aan hebt bijgedragen. 
 
Dr. A.E.J. de Jager, beste Aeiko ik wil je bedanken voor de deskundige en empathische wijze 
waarop je mij hebt ingewijd in de problematiek van mensen met een neuromusculaire 
aandoening. Je hebt mij geleerd oog te hebben voor de fysieke en psychosociale klachten die 
deze groep mensen onder ogen krijgt. Dit heeft mij gesterkt in mijn blijvende keuze voor het 






Ook gaat mijn dank uit naar Kyra van der Beek, Hanna Bosman, Ronald Brands. Inmiddels 
zijn jullie socioloog, maar als masterstudent hebben jullie bijgedragen aan het onderzoek door 
het vormgeven en versturen van de vragenlijsten, en het controleren en invoeren van de 
geretourneerde vragenlijsten. Jullie bijdrage was tevens onderdeel van jullie 
afstudeeronderzoek. Met gegevens uit het onderzoek konden jullie je afstudeeronderzoek 
realiseren en de master-bul behalen. Fijn Kyra dat je onderzoek geleid heeft tot een publicatie 
in dit proefschrift. Mijn dank gaat ook uit naar Annelies, Carolien en Marieke Verschure voor 
het invoeren van de vragenlijsten, die jullie enthousiast en nauwkeurig verwerkt hebben 
tijdens jullie vakanties. 
 
Drs. M.W. Posthumus, manager Neurologie en Neurochirurgie, beste Marga ik wil je 
bedanken voor de snelle toezeggingen om de kosten te regelen voor correctie en publicatie 
van de artikelen en de presentatie van mijn onderzoeksresultaten in het buitenland.  
 
Henriette-mijn paranimf, wij samen zijn één en jouw aandeel is enerverend harmonieus. 
Samen huishouden, een serie kijken of reizen gaat ons goed af. Je was blij dat ik wat om 
handen had maar niet minder nu meer tijd beschikbaar is voor gezamenlijke uitdagingen.  
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